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Chapter 1
Cancer: ‘The Emperor of All Maladies’
In 1971, President Nixon of the United States of America declared the ‘War on Cancer’ by 
signing the National Cancer Act. Many hoped and expected that this financial burst for cancer 
research would lead to a cure for cancer within a ‘few’ years after the start of this ‘War’. Yet, 
despite the enormous progress that has been made in our understanding of cancer biology 
and the increase in cancer survival rates, it remains one of the leading causes of death in 
the developed world. This is primarily due to the fact that research over the past 30 years 
has shown that every cancer subtype is heterogeneous and highly adaptive to treatment, 
so that there will be no single cure to cancer. It is foreseen that ultimately the majority of 
cancers will become chronic diseases rather than curable diseases. Physician, researcher and 
writer Siddhartha Mukherjee therefore rightfully called cancer ‘The Emperor of All Maladies’ 
(Mukherjee, 2011). Hence, as we are entering the age of personalized medicine, it is ever more 
important to dissect cancer’s diverse biology and fundamentally understand signaling pathways 
that contribute to cancer progression, as this will ultimately allow a complete personalization of 
a cancer treatment based on the individual’s cancer biology.
The Hallmarks of Cancer
Despite its heterogeneity and complexity, most cancers seem to follow a common multistep 
process leading to the transformation from a normal cell into a malignant cell. In their landmark 
paper ‘The Hallmarks of Cancer’, which was published in 2000, Hanahan and Weinberg 
described six alterations in cells that drive malignant transformation: (1) self-sufficiency in growth 
signals, (2) insensitivity to anti-growth signals, (3) evasion of apoptosis, (4) limitless replicative 
potential, (5) inducing angiogenesis and (6) tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). In 2011 Hanahan and Weinberg published an updated version of their paper 
called ‘The Hallmarks of Cancer: The Next Generation’ in which two emerging hallmarks were 
added to the list: (1) avoiding immune destruction and (2) deregulating cellular energetics 
(Hanahan and Weinberg, 2011). Although these processes all significantly contribute to cancer 
development and progression, metastases are responsible for ~90% cancer-associated 
mortality.
 Whereas gene-altering mutations play a key role in all of the hallmarks of cancer, 
signals from the surrounding tumor microenvironment are paramount in driving metastasis 
(Gonzalez and Medici, 2014). These signals can be released from cells that reside within the 
proximity of the tumor, such as fibroblasts and immune cells, and include growth factors and 
cytokines (Goubran et al., 2014). Moreover, research over the past decade has shown that, 
in addition to these biological signaling molecules, physical or mechanical signals that are 
relayed by mechanosensitive plasma membrane molecules such as integrins and certain ion 
channels, can equally impinge on tumor behavior (Butcher et al., 2009). The transient receptor 
potential (TRP) family of cation channels, a family of ion channels that responds to extracellular 
signals including mechanical cues, has been implicated in the regulation of cancer-associated 
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processes such as proliferation and migration (Prevarskaya et al., 2011). However, if and how 
TRP channels play a role in cancer progression remains largely undetermined. This thesis 
revolves around understanding the role of the TRP family member TRPM7 in metastatic 
processes.
Tumor metastasis
The sequence of events leading to the formation of metastases is known as the metastatic 
cascade (Fidler, 2003; Hanahan and Weinberg, 2011). This multistep process starts with local 
invasion and migration of tumor cells into the surrounding tissue, intravasation of tumor cells 
into blood or lymphatic vessels, transportation and survival in the blood and lymph circulatory 
systems, escape from blood or lymph vessels (extravasation) and is finally followed by the 
formation of micrometastases and transformation of micrometastases into macrometastases 
(colonization) (Figure 1).
 The vast majority of human cancers arises from epithelial tissues. These so-called 
carcinomas do not inherently possess the ability to invade and migrate. Epithelial cells are well-
differentiated, grow in polarized sheets and are interconnected through several types of cell-cell 
adhesion structures, including adherens junctions and tight junctions (Lamouille et al., 2014). 
Moreover, the underlying basement membrane anchors the epithelial cells to the connective 
tissue and maintains apical-basal polarity via connections between hemidesmosomes and 
intermediate filaments. Both adhesion to adjacent cells and the basement membrane are 
required for maintenance of the epithelial phenotype. To become invasive and migratory, 
carcinoma cells need to lose their cell-cell adhesions and their connection to the basement 
membrane. Hence, cytoskeletal dynamics are critical for cancer cells to adopt invasive and 
migratory properties. In addition, cells need to increase the production of matrix proteases to 
allow matrix degradation. Moreover, for carcinoma cells to survive in the circulatory system after 
intravasation, cells need to acquire anoikis resistance, which is the ability of cells to survive and 
grow in an anchorage-independent manner. It is now well established that a developmental 
program known as epithelial-mesenchymal transition (EMT) endows tumor cells with these 
metastatic properties (Kalluri and Weinberg, 2009; Thiery et al., 2009).
Epithelial-mesenchymal transition
EMT during embryogenesis enables immotile epithelial cells to acquire invasive and migratory 
properties, orchestrating embryonic processes such as gastrulation, mesoderm formation and 
neural crest development. In addition, EMT plays a role during repair of injured or damaged 
tissues, by allowing epithelial cells to transit into fibroblasts that assist in the regeneration 
of tissues. This type of EMT also contributes to organ fibrosis (Kalluri and Weinberg, 2009). 
Tumor cells are able to hijack the EMT program thereby enhancing their metastatic properties 
(Figure 1).
 EMT is a complex transcriptionally regulated program, in which increasing numbers of 
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transcription factors are shown to be involved (Lamouille et al., 2014; Moustakas and Heldin, 
2014). However, a select set of EMT-inducing transcription factors (EMT-TFs) consisting of 
Snail, Slug (Snail2), Twist1, ZEB1 and ZEB2 is generally seen as core EMT-TFs. Additional 
transcriptions factors known to regulate EMT include LEF-1, Goosecoid and SOX4. One of the 
hallmarks of EMT is loss of the adherens junction protein E-cadherin (CDH1). Consistently, 
core EMT-TFs are able to directly inhibit transcription of CDH1 by repressing its promoter.
Figure 1. Metastatic cascade, role tumor microenvironment and epithelial mesenchymal transition. Schematic 
overview of the metastatic cascade, showing that signals from cells residing in the tumor microenvironment (examples 
given are macrophages in blue, cancer-associated fibroblasts in grey)  are able to enhance metastatic properties. In 
addition, mechanical cues from the ECM similarly may enhance metastatic properties of tumor cells. Cells receiving 
EMT inducing signals, will disseminate from the primary tumor to invade and migrate through surrounding tissue 
(A) subsequently intravasating the blood stream (B). Through circulation and survival in the bloodstream (C) tumor 
cells will be captured by small capillaries, which in turn results in extravasation from the capillary (D). Depending 
on the pro-survival and pro-proliferative properties of the metastatic site, metastasized cells may be able to form 
macroscopic metastases (E), which in addition likely involves tumor cells to undergo MET.
A
B
C
D
E
ECM
EMT MET
Tumor
microenvironment Blood vessel
Metastatic
site
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Furthermore, initiation of EMT is accompanied by the full dissolution of cell-cell adhesions, loss 
of apical-basal polarity and subsequent acquisition of a spindle-shaped morphology, increased 
expression of ECM components and matrix proteases, increased migratory properties and 
elevated resistance to apoptosis (Gonzalez and Medici, 2014; Kalluri and Weinberg, 2009; 
Lamouille et al., 2014; Thiery et al., 2009). EMT has also been shown to induce stem cell-like 
properties, which would endow tumor cells with self-renewal capability (Mani et al., 2008; Tsai 
and Yang, 2013). Several recent papers have provided clinical evidence of an EMT signature 
during several steps of the metastatic cascade, including invasion, intravasation and transport 
through the circulatory systems (reviewed in (Tsai and Yang, 2013)). In contrast, macroscopic 
metastases generally have an epithelial phenotype, suggesting that metastasized cells lose 
their mesenchymal phenotype after extravasation (Chao et al., 2010; Peinado et al., 2007). 
Indeed, the reverse process, mesenchymal-epithelial transition (MET) has been shown to be 
required for the outgrowth of macroscopic tumors in in vivo mouse models (Ocana et al., 
2012; Tsai et al., 2012). Hence, the ability of tumor cells to switch between an epithelial and a 
mesenchymal state therefore seems essential at different stages of the metastatic cascade. 
EMT and MET can be regulated by a wide variety of extracellular signals, in which the tumor 
microenvironment plays an essential role. Therefore, as sensors of extracellular stimuli, it might 
well be that TRP channels in general, and TRPM7 specifically, contribute to the regulation EMT.
Tumor microenvironment
Our view of cancer has changed from cancer being an autonomous, relatively homogeneous 
clump of cells that proliferates uncontrollably, to being an organ with a complexity that 
approaches or even exceeds that of normal healthy organs (Hanahan and Weinberg, 2000, 
2011). Indeed, a tumor does not consist only of tumor cells, but also contains several types tumor-
associated or –infiltrated cells such as endothelial cells, fibroblasts and leukocytes. Reciprocal 
interactions between tumor cells and their associated cells contribute to tumor progression. 
For instance, tumor cells can release interleukins or growth factors which in turn may induce 
leukocytes or fibroblasts to release growth factors that promote tumor progression (Goubran 
et al., 2014; Hanahan and Weinberg, 2011). Moreover, EMT is regulated by growth factors 
and interleukins such as TGF-β, EGF and IL-6, that are released from tumor-associated cells, 
thereby enhancing their invasive and migratory properties (Goubran et al., 2014; Lamouille et 
al., 2014; Tsai and Yang, 2013).
 In addition to tumor-associated cells, the extracellular matrix (ECM) in which the cells 
are embedded also contributes to tumor progression (Butcher et al., 2009; Pickup et al., 
2014)). In healthy tissues, the ECM is required for development and maintenance of tissue 
homeostasis (Mouw et al., 2014a). ECM composition is tissue-specific and tightly controlled 
by stromal cells, mainly fibroblasts. In addition to providing structural tissue integrity, the ECM 
regulates availability of cytokines and growth factors and plays a key role in processes such 
as migration, differentiation and proliferation. It is therefore not surprising that changes in ECM 
composition or physics can contribute to tumor progression (Box I + Bonnans et al., 2014; 
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Box I – Influence of ECM on the Hallmarks of Cancer
ECM composition and physics can affect the different hallmarks of cancer, which will 
be described in brief for each of these hallmarks (Pickup et al., 2014) (for invasion and 
metastasis see above).
Self-sufficiency in growth signals: adhesion of cells to the ECM via integrins is known to 
be required for optimal proliferation (Seguin et al., 2015a). By altering and/or increasing 
ECM production, tumor cells are able to prevent suppression of proliferation, allowing growth 
in inhospitable environments (Naba et al., 2014; Zahir and Weaver, 2004). In addition, 
stiffening of the ECM, which is often found in solid tumors, sensitizes cells for growth factor-
induced proliferation (Provenzano et al., 2009; Provenzano and Keely, 2011). This occurs 
via elevated ERK, PI3K and Rac signaling, which increase cyclin D1 expression, thereby 
accelerating cell cycle progression (Chambard et al., 2007; Provenzano et al., 2009).
Insensitivity to anti-growth signals: Proteins that block cell cycle progression, such as p53, 
PTEN and BRCA1, are often downregulated in cancers and their expression and activity 
can be regulated by the ECM. For instance, integrin ligation to ECM proteins has been 
shown to reduce expression of p15 and p21 leading to cell cycle arrest (Kim et al., 2008). 
Moreover, stiffening of the ECM may induce microRNA expression, causing a reduction 
in the expression of PTEN (Mouw et al., 2014b). Moreover, increased matrix stiffness can 
decrease expression of genes that block cell cycle progression (Schrader et al., 2011). This 
may occur by stiffness-induced translocation of the transcriptional regulators YAP and TAZ, 
which are known for their role in proliferation and apoptosis (Dupont et al., 2011).
Evasion of apoptosis: Ligation of cells to ECM proteins can inactivate pro-apoptotic 
pathways and activate anti-apoptotic pathways. In addition, the ECM may endow tumor 
cells with increased resistance to apoptosis induction. For instance, increased ECM stiffness 
is associated with a reduced response to chemotherapeutics, which may occur via integrin-
mediated suppression of p53-induced apoptosis (Hayashi et al., 2012; Lewis et al., 2002).
Limitless replicative potential: Cancer cells can reactivate telomerase, thus preventing 
telomerase shortening and enabling limitless replicative potential. However, no direct 
evidence has been found for ECM-mediated regulation of telomerase in cancer cells. On 
the other hand, epithelial cells expressing increased levels integrin β1 and EGFR showed 
enhanced telomerase activity (Kunimura et al., 1998).
Inducing angiogenesis: To provide tumor cells with necessary oxygen and nutrients, tumor 
cells are able to induce angiogenesis. The ECM contains both pro- and anti-angiogenic 
proteins such as VEGF family members, which are important drivers of angiogenesis. 
Angiogenesis requires the migration of endothelial cells into the tumor stroma, which can be 
stimulated by increased stromal stiffness (Liu and Agarwal, 2010; Mammoto et al., 2009). 
On the other hand, too much stiffness may compromise the integrity of newly formed vessels 
(Jones et al., 2006).
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Pickup et al., 2014). For example stiffening of the ECM is frequently observed in solid tumors, 
while high mammographic density correlates with an increased risk of developing breast 
cancer (Boyd et al., 2007). Similarly, fibrosis can predispose tissues to cancer development, 
which is the case during for instance liver cirrhosis (Sorensen et al., 1998).
 To maintain a healthy ECM, cells within a tissue need the ability to sense and respond 
to changes in ECM composition while loss of this ability can contribute to tumor progression. 
The ECM not only provides biochemical signals, but also delivers biomechanical/biophysical 
signals to cells (Humphrey et al., 2014). Whereas biochemical signals are sensed by a diverse 
set of receptors such as receptor tyrosine kinases or G-protein coupled receptors, the physical 
properties of the ECM are sensed by specialized adhesion structures such as focal adhesions 
and podosomes (Humphrey et al., 2014; van den Dries et al., 2014). The process of force 
sensing and transmission, followed by translation into a biochemical signal has been coined 
mechanotransduction.
 Adhesion structures act to relay mechanical signals from the ECM to the cytoskeleton, 
allowing cells to respond to changes in the mechanical composition of the ECM. This implies 
that these adhesion structures contain proteins that are able to transmit forces into the cell. 
Indeed, integrins, which provide the physical linkage between the ECM and the cytoskeleton, 
are able to sense and transmit forces to focal adhesion-associated proteins and the connected 
actomyosin cytoskeleton (Humphrey et al., 2014). Not surprisingly, altered integrin expression 
and function have been correlated with tumor progression (Seguin et al., 2015b). Whereas 
integrins are well-known for their role in mechanotransduction, ion channels, including TRP 
channel family members are also considered important transducers of mechanical signals 
(Box II). Hence, by interpreting (mechanical) signals from the tumor microenvironment and 
eliciting intracellular signaling TRP channels may contribute to metastasis formation.
TRP channels as environmental sensors
The TRP channel family of cation channels consists of 28 mammalian members, which are 
subdivided into six subfamilies, based on sequence homology: canonical (TRPC), vanilloid 
(TRPV), melastatin (TRPM), ankyrin (TRPA), polycystic (TRPP) and mucolipin (TRPML) TRP 
channels. The first TRP channel was identified in Drosophila, in which a mutation in the trp 
gene led to a transient instead of a prolonged photoreceptor response to light; hence the name 
transient receptor potential (Montell and Rubin, 1989). TRP channels are considered key 
players in sensory perception, including temperature, taste, light and pain (Clapham, 2003). In 
addition, TRP channels play a prominent role in the response to mechanical cues (Christensen 
and Corey, 2007; Lin and Corey, 2005; Pedersen and Nilius, 2007). TRP channels are part 
of macromolecular complexes that are linked to the actomyosin cytoskeleton (Clark et al., 
2008d; Montell, 2005). Consistently, several TRP channels regulate cytoskeletal dynamics in 
response to mechanical stimuli, thereby regulating biological processes such as migration, 
axonal outgrowth and endothelial alignment (see Chapter 2 and (Kuipers et al., 2012). 
However, evidence is emerging showing that TRP channels do not only exert immediate 
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Box II – Modes of mechanical activation of TRP channels
Biochemical outside-in signaling in cells occurs via the binding of extracellular ligands to 
ligand-specific receptors, which elicit intracellular signaling. In contrast, physical cues from for 
instance the ECM are able to activate intracellular signaling without the need of a molecular 
ligand. This process known as mechanotransduction can be divided into three consecutive 
steps: mechanotransmission, mechanosensing and a mechanoresponse (Hoffman et al., 
2011). Forces need to be transmitted to mechanosensitive proteins before they are sensed. 
Mechanotransmission typically occurs along cytoskeletal filaments, that are relatively stiff and 
stable. Subsequently, transmitted forces induce conformational changes in mechanosensitive 
proteins thereby altering their function. For instance, stretching of the integrin-binding protein 
talin, reveals a binding site for its interactor vinculin (del Rio et al., 2009). Mechanosensing 
ultimately results in a biological response. Force-induced vinculin binding to talin leads to 
strengthening and growth of adhesion sites. In addition, force sensing may cause translocation 
of transcriptional regulators to the nucleus, affecting gene expression (Dupont et al., 2011; 
Medjkane et al., 2009).
 Mechanosensitive ion channels can be operated by different modes of direct or indirect 
mechanical activation (Clark et al., 2008d). First, channels may be directly activated/opened 
by membrane stretch, thereby allowing ion influx. This has been described for NOMPC, a 
TRP channel homologue found in Drosophila (Yan et al., 2013). Second, channels can be 
activated by secondary messengers downstream of a mechanically activated receptor, such 
as angiotensin receptor (Zou et al., 2004). Finally, because TRP channels reside within 
macromolecular complexes that are linked to the actomyosin cytoskeleton, actomyosin-based 
tension may force channel opening. This either occurs by intracellularly-induced tension or by 
extracellular force transmitted to the actomyosin cytoskeleton (Clark et al., 2008d). However, 
in most cases it remains to be determined how TRP channels are activated by mechanical 
cues.
effects on cell behavior, but can also exert sustained effects via the (indirect) activation of 
transcription factors. For instance, TRPC channels are able to activate the calcineurin/NFAT 
pathway (Nijenhuis et al., 2011). Because of their role in mechanosensing, TRP channels also 
contribute to progression of diseases in which the physical environment is altered, such as 
hypertension, atherosclerosis (see Chapter 2 and (Kuipers et al., 2012). By taking a central 
role in sensing extracellular cues TRP channels may well contribute to cancer progression. 
Indeed, several TRP channels regulate cancer-associated processes such as proliferation and 
migration (Fiorio Pla and Gkika, 2013; Prevarskaya et al., 2011). Consequently, by interpreting 
(mechanical) cues, TRPM7 could contribute to cancer progression by controlling invasion, 
migration and transcriptional programs such as EMT. Indeed, as outlined below, its known 
functions make TRPM7 a likely metastasis-controlling protein.
TRPM7
TRPM7 was cloned and characterized in 2001 by Runnels and colleagues who at that time 
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named the protein TRP-PLIK (TRP-Phospholipase C-Interacting Kinase) (Runnels et al., 2001), 
which after receiving several names was renamed TRPM7, when TRP channel nomenclature 
was settled (Clapham et al., 2005; Montell et al., 2002). As its earliest name already suggested, 
TRPM7, in addition to being a channel, also functions as a kinase (see Box III for model of 
structure). A serine/threonine kinase domain, belonging to the family of atypical α-kinases, 
is fused C-terminally to the channel domain (Middelbeek et al., 2010). This channel-kinase 
bi-functionality is unique in nature and only its closest related TRP family member, TRPM6, 
contains a similar α-kinase domain. Because of its bi-functional properties TRPM7 is now also 
referred to as a ‘chanzyme’ (Krapivinsky et al., 2014). TRPM7 is ubiquitously expressed, but 
expression in humans is highest in bone, liver, heart and adipose tissue (Fonfria et al., 2006; 
Nadler et al., 2001).
TRPM7 regulation and activation
The channel domain of TRPM7 is constitutively open and non-selective, but under physiological 
conditions predominantly permeable to Mg2+ and Ca2+ (Penner and Fleig, 2007). There has 
however been a long standing debate about the biological significance of Mg2+ influx through 
TRPM7 pores. Initially it was shown that a growth arrest that was found in TRPM7-deficient 
chicken DT-40 B cells could be rescued by supplementing these cells with high levels of 
extracellular Mg2+ (Nadler et al., 2001; Schmitz et al., 2003). Furthermore, reduced intracellular 
[Mg2+] or Mg2+ influx was found in several TRPM7-deficient cells, including DT-40 B cells 
(Abed and Moreau, 2009; Chen et al., 2012; He et al., 2005). However, both TRPM7 knockout 
thymocytes, cardiac cells and neural stem cells did not have altered [Mg2+] and had a similar 
ability to mediate Mg2+ influx as compared to wildtype cells (Jin et al., 2008; Sah et al., 2013). 
On the other hand, several papers found that TRPM7 regulates both basal Ca2+ levels as 
well as localized and transient Ca2+ influxes (Clark et al., 2006; Langeslag et al., 2007; Visser 
et al., 2013; Wei et al., 2009). Moreover, it was recently shown that intracellular [Zn2+] was 
dependent on TRPM7 and that the kinase domain could be cleaved to exert a transcription 
regulatory function in a Zn2+-dependent manner (Krapivinsky et al., 2014). Together, these 
results suggest that ion influx through TRPM7 may differ depending on the cell type or for 
instance heteromerization with other TRP channels.
 The kinase domain belongs to the atypical α-type kinase family, which is a poorly 
characterized kinase family in mammalian cells (Middelbeek et al., 2010). In Dictyostelium, 
members of the α-kinase family mediate phosphorylation of the myosin heavy chain, which 
thereby regulate cytoskeletal dynamics by controlling myosin II filament stability. The closest 
mammalian kinase homologue of TRPM7, apart from TRPM6, is eukaryotic elongation factor-2 
kinase (eEF2K) (Middelbeek et al., 2010). While initially it was thought that the kinase domain was 
necessary for ion influx (Nadler et al., 2001; Runnels et al., 2001), it has now been established 
that it rather acts to phosphorylate downstream targets, which include annexin-1, eEF2k, 
PLCy2 and the three myosin II heavy chain isoforms (A, B and C) (Clark et al., 2006; Clark et 
al., 2008a; Clark et al., 2008b; Deason-Towne et al., 2012; Dorovkov et al., 2008; Dorovkov and 
Ryazanov, 2004; Matsushita et al., 2005). In addition, the kinase domain undergoes extensive 
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autophosphorylation, which appears to be necessary for recognition and phosphorylation of its 
substrates (Clark et al., 2008c; Matsushita et al., 2005; Ryazanova et al., 2004). Interestingly, 
phosphorylation of substrates is Ca2+-dependent, suggesting that channel activation induces 
Ca2+ influx to allow kinase-substrate interactions and subsequent phosphorylation. Recently, 
a surprising new function for the TRPM7 kinase domain was discovered. Krapivinsky and 
colleagues showed that the kinase domain can be cleaved, subsequently translocating to the 
nucleus to phosphorylate histone residues, in turn affecting expression of genes (Krapivinsky 
et al., 2014). That the kinase domain can be proteolytically cleaved was discovered earlier by 
Desai and colleagues, who showed that caspases can cause release of the kinase domain 
(Desai et al., 2012). 
Box III – TRPM7 structure and domains
The gene encoding TRPM7 is found on chromosome 15 and consists of 39 exons that span 
over 134.34 kb. Of the nine splice variants, only four encode protein variants. Full-length 
TRPM7 measures 7263 nucleotides which encode 1865 amino acids, leading to a protein of 
212.7 kDa in size.
 TRP channels contain six transmembrane domains or segments (S1-S6) of which 
a short stretch of amino acids between domains 5 and 6 contributes to the channel pore. 
Functional pores consist of either homo- or hetero tetramers, which allows the formation of a 
channel between the four amino acid stretches between domains 5 and 6 (Pedersen et al., 
2005). Transmembrane domains S1 to S4 are considered ‘sensor’ domains, parts of the protein 
that are able to bind ligands or that change in shape in response to physical stimuli, leading 
to opening or closing of the channel. For instance, capsaicin, a compound found in pepper, 
binds to the S2-S3 region of TRPV1, leading to pore opening and a subsequent artificial heat 
sensation (Caterina et al., 1997; Jordt and Julius, 2002). For TRPM7 there is no known direct 
biochemical ligand.
 Because TRP channels contain six transmembrane domains, their N- and C-termini are 
located in the cytoplasm. These cytoplasmic domains have a diverse range of functions and 
contain ankyrin repeats for protein-protein interactions, calmodulin-binding sites and enzymatic 
domains (Pedersen et al., 2005). The N-terminus of TRPM7 contains four regions of high 
sequence homology, the so-called TRPM homology regions (MHRs), which are only found in 
the TRPM subfamily. However, no high sequence homology of MHRs is found outside of the 
TRPM subfamily. It is suggested that these stretches function in oligomerization or trafficking of 
TRPM channels. At the C-terminal side, proximal to S6, there is a conserved stretch of amino 
acids that has been termed the TRP box, since it is present in all TRP channels. The TRP box 
is followed by a coiled-coil region (CCR), which is specific for members of the TRPM subfamily 
and likely involved in oligomerization (Fujiwara and Minor, 2008). In TRPM6 and TRPM7, 
a serine/threonine-rich domain is present immediately C terminal to the CCR. This domain 
is heavily phosphorylated by the C-terminal kinase domain, allowing it to associate with the 
actomyosin cytoskeleton (Clark et al., 2008c). 
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Box III – continued
N C
MHR
TRP box
CCR
Serine/threonine
rich region
α-kinase domain
S1 S3 S5 S6
Pore forming
domain
‘Sensor’
domain
Extracellular
Intracellular
 Channel activity can be inhibited by free intracellular Mg2+ and Mg2+-nucleotides (Nadler 
et al., 2001; Penner and Fleig, 2007). Consequently, reducing intracellular Mg2+ increases 
channel activity (Penner and Fleig, 2007). In addition, TRPM7 channel activity is sensitive to 
G-protein coupled receptor signaling (Langeslag et al., 2007), pH (Jiang et al., 2005; Kozak et 
al., 2005), cAMP (Takezawa et al., 2004) and PLC/PIP2 (Gwanyanya et al., 2006; Langeslag 
et al., 2007; Macianskiene et al., 2008; Runnels et al., 2002). Furthermore, TRPM7 activity can 
also be modulated by mechanical cues. Oancea and colleagues initially described that TRPM7 
currents increase in response to shear stress exerted by fluid flow, as a result of fusion of 
TRPM7-containing vesicles with the plasma membrane (Oancea et al., 2006). Two additional 
papers showed that TRPM7 activity is directly regulated by osmosis-induced cell swelling 
(Numata et al., 2007a, b). However, these results were contradicted in another paper, in which 
it was suggested that rather than being activated by swelling, TRPM7 activity is responsive to 
molecular crowding of solutes induced by osmosis (Bessac and Fleig, 2007). More recently, 
TRPM7 was found to mediate mechanically-induced local and transient ‘Ca2+-flickers’ in the 
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leading edge of fibroblasts (Wei et al., 2009). Similar mechanically-induced and TRPM7-
mediated Ca2+ signals were found in smooth muscle cells, osteoblasts and mesenchymal stem 
cells (Roy et al., 2014; Song et al., 2014; Xiao et al., 2015).
 In addition to these physiological regulators of TRPM7, a number of compounds 
have been shown to regulate TRPM7 activity (Chubanov et al., 2014). Inhibitors of TRPM7 
include 2-APB, NS8593, NDGA and Waixenicin A. Although most of these compounds are not 
specific for TRPM7, Waixenicin A, a compound isolated from the soft coral species Sarcothelia 
edmondsoni, seems to be an exception, showing selectivity for TRPM7 (Chubanov et al., 
2014; Zierler et al., 2011). In addition, a number of compounds are able to increase activity 
of TRPM7. These include naltriben, clozapine and doxepin (Hofmann et al., 2014). Of these 
compounds, naltriben has been tested in further detail and was shown not to act on other 
TRP channels tested and interfered with the inhibitory effect of NS8593, which makes it an 
interesting compound to use in TRPM7-related research subjects (Hofmann et al., 2014).
TRPM7 function in biological and pathological processes
There is a large body of literature showing a role for TRPM7 in different physiological and 
developmental processes, such as embryonic development, cell proliferation, migration and 
differentiation. 
 TRPM7 is essential for early embryonic development; embryos deficient for TRPM7 
die around embryonic day 7.5 (E7.5) (Jin et al., 2008). However, when TRPM7 is lost at later 
stages during embryonic development (>E14.5), mice are viable and develop without any major 
developmental defects (Jin et al., 2012). The Clapham laboratory further studied the tissue 
specific role of TRPM7 during embryonic development using conditional TRPM7 knockout 
mice. For instance, TRPM7 knockout in the T-cell lineage led to disrupted thymopoiesis (Jin et 
al., 2008). In addition, TRPM7 deletion in the metanephric mesenchyme, from which nephrons 
derive, resulted in abnormal kidney development (Jin et al., 2012). In contrast, when deleted 
in the ureteric bud, from which collecting ducts derive, kidneys appeared normal, showing a 
spatiotemporal requirement of TRPM7 during kidney development (Jin et al., 2012). Similarly, 
loss of TRPM7 expression in the brain after E10.5 does not affect mouse brain development (Jin 
et al., 2012). When deleted in the neural crest at early developmental stages, a loss of pigment 
cells and dorsal ganglion neurons was observed (Jin et al., 2012). In the mouse heart, TRPM7 
is required for proper development up to E9, but no effect was found when deleted during 
later stages of cardiac development (>E12.5) (Sah et al., 2013). Further evidence for a role for 
TRPM7 in development was found in Xenopus and zebrafish. In Xenopus, both overexpression 
and downregulation using morpholinos directed against TRPM7 severely affected gastrulation 
(Liu et al., 2011). In zebrafish, morpholino-induced loss of TRPM7 and expression of TRPM7 
mutants affects development of skin melanophores, the skeleton, exocrine pancreas and 
dopaminergic neurons (Decker et al., 2014; Elizondo et al., 2005; McNeill et al., 2007; Yee et 
al., 2011).
 Initially, it was observed that targeted deletion of both TRPM7 alleles in DT-40 B cells 
induced a failure in the long-term survival of cell clones (Nadler et al., 2001; Schmitz et al., 
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2003). This observation suggested that TRPM7 is critical for cell survival. Indeed, several 
additional studies reported that TRPM7 functions in cell proliferation, growth and survival of 
cells including mast cells, retinoblastoma cells and breast cancer cells (reviewed in (Visser 
et al., 2014). However, others observed that either complete loss of TRPM7 using knockout 
models, or stable knockdown of TRPM7 does not affect cell proliferation or viability (Jin et 
al., 2008; Jin et al., 2012; Sah et al., 2013). Loss of TRPM7 was even shown to enhance 
growth of endothelial cells (Inoue and Xiong, 2009). These discrepancies may be explained 
by differences in the amount of TRPM7 reduction, cell type specific functions of TRPM7, 
compensatory mechanisms when TRPM7 is removed or methodological differences used to 
decrease TRPM7 expression levels (e.g. transient vs stable knockdown). How exactly TRPM7 
affects proliferation remains to be established for most cells. One suggestion was given by 
Sahni and Scharenberg, who showed that growth arrest in TRPM7-deficient lymphocytes 
could be rescued by activation of the PI3K/AKT/mTOR pathway, which plays a critical role in 
cell cycle regulation (Sahni and Scharenberg, 2008).
 Another prominent feature of TRPM7 is its role in adhesion dynamics and migration. 
Earlier research in our group showed that moderate overexpression of TRPM7 in N1E-115 
mouse neuroblastoma cells caused relaxation of the actyomyosin cytoskeleton, increased cell 
spreading, actin reorganization and the formation of invadosomes (invadopodia/podosomes) 
(Clark et al., 2006). Accordingly, RNAi-mediated knockdown of TRPM7 in HEK cells increased 
the formation of focal adhesions (Su et al., 2006).
 Adhesion dynamics and migration are intimately linked. It is therefore not surprising 
that TRPM7 has an effect on migratory properties of cells. Indeed, there is a growing list of 
publications showing that TRPM7 regulates migration in vitro, including several tumor cell lines, 
but also in ‘normal’ cells such as fibroblasts, endothelial cells and vascular smooth muscle cells 
(see (Visser et al., 2014) for a comprehensive list). Although in most cells TRPM7 expression 
or activity positively correlates with migration, loss of TRPM7 was shown to enhance migration 
in some cell types. For instance, TRPM7 knockdown in HUVECs or HEK-293 increases 
migration (Baldoli et al., 2013; Su et al., 2006; Zeng et al., 2014). Moreover, very recently it was 
shown that TRPM7 knockdown or inhibition using waixenicin A, increased axonal outgrowth, a 
process related to migration (Turlova et al., 2014).
 How TRPM7 exactly affects adhesion and migration is not fully understood, although 
both cation influx and substrate phosphorylation by the kinase domain seem to be involved. 
Moreover, downstream signaling might differ between different cell types, depending on 
heteromerization with other TRP channels and distinct composition of macromolecular 
complexes associated with TRPM7 (Chapter 2 and (Kuipers et al., 2012). Local and transient 
TRPM7-dependent Ca2+ influxes were shown to be required for directed migration of fibroblasts 
(Wei et al., 2009). Mg2+ influx through TRPM7 was also suggested to affect adhesion and 
migration (Abed and Moreau, 2009; Callera et al., 2009; Rybarczyk et al., 2012; Su et al., 
2011). In addition, TRPM7-induced increases in reactive oxygen species (ROS) and nitric 
oxide (NO) caused activation of p38 MAPK and JNK (Su et al., 2010), leading to activation of 
m-calpain, a protease involved in cell adhesion regulation (Wells et al., 2005). However, we 
20 |
Chapter 1
recently showed that TRPM7-induced formation of invadosomes in N1E-115 cells was neither 
dependent on transient Ca2+ influx nor on basal increases in [Ca2+] (Visser et al., 2013). On 
the other hand, waixenicin A-mediated inhibition of TRPM7 caused a contractile response and 
rapid dissolution of invadosomes and formation of focal adhesions in N1E-115 cells (Visser et 
al., 2013). This is in agreement with our observation that TRPM7 regulates actomyosin based 
tension (Clark et al., 2006). We previously showed that TRPM7 interacts with the actomyosin 
cytoskeleton in a Ca2+- and kinase-dependent manner (Clark et al., 2006). In addition, we 
showed that, similar to its relatives in Dictyostelium, the TRPM7 kinase domain is able to 
phosphorylate the myosin heavy chain-II, causing dissolution of myosin II filaments, which in 
turn leads to reduced actomyosin-based cellular tension (Clark et al., 2006; Clark et al., 2008a; 
Clark et al., 2008b; Guilbert et al., 2013).
TRPM7 and cancer
The above described functions of TRPM7 are likely to play an important role in determining 
cancer cell behavior. First of all, cancer cells are able to adopt developmental programs, such 
as EMT, to enhance their metastatic properties. Secondly, affected control over proliferation 
and survival is one of the hallmarks of cancer. Finally, cell migration is crucial for effective 
metastasis to occur. By responding to changes in the physical microenvironment TRPM7 may 
regulate these functions.
 A few papers have indeed linked TRPM7 expression to tumor progression. For 
instance, a TRPM7 polymorphism (T1482I), which showed an increased sensitivity to Mg2+ 
inhibition (Hermosura et al., 2005), was found to increase the risk of colorectal adenoma or 
hyperplastic polyps, when combined with a high Ca2+/Mg2+ diet (Dai et al., 2007). In addition, 
TRPM7 expression was found to be higher in tumor tissue of the breast (Dhennin-Duthille 
et al., 2011; Guilbert et al., 2009). However, if TRPM7 expression levels are of prognostic 
value in (breast) cancer patients or if and how TRPM7 contributes to metastasis formation 
has remained unexplored. Furthermore, the signaling mechanisms downstream of TRPM7 
have remained elusive. As a regulator of cytoskeletal dynamics, can TRPM7 be considered a 
general regulator of cancer cell migration? Does TRPM7 affect transcriptional programs that 
are involved in metastasis formation, such as EMT, and if so via which mechanisms?
Scope of this thesis
TRPM7 functions in a wide variety of physiological processes, including proliferation, adhesion, 
cytoskeletal dynamics and differentiation, each of which are important to cancer progression. 
Therefore, as part of this thesis work, we have tried to answer if and how TRPM7 may 
contribute to cancer progression. In Chapter 2, the role of TRP channels in mechano-regulated 
cytoskeletal dynamics in a diverse set of biological processes is discussed, highlighting the 
function of these channels as interpreters of mechanical signals.
 In Chapter 3 we explore the role of TRPM7 in breast cancer metastasis. We show in 
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two independent breast cancer patient cohorts that TRPM7 mRNA expression levels at the time 
of diagnosis correlate with poor patient survival and distant metastasis formation. Moreover, 
loss of TRPM7 expression in highly invasive breast cancer cells affects the metastatic potential 
of these cells in mouse xenografts. In vitro analysis of the cell behavior and biology revealed 
that TRPM7 is required for the migratory potential of breast cancer cells and maintains a 
‘relaxed’ state of the cytoskeleton. In Chapter 4, we follow up on these findings and put 
forward the hypothesis that TRPM7’s tension-regulating abilities might be coupled to its role 
in differentiation, affecting gene expression programs involved in metastasis formation. We 
find that TRPM7 maintains the mesenchymal phenotype of mesenchymal breast cancer cells 
by regulating expression of the EMT transcription factor SOX4. Moreover, SOX4 expression 
inversely correlates with cytoskeletal tension, which indicates that TRPM7 preserves SOX4 
expression by maintaining mesenchymal cells in a ‘relaxed’ tensional state. In Chapter 
5 we describe a function for TRPM7 in neuroblastoma metastasis formation. Similar to our 
findings in breast cancer cells, TRPM7 affects the migratory and metastatic potential of several 
neuroblastoma cells. In these neuroblastoma cells, TRPM7 regulates expression of the EMT 
transcription factor SNAI2, showing that TRPM7 exerts control over EMT in several cancer 
types. In Chapter 6, we studied the TRPM7 target gene RhoJ, a Rho GTPase with similar 
cytoskeletal-regulatory functions as TRPM7 and therefore a possible contributor to a TRPM7-
governed phenotype.
 In Chapter 7, the findings in this thesis are discussed in relation to the literature and 
preliminary data and are integrated into a model describing how TRPM7 may control metastatic 
behavior.
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Abstract
The ability of cells to respond to mechanical stimulation is crucial to a variety of biological 
processes, including cell migration, axonal outgrowth, perception of pain, cardiovascular 
responses and kidney physiology. The translation of mechanical cues into cellular responses, 
a process known as mechanotransduction, typically takes place in specialized multiprotein 
structures such as cilia, cell-cell or cell-matrix adhesions. Within these structures, mechanical 
forces such as shear stress and membrane stretch activate mechanosensitive proteins, 
which set off a series of events that lead to altered cell behavior. Members of the transient 
receptor potential (TRP) family of cation channels are emerging as important players in 
mechanotransductory pathways. Localized within mechanosensory structures, they are 
activated by mechanical stimuli and trigger fast as well as sustained cytoskeletal reponses. In 
this review, we will provide an overview of how TRP channels affect cytoskeletal dynamics in 
various mechano-regulated processes. 
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Introduction
Many basic cellular functions, particularly cell proliferation, differentiation, adhesion and 
migration, are dependent on mechanical forces. As a consequence, cellular responses to 
mechanical cues are essential for proper embryonic development as well as for maintaining 
healthy organ physiology (Eyckmans et al., 2011). The translation of mechanical cues into 
biochemical signals has been coined ‘mechanotransduction’. This process involves force 
transmission and the perception of force, followed by a distinct cellular response. Cell adhesion 
structures as well as cilia play a central role in this sequence of events (Gardel et al., 2010; 
Geiger et al., 2009). Force transmitted through adhesion sites can induce conformational 
changes in mechanosensitive proteins, present either in the plasma membrane or the 
underlying cytoskeleton, which in turn leads to the activation of downstream signaling events. 
For instance, force-induced stretching of focal adhesion protein talin reveals cryptic binding 
sites for its interactor vinculin (del Rio et al., 2009). Binding of vinculin to stretched talin is 
necessary for the growth of adhesion sites (Humphries et al., 2007). Alternatively, mechanically 
activated cation channels trigger local Ca2+ signaling events to affect downstream cellular 
responses. Similar to integrin-mediated mechanisms of mechanotransduction, mechanically-
activated cation channels affect cytoskeletal organization and cell behavior. These effects 
include immediate responses, through the local regulation of cytoskeletal proteins, as well as 
more sustained effects, for instance by activation of Ca2+-sensitive transcription factors such as 
members of the nuclear factor of activated T cells (NFAT) family. Although a variety of different 
cation channels has been implicated in the perception and interpretation of mechanical forces 
(Arnadottir and Chalfie, 2010), this review focuses on the emerging roles of transient receptor 
potential (TRP) channels as mechanosensors.
TRP channels
Members of the TRP cation family are considered important relays of mechanical signals (Table 
1). In support of this notion, TRP channels have been implicated in mechanotransduction-
related pathologies, such as progressive renal failure (Dietrich et al., 2010), cardiovascular 
diseases  (Firth et al., 2007; Vennekens, 2011), hearing and balance disorders (Cuajungco 
et al., 2007), neuropathic pain syndromes (Levine and Alessandri-Haber, 2007) and cancer 
(Lehen’kyi and Prevarskaya, 2011; Prevarskaya et al., 2011).
 TRP channels were first identified in Drosophila, where they were found to be essential 
for proper photoreceptor function in complex with cytoskeletal proteins (Montell and Rubin, 
1989) (for review see (Minke and Cook, 2002). To date, 28 mammalian TRP channels have 
been identified (Ramsey et al., 2006). Based on sequence homology, TRP channels are 
subdivided into six subfamilies: canonical TRP channels (TRPC), melastatin TRP channels 
(TRPM), vanilloid TRP channels (TRPV), mucolipin TRP channels (TRPML), polycystin 
TRP channels (TRPP) and ankyrin TRP channels (TRPA). TRP channels usually contain six 
transmembrane domains, of which transmembrane domain 5 and 6 contribute to the channel 
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TRP 
channel
Mechanical 
stimulus Biol. Process Cell type
Mech. 
Structure Mechanism
Related 
pathologies References
TRPC1 Shear stress 
- forms 
heteromeric 
channels with 
TRPV4
Cardiovascular 
homeostasis
EC NS. Cooperates with 
TRPV4 in promoting 
VSMC relaxation
- Ma 2010
Indirect via 
mechanically 
activated 
GPCR (AT1R)
Cardiovascular 
homeostasis
Cardiac 
myocytes
NS. Loss of TRPC1 
prevents mechanical 
stress-induced 
pathologic cardiac 
remodeling
Cardiac 
hypertrophy
Seth 2009
NS. - forms 
heteromeric 
channels with 
TRPP2
NS.
Renal 
epithelial cells
Primary 
cilia
NS. - Kobori 2009; 
Raychowdhury 
2005
TRPC3 Indirect via 
mechanically 
activated 
GPCR (AT1R)
Cardiovascular 
homeostasis
Cardiac 
myocytes
NS. Calcineurin/NFAT 
mediated activation of 
fetal gene expression 
program
Cardiac 
hypertrophy
Bush 2006; 
Onohara 2006
TRPC4 NS. - likely to 
be activated 
by shear 
stress
Cardiovascular 
homeostasis
EC AJ Increasing vascular 
permeability 
(hypothetically 
through AJ 
disassembly )
- Graziani 2010; 
Tirupatthi 2006
TRPC6 NS. - interacts 
with TRPV4
Mechanical 
nociception 
Nociceptors NS. Essential for TRPV4-
mediated mechanical 
hyperalgesia
Mechanical 
hyperalgesia
Alessandri-
Haber 2009
Indirect via 
mechanically 
activated 
GPCR (AT1R)
Cardiovascular 
homeostasis
Cardiac 
myocytes
NS. Calcineurin/NFAT 
mediated activation of 
fetal gene expression 
program
Cardiac 
hypertrophy
Kuwahara 
2006; Onohara 
2006
Indirect via 
mechanically 
activated 
GPCR (AT1R)
Glomerular 
filtration
Podocytes Slit 
diaphragm
Dissolution of actin 
fibers  & calcineurin/
NFAT mediated gene 
expression
Progressive 
kidney 
failure
Asanuma 2006; 
Faul 2008; 
Wang 2010
TRPV1 NS. Mechanical 
nociception 
Nociceptors NS. Triggers microtubule 
disassembly
Mechanical 
hyperalgesia
Jones 2005; 
Goswami 2007
TRPV2 Mechanical 
stretch - 
unknown 
whether direct 
or indirect
Axonal 
outgrowth
NeuroNS. NS. Stretch-induced axon 
outgrowth
- Shibasaki 2010
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TRP 
channel
Mechanical 
stimulus Biol. Process Cell type
Mech. 
Structure Mechanism
Related 
pathologies References
TRPC1 Shear stress 
- forms 
heteromeric 
channels with 
TRPV4
Cardiovascular 
homeostasis
EC NS. Cooperates with 
TRPV4 in promoting 
VSMC relaxation
- Ma 2010
Indirect via 
mechanically 
activated 
GPCR (AT1R)
Cardiovascular 
homeostasis
Cardiac 
myocytes
NS. Loss of TRPC1 
prevents mechanical 
stress-induced 
pathologic cardiac 
remodeling
Cardiac 
hypertrophy
Seth 2009
NS. - forms 
heteromeric 
channels with 
TRPP2
NS.
Renal 
epithelial cells
Primary 
cilia
NS. - Kobori 2009; 
Raychowdhury 
2005
TRPC3 Indirect via 
mechanically 
activated 
GPCR (AT1R)
Cardiovascular 
homeostasis
Cardiac 
myocytes
NS. Calcineurin/NFAT 
mediated activation of 
fetal gene expression 
program
Cardiac 
hypertrophy
Bush 2006; 
Onohara 2006
TRPC4 NS. - likely to 
be activated 
by shear 
stress
Cardiovascular 
homeostasis
EC AJ Increasing vascular 
permeability 
(hypothetically 
through AJ 
disassembly )
- Graziani 2010; 
Tirupatthi 2006
TRPC6 NS. - interacts 
with TRPV4
Mechanical 
nociception 
Nociceptors NS. Essential for TRPV4-
mediated mechanical 
hyperalgesia
Mechanical 
hyperalgesia
Alessandri-
Haber 2009
Indirect via 
mechanically 
activated 
GPCR (AT1R)
Cardiovascular 
homeostasis
Cardiac 
myocytes
NS. Calcineurin/NFAT 
mediated activation of 
fetal gene expression 
program
Cardiac 
hypertrophy
Kuwahara 
2006; Onohara 
2006
Indirect via 
mechanically 
activated 
GPCR (AT1R)
Glomerular 
filtration
Podocytes Slit 
diaphragm
Dissolution of actin 
fibers  & calcineurin/
NFAT mediated gene 
expression
Progressive 
kidney 
failure
Asanuma 2006; 
Faul 2008; 
Wang 2010
TRPV1 NS. Mechanical 
nociception 
Nociceptors NS. Triggers microtubule 
disassembly
Mechanical 
hyperalgesia
Jones 2005; 
Goswami 2007
TRPV2 Mechanical 
stretch - 
unknown 
whether direct 
or indirect
Axonal 
outgrowth
NeuroNS. NS. Stretch-induced axon 
outgrowth
- Shibasaki 2010
TRPV4 NS. - interacts 
with a2b1 
integrins and 
SRC
Mechanical 
nociception
Nociceptors NS. Triggers microtubule 
disassembly
Mechanical 
hyperalgesia
Alessandri-
Haber 
2003,2004; 
Goswami 2010
Shear stress Cardiovascular 
homeostasis
EC Primary 
cilia
Promoting VSMC 
relaxation
- Mendoza 2010
Mechanical 
stretch
Cardiovascular 
homeostasis
EC FA Realignment of FAs 
and stress fibers
- Thodeti 2009; 
Katoh et al 
2008
NS. - forms 
heteromeric 
channels with 
TRPP2
NS. Renal 
epithelial cells
Primary 
cilia
NS. - Kotggen 2008
NS. NS. Keratinocytes AJ AJ assembly - Sokabe et.al., 
2010
TRPM7 Shear stress 
- unknown 
whether direct 
or indirect
Migration Various FA Adhesion dynamics  
via activation calpain 
and phosphorylation 
MHC
Cancer Clark 2006; 
Langeslag 
2007; Wei 2009
Indirect by 
mechanically 
activated 
GPCR (BKR)
TRPP1/ Shear stress Cardiovascular 
homeostasis
EC Primary 
cilia
Promoting VSMC 
relaxation
- AbouAlaiwi 
2009; Nauli 
2008
TRPP2
Blood 
pressure
Cardiovascular 
homeostasis
VSMC NS. TRPP1/TRPP2 
ratio regulates SAC 
mechanoseNS.itivity
- Sharif-Naeini 
2009
Shear stress NS. Renal 
epithelial cells
Primary 
cilia
NS. ADPKD Nauli 2003
NS. - likely 
through 
its direct 
interaction 
with the ECM
NS. NS. FA Regulates FA 
dynamics by 
interacting with FAK 
and paxillin
- Joly 2006; 
Israeli 2010
NS. - likely to 
be activated 
by shear 
stress
Cardiovascular 
homeostasis
EC AJ AJ disassembly - Boca 2007
Table 1. TRP channels are involved in mechano-regulated biological processes. 
ADPKD, autosomal dominant polycystic kidney disease; AJ, adherens junctions; AT1R, angiotensin II type 1 
receptor; BKR, bradykinin receptor; EC, endothelial cells; ECM, extracellular matrix; FA, focal adhesions; FAK, 
focal adhesion kinase; MHC, myosin heavy chain; NFAT, nuclear factor of activated T cell; NS., not specified; SAC, 
stretch-activated ion channels; VSMC, vascular smooth muscle cells.
34 |
Chapter 2
pore (Clapham, 2003). An exception to this rule is TRPP1 (also known as polycystin-1), which 
contains 11 transmembrane domains of which the C-terminal 6 transmembrane domains are 
highly homologous to TRP-like channel domains. In contrast to the other TRP-family members, 
TRPP1 does not contain a functional channel domain and it is therefore a point of debate 
whether TRPP1 is a bona fide TRP channel (Wu et al., 2010a). The N- and C-terminal ends of 
TRP channels are cytoplasmic and comprise a large variety of additional functional domains, 
such as domains that mediate protein-protein interactions as well as domains that exhibit a 
specific enzymatic activity. In addition, TRP cytoplasmic domains play a role in multimerization. 
Functional channels are formed by homo- or heteromerization of TRP channel subunits, 
usually in a tetrameric organization, and the specific composition of these multimeric channels 
determines their characteristics (Clapham, 2003).
 TRP channels play an essential role in the perception of sensory information, such 
as temperature sensing, smell and taste (Damann et al., 2008). The role of TRP channels 
in mechanotransduction has been appreciated for about a decade (Montell, 2001) but for 
most TRP channels it remains unclear whether they are directly gated by mechanical stress 
or act downstream of mechanically activated signaling cascades (Christensen and Corey, 
2007). Several mechanisms that lead to TRP channel activation in response to mechanical 
stimulation have been described. First of all, channel opening can be induced by stretch-
induced membrane tension (Kang et al., 2010). Secondly, TRP channels associated with 
the cytoskeleton may be opened in response to actomyosin-induced tension (Clark et al., 
2008). Thirdly, mechanosensitive proteins in complex with TRP channels may affect channel 
opening (Clark et al., 2008). For instance, force exerted on integrin-containing adhesion sites 
will lead to increased actomyosin tension, which in turn may induce channel opening. Finally, 
mechanically activated receptors, such as the angiotensin II receptor (Zou et al., 2004) and 
the bradykinin receptor (Chachisvilis et al., 2006) can trigger TRP channel opening through the 
activation of second messenger signaling cascades (Large et al., 2009; Mederos y Schnitzler 
et al., 2008). Finally, force-induced stretch can increase plasma membrane expression of TRP 
channels by promoting the translocation of vesicle-stored TRP channels (Oancea et al., 2006).
 TRP channels form large macromolecular complexes linked to the actomyosin 
cytoskeleton which may serve to localize signal transduction pathways and/or enhance the 
rate of signal transmission. Such macromolecular complexes were first identified in Drosophila 
and were termed ‘signalplexes’ (Montell, 2005). In mammalian cells, proteomic analyses of 
TRPC5 and -6 associated molecules identified several binding partners involved in cytoskeletal 
dynamics and endocytosis, including drebrin, α-actinin and dynamin (Goel et al., 2005). It 
now seems that the interaction with the cytoskeleton within multiprotein complexes is a more 
general feature of this cation channel family (reviewed in (Clark et al., 2008; Goswami and 
Hucho, 2008). Here, we will review recent literature on mechanoregulation of cytoskeletal 
dynamics by TRP channels, describing those cellular and biological processes in which TRP 
channel function has been well-established.
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Figure 1. Mechanically triggered TRP channel activation regulates cytoskeletal dynamics. (A) Shear stress 
by fluid flow physically bends primary cilia, which leads to activation of TRP channels. Subsequent Ca2+ influx 
affects VSMC cytoskeletal dynamics by inducing the release of vasodilators such as NO and EDHF. (B) & (C) Shear 
stress and force applied directly to cell-matrix or cell-cell adhesions locally activate TRP channels by interacting with 
adhesion molecules, such as integrins. TRP channel-mediated Ca2+ influx affects cell-matrix and cell-cell adhesion 
turnover by regulating cytoskeletal contractility, modulating the activity of FAK (cell-matrix) and activating the Ca2+ 
dependent protease calpain, which cleaves adhesion plaque molecules. (C) & (D) Mechanically activated G-protein 
coupled receptors (GPCRs), such as the angiotensin II type 1 receptor, can trigger TRP channel opening through 
activation of PLC signaling. Subsequent Ca2+ influx activates the calcineurin/NFAT pathway, leading to changes in 
transcription of genes involved in cytoskeletal dynamics.
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TRP channels in mechanosensing structures
 
Cilia
Cilia are microtubule-based, finger-like cell protrusions that can be found on most cell types, 
although best described in epithelial cells and vascular endothelial cells (ECs). Mechanical 
stimulation of cilia elicits local Ca2+ signaling events that affect the motile properties of cilia 
and activate downstream signaling pathways (Jones and Nauli, 2012; Salathe, 2007). Cilia 
are divided into cilia that are either motile or immotile. Motile cilia are essential in mediating 
movement of extracellular fluids along cell surfaces, such as the removal of mucus from the 
airways. The ciliary beat frequency (CBF), the frequency of ciliary bending which is mediated by 
dynein-dependent sliding of microtubules, and subsequent relaxation, is controlled by both the 
chemical and mechanical characteristics of the fluid (Salathe, 2007). Mechanical stimulation of 
ciliated cells, for example by increased mucus load or viscosity, activates Ca2+ influx pathways 
that in turn, increase CBF which is sustained even after Ca2+-influx drops back to basal 
levels (Salathe, 2007). Interestingly TRPV4 was shown to be necessary for Ca2+-dependent 
increases in CBF after exposure to increased viscous load in both hamster oviductal cells 
and mouse ciliated tracheal cells (Andrade et al., 2005; Lorenzo et al., 2008). How increased 
Ca2+ influx results in increased CBF remains to be elucidated. However, it is likely that Ca2+-
activated proteins regulate dynein-dependent sliding of microtubules. In addition, Ca2+ influx 
may activate kinases or phosphatases to sustain the elevation in CBF (Salathe, 2007).
 Immotile or primary cilia function in a wide range of sensory processes, including 
odorant detection, photoreception and mechanosensation (Berbari et al., 2009; Praetorius 
et al., 2003; Praetorius and Spring, 2001). Primary cilia are sensitive to touch, pressure 
and shear stress exerted by fluid flow. Nauli and colleagues were the first to show that TRP 
channels are required for mechanosensation by primary cilia (Fig. 1A). Mouse kidney cells 
lacking functional TRPP1 or TRPP2, which localize to primary cilia, exhibit perturbed Ca2+ 
responses after stimulation by shear stress (Nauli et al., 2003). TRPP1 and TRPP2 were 
shown to act as a heteromeric complex involved in mechanosensing (Hanaoka et al., 2000; 
Nauli et al., 2003). In this complex, TRPP1 may function as the mechanosensor, as the 
N-terminal tail of TRPP1 can be stretched when force is applied (Forman et al., 2005; Qian 
et al., 2005), while Ca2+ influx is mediated by TRPP2. Strikingly, mutations in either TRPP1 or 
TRPP2 were found to be causal for the development of autosomal dominant polycystic kidney 
disease (ADPKD), which is characterized by renal and extrarenal cysts. In addition, ADPKD 
patients, show cardiovascular complications, such as hypertension and aneurysms (Torres 
and Harris, 2009). Loss of TRPV4, which also localizes to primary cilia and interacts with 
TRPP2, similarly abolishes shear stress-induced Ca2+ influx in renal epithelial cells (Kottgen et 
al., 2008). Additionally, TRPC1, another TRP channel localized to primary cilia, also interacts 
with TRPP2 to form heteromeric channels (Kobori et al., 2009; Raychowdhury et al., 2005; 
Tsiokas et al., 1999). This suggests that TRPP1/TRPP2, TRPC1 and TRPV4 are part of a 
heteromeric mechanosensing channel in primary cilia. How the loss of mechanosensing in 
primary cilia contributes to the development of cysts remains unclear. It has been suggested 
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that perception of the direction of flow is required for proper cell alignment and hence, tissue 
morphogenesis (Fischer et al., 2006).
Cell adhesion structures
Integrin-containing cell-matrix adhesions, such as focal adhesions (FAs), physically and 
functionally link the extracellular matrix (ECM) to the actomyosin cytoskeleton. These 
macromolecular assemblies not only provide anchorage to the cell, but also form large 
signaling hubs that constantly probe the ECM, affecting basic cellular functions such as 
cell proliferation, survival, differentiation and motility. Similarly, cadherin-mediated cell-cell 
adhesion by adherens junctions (AJs) and desmosomes not only maintain tissue polarity and 
integrity but also steer cellular processes involved in tissue morphogenesis (Takeichi, 2011). 
Importantly, the formation, maturation and turnover of both cell-matrix and cell-cell adhesions 
are determined by the mechanical forces perceived by the structure itself (Gardel et al., 2010; 
Geiger et al., 2009; Gomez et al., 2011; Leckband et al., 2011). For instance, cells grow larger 
and more stable FAs on rigid substrates in comparison to more pliable substrates, which show 
irregular and highly dynamic FAs (Pelham and Wang, 1997). In addition, increased substrate 
rigidity, sensed through FAs, enhances cytoskeletal contractility and increases stress fiber 
formation (Discher et al., 2005). Likewise, force generated by the actomyosin cytoskeleton 
is required for formation and remodeling of endothelial hormone-induced cadherin-mediated 
adhesions (Huveneers et al., 2012).
 Local Ca2+ signaling plays an essential role in regulating cell adhesion dynamics. For 
instance, the disassembly of FAs in the rear of migrating cells is achieved by actomyosin-
based contraction, which involves phosphorylation of the myosin regulatory light-chain (MLC) 
by the Ca2+-dependent MLC kinase (Ridley et al., 2003). In addition, cleavage of FA proteins 
such as talin, vinculin and FAK by the Ca2+-dependent protease calpain plays an important role 
in FA disassembly allowing the rear end of the cell to retract (Ridley et al., 2003). Moreover, 
residency of focal adhesion kinase (FAK), an essential protein in FA turnover, is enhanced by 
Ca2+ (Giannone et al., 2004).
 Recently, local transient Ca2+ signals were found at the leading edge of migrating 
fibroblasts. These ‘Ca2+ flickers’ are mediated by shear stress-activated TRPM7 and are 
required for chemotactic turning of the leading edge (Wei et al., 2009). This suggests that, 
in addition to regulating FA disassembly at the rear end of cells, local Ca2+ signaling events, 
mediated by TRP channels, also affect adhesion turnover at the leading edge (Wei et al., 
2009). Consistent with such a model, a number of different TRP channels localize to FAs and 
regulate FA dynamics in the response of ECs to shear stress or in cell migration (see below) 
(Fig. 1B).
 TRPP1, which is frequently mutated in ADPKD, localizes to FAs and associates with 
FA components such as FAK, paxillin and vinculin (Torres and Harris, 2009). Interestingly, 
TRPP1 appears to be involved in regulating FA-dynamics as phosphorylation of FAK and 
paxillin and the formation of adhesion complexes are enhanced by expression of the TRPP1 
C-terminus (Joly et al., 2006). Moreover, cells carrying a mutation in TRPP1 (an epithelial 
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cell clone derived from an ADPKD-patient) show a reduction in activated FAK levels leading 
to larger FAs (Israeli et al., 2010). Furthermore, the extracellular N-terminus of TRPP1 binds 
several ECM components, indicating force sensing by TRPP1 is mediated via its interaction 
with the ECM (Malhas et al., 2002). Because of the suggested formation of a mechanosensing 
complex with TRPP2 (see above) (Hanaoka et al., 2000; Nauli et al., 2003), TRPP1 may exert 
its effects on FAs in cooperation with TRPP2. Taken together, a FA-associated TRPP1/TRPP2 
complex may function to sense forces exerted on the extracellular matrix to affect FA dynamics 
and the cytoskeleton.
 Similar to FA dynamics, Ca2+-dependent actomyosin contraction as well as Ca2+-
mediated activation of calpain are involved in AJ disassembly (Komarova and Malik, 2010). 
Interestingly, in addition to regulating FA turnover, several TRP channels are also implicated 
in regulating AJ dynamics (Fig. 1C). The TRPP1/TRPP2 complex (Huan and van Adelsberg, 
1999; Roitbak et al., 2004), TRPV4 (Sokabe et al., 2010) and TRPC4 (Graziani et al., 2010) all 
co-localize and co-immunoprecipate with E-cadherin and β-catenin. In a wound-healing assay 
using an epithelial monolayer, TRPP1 overexpression induced increased reabsorption of AJ 
components at the migrating front. This resulted in induction of single cell migration, probably 
caused by TRPP1-induced AJ disassembly (Boca et al., 2007). TRPC4 is involved in Ca2+-
mediated inflammation-induced increases in vascular permeability (Tiruppathi et al., 2006) and 
its localization to AJs (Graziani et al., 2010) suggests it could also be involved in shear stress 
induced AJ disassembly. On the other hand, TRPV4 appears to be involved in Ca2+-dependent 
assembly of cell-cell adhesions in multilayered keratinocytes. This discrepancy is not well 
understood, but may be explained by differences in AJ barrier structure between mono- and 
multilayered cells (Sokabe et al., 2010).
TRP channels in mechano-regulated biological processes
Migration
Directed cell migration is not only a driving force during embryonic development, but also 
immunity and wound healing completely rely on the ability of cells to migrate towards chemical 
or mechanical gradients (Aman and Piotrowski, 2010; Rose et al., 2007). The inability of cells 
to migrate properly will lead to defects in aforementioned processes, resulting in, for instance, 
malformations in the growing embryo (Theveneau and Mayor, 2011). To the converse, cancer 
cells may aberrantly switch on an embryonic migratory program, to enable metastasis from the 
primary tumor to distant sites. 
 Cell migration is a dynamic multistep process, comprising the formation and adhesion 
of protrusions at the front of the cell, generation of traction forces and the release of cell 
adhesions at the cell rear (Lauffenburger and Horwitz, 1996). Migration efficiency critically 
depends on spatial and temporal regulation of adhesion dynamics (Gardel et al., 2010) and 
there is increasing evidence for a role of localized Ca2+ signaling in this regulation (Tsai and 
Meyer, 2012). For instance, calcium release-activated calcium channel protein 1 (ORAI1) and 
stromal interaction molecule 1 (STIM1), channels implicated in store-operated Ca2+ entry, were 
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shown to be important determinants of tumor cell migration and metastasis (Prevarskaya et 
al., 2011). Similarly, the activity of a number of TRP channels has been linked to (tumor) cell 
migration. Activation of TRPV1 (Waning et al., 2007), TRPV2 (Monet et al., 2009; Monet et 
al., 2010), TRPV3 (Miyamoto et al., 2011), TRPV4 (Fiorio Pla et al., 2011), TRPM7 (Chen et 
al., 2010; Wei et al., 2009) and TRPM8 (Wondergem and Bartley, 2009; Wondergem et al., 
2008) were shown to enhance cell migration. In addition, TRPC1 is recruited to the leading 
edge of EGF-induced migrating glioma cells while inhibition of TRPC1 leads to inhibition of 
chemotaxis (Bomben et al., 2011). To date, at least two different TRP channels, TRPC1 and 
TRPC6, were shown to act in association with ORAI1 to mediate Ca2+ influx in neutrophils 
(Brechard et al., 2008). ORAI1 was shown to mediate shear stress-induced Ca2+ transients 
that affect cytoskeletal dynamics and cell polarization during transendothelial migration of 
neutrophils (Dixit et al., 2011; Schaff et al., 2010) As loss of TRPC6 in neutrophils strongly 
reduced chemokine-induced migration (Damann et al., 2009), this may suggest that TRPC1, 
TRPC6 and ORAI1 cooperate in mediating transendothelial migration of neutrophils under 
shear stress. In most of these studies, however, TRP channels were activated in response to 
chemotactic factors, rather than in response to mechanical stimulation.
 In a recent report by Wei and colleagues, shear stress was found to elicit ‘Ca2+ flickers’ at 
the leading edge of migrating fibroblasts. Knockdown of TRPM7 abolished these mechanically 
triggered local Ca2+ signaling events while cell polarization and migratory properties were 
strongly reduced. (Wei et al., 2009). Hence, TRPM7-mediated Ca2+ flickers may influence 
adhesion dynamics, for instance by activating the Ca2+-dependent protease calpain, to modulate 
the turnover of adhesion structures (Su et al., 2006). In addition, we previously showed that 
TRPM7 modulates adhesion dynamics by affecting actomyosin based contractility (Clark et 
al., 2006). How mechanical stimulation leads to activation of TRPM7 remains unclear. It was 
shown in vascular smooth muscle cells (VSMCs) that TRPM7 accumulates at the plasma 
membrane in response to shear stress which coincides with increased TRPM7-mediated 
currents (Oancea et al., 2006). Shear stress-mediated activation of TRPM7 may also involve 
G-protein coupled receptors such as the bradykinin receptor, a known activator of TRPM7 (Fig. 
1D) (Clark et al., 2006; Langeslag et al., 2007). Interestingly, this ligand-operated receptor can 
also be activated by mechanical stimuli in the absence of bradykinin (Chachisvilis et al., 2006). 
Together, these results suggest that TRPM7 can be mechanically activated. To determine how 
TRPM7, and other TRP channels, exert their effects on cell migration, it will be crucial to 
identify the downstream effectors of these cation channels.
Axonal outgrowth
Axon pathfinding and elongation are essential for synapse formation and maintenance of 
neuronal communication during embryonic development and in the adult. The neuronal growth 
cone, a highly dynamic fan-shaped structure at the distal tip of the axon, is responsible for the 
interpretation of environmental cues and the subsequent remodeling of the axon. Lamellipodia 
and filopodia extend from the growth cone periphery to sample the local environment for 
guidance cues and guide axonal elongation (reviewed in (Dent et al., 2011). Environmentally 
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induced Ca2+ signaling events modulate cytoskeletal dynamics in the growth cone and thereby 
steer growth cone turning and axon extension (Gomez et al., 2001; Gomez and Spitzer, 
1999; Lohmann et al., 2005). The role of Ca2+-permeable TRP channels in axon remodeling 
in response to chemical cues has been extensively studied (Ramsey et al., 2006; Tai et 
al., 2009). TRPC channels are required for neuronal growth cone remodeling in response 
to neurotrophins and chemoattractants such as brain derived nerve factor (BDNF), bone 
morphogenic proteins (BMP) and Netrin-1 (reviewed in (Bashaw and Klein, 2010; Talavera et 
al., 2008). For instance, TRPC1 Ca2+ conductance controls the directional response of growth 
cones to BMP7 gradients, through the asymmetric activation of the actin depolymerizer ADF/
cofilin (Wen et al., 2007).
 In addition to chemical guidance cues, both growth cone turning and the actual axon 
elongation are subject to mechanical stimulation (Suter and Miller, 2011). Moreover, mechanical 
tension has been recognized as a major stimulus for axonal elongation. Traction forces on cell-
matrix interactions within the axon growth cones, are generated by extension of the microtubule 
network and myosin driven retrograde flow of actin polymers (Conde and Caceres, 2009; 
Thoumine, 2008; Vallee et al., 2009). Additionally, axons are subjected to externally applied 
tensile forces after synapse formation, due to the increase in body size of the growing animal 
that causes stretching of the axon (Lamoureux et al., 1989; Lamoureux et al., 2010).
 In general, the application of mechanical stress enhances axonal elongation (Suter and 
Miller, 2011). Consistent with this notion, the thermo-TRP channel TRPV2 has been implicated 
in membrane stretch-evoked responses during axon outgrowth (Shibasaki et al., 2010). 
TRPV2, which is best known as a heat activated channel (Tominaga and Caterina, 2004), is 
expressed by developing motor neurons and localizes to both growth cones and axon shafts. 
It was shown that, in addition to high temperatures, membrane stretch can induce a TRPV2-
mediated Ca2+ influx to enhance axonal elongation. Interestingly, overexpression of a TRPV2 
dominant-negative mutant strongly inhibited the increase in intracellular [Ca2+] in response 
to membrane stretch, suggesting that TRPV2 is essential for mechanically-induced axon 
elongation. Membrane stretch similarly induces TRPV2-mediated Ca2+ influx in smooth muscle 
cells (Muraki et al., 2003). In both of these cases, it is unclear whether TRPV2 is intrinsically 
sensitive to mechanical stimulation or is activated through its interactions with the cytoskeleton 
(McCleverty et al., 2006; Muraki et al., 2003). Furthermore, how TRPV2 exerts its cytoskeletal 
effects in response to activation remains to be determined. Based on recent literature, TRPV2 
activation possibly affects neurite outgrowth via calmodulin-mediated activation of LIM 
kinases, which regulate actin polymerization through phosphorylation and inactivation of the 
actin depolymerizing factor cofilin (Holakovska et al., 2011; Takemura et al., 2009). Indeed, 
stretch-induced TRPV2 Ca2+ influx favors the formation of Ca2+/calmodulin complexes that 
associate with the TRPV2 C-terminus (Holakovska et al., 2011). These complexes activate 
Ca2+/calmodulin dependent kinases (CaMKs) which, in turn, activate cytoskeletal regulators 
such as LIM kinases (Takemura et al., 2009). In line with this hypothesis, both CaMKs and LIM 
kinase activation were shown to be essential for Ca2+-induced actin filament assembly during 
neurite extension (Takemura et al., 2009; Wayman et al., 2004).
| 41
2
Mechanoregulation of cytoskeletal dynamics by TRP channels
 Although mechanical stimulation of TRPV2 clearly enhances axonal elongation, the 
role of mechanically induced Ca2+ signaling events in shaping axons is less straightforward. For 
instance, Ca2+ influx, mediated by stretch activated ion channels (SACs), can also inhibit neurite 
outgrowth (Gomez et al., 2011; Gomez et al., 2001; Jacques-Fricke et al., 2006; Lohmann et 
al., 2005). A potential explanation for this apparent paradox is that Ca2+-mediated cytoskeletal 
responses, as they occur during axon pathfinding, are highly dependent on the spatiotemporal 
characteristics of these Ca2+ signals (Nicol et al., 2011). In support of this notion, the activity of 
Ca2+/calmodulin-dependent kinases (CaMKs), was shown to be dependent on both amplitude 
and frequency of Ca2+ signaling events (Chao et al., 2011). In conclusion, the specific effects 
of mechanically regulated (TRP) channels on axonal outgrowth are dictated by their gating 
properties, subcellular localization and the specific cytoskeletal assemblies associated with 
the channels. It will be a formidable challenge to fully understand how these complex signaling 
networks cooperate during axon guidance.
Nociception
The sensation of pain involves activation of ion channels by noxious stimuli such as heat or 
pressure. Ion channel activation in so-called nociceptors, specialized sensory neurons, triggers 
action potentials that transduce the pain signal from the peripheral sensory site to the synapse 
in the central nervous system (McCleskey and Gold, 1999). TRP channels, of which TRPA1 
and TRPV1 are best characterized, play an essential role in the perception and transduction 
of pain signals (nociception) (Chung et al., 2011). In addition, TRPV3, TRPV4 and TRPM8 are 
implicated in nociception, although their role has been less well studied (Chung et al., 2011). 
Moreover, perturbed channel function contributes to neuropathic pain (Cortright and Szallasi, 
2009). In response to continued inflammation or nerve damage, TRP channels can become 
either sensitized and consequently responsive to non-noxious stimuli, e.g. the sensation of a 
warm shower on badly sunburned skin or muscle soreness after exercise, or hyper-responsive 
to noxious stimuli, a state known as hyperalgesia.
 TRPA1 may also be involved in mechanical hyperalgesia, as a TRPA1 antagonist was 
able to reduce sensitivity to mechanical hyperalgesia (da Costa et al., 2010; Eid et al., 2008; 
Kerstein et al., 2009). TRPA1 probably induces pain sensation via the release of neuropeptides 
such as substance P and calcitonin gene-related peptide (Geppetti et al., 2008). If and how 
TRPA1 affects cytoskeletal dynamics is currently unknown, but it is clear that cytoskeletal 
changes can affect pain sensation. Microtubule-stabilizing anti-cancer drugs, such as Taxol 
induce severe neuropathic pain (Malik and Stillman, 2008), while microtubule destabilizing 
agents, such as Nocodazole, reduce pain sensation (Dina et al., 2003). Both TRPV1 and 
TRPV4 are known to modulate microtubule assembly and disassembly upon activation by 
noxious stimuli. TRPV1 is one of the best characterized nociceptive ion channels. TRPV1 
has been recognized as a heat sensitive cation channel that is predominantly expressed 
by nociceptors (Davis et al., 2000). Interestingly, inflammatory agents, such as bradykinin 
and prostaglandins, can reduce the heat activation threshold of TRPV1 and cause thermal 
hyperalgesia (reviewed in (Cortright and Szallasi, 2009). Originally, TRPV1 was not recognized 
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as a transducer of mechanical hyperalgesia as complete Freud’s adjuvant-induced mechanical 
hyperalgesia was similar in TRPV1-/- mice compared to wildtype mice (Caterina et al., 2000). 
However, recent studies have shown an involvement of TRPV1 in mechanical hyperalgesia. 
For instance, mechanical hyperalgesia in exercised muscle can be suppressed by TRPV1 
antogonists (Ro et al., 2009). Additionally, TRPV1 is required for the mechanosensitivity of 
mouse colon afferent fibers (Jones et al., 2005).
 The mechanosensitive TRPV4 channel contributes to the perception of mechanically 
induced pain and mechanical hyperalgesia (Alessandri-Haber et al., 2004; Alessandri-Haber et 
al., 2003). Mice lacking the TRPV4 gene show an increase in mechanical nociceptive threshold 
(Suzuki et al., 2003). Moreover, TRPV4 is essential in Taxol-induced mechanical hyperalgesia 
(Alessandri-Haber et al., 2004). TRPV4 is found to reside within a mechanosensing complex 
that localizes to growth cone filopodia and lamellipodia (Goswami et al., 2010). In contrast 
to stretch activated Ca2+ channels, TRPV4 is not gated directly by mechanical forces, but is 
activated by mechanical stress through its interaction with integrin α2β1 and SRC tyrosine 
kinase (Alessandri-Haber et al., 2008). It was recently suggested that TRPC6 may cooperate 
in this TRPV4/integrin/SRC complex to mediate mechanosensory signaling, as RNAi oligos 
against TRPC6 blocked TRPV4-mediated hyperalgesia (Alessandri-Haber et al., 2009). While 
inactive TRPV1 and TRPV4 stabilize the microtubule network, their activation induces rapid 
disassembly of microtubules (Goswami et al., 2010; Goswami et al., 2007). This is somewhat 
paradoxal since TRPV4 activity is required for the neuropathic effect of microtubule stabilizers 
such as Taxol (Alessandri-Haber et al., 2004; Malik and Stillman, 2008). Although both 
channels directly interact with microtubules through their C-terminals tails (Goswami et al., 
2010; Goswami et al., 2007), the precise mechanism by which TRPV1 and TRPV4 activation 
affect the microtubule network is unknown. Moreover, TRPV4 channel opening may, in turn, 
be modulated by microtubule and actin cytoskeletal integrity (Goswami et al., 2010; Suzuki 
et al., 2003). These complex reciprocal interactions between nociceptive TRP channels and 
cytoskeletal dynamics are likely at the root of neuropathic pain caused by inflammatory agents 
and microtubule stabilizing chemotherapeutic agents.
Cardiovascular homeostasis
During exercise, components of the cardiovascular system respond to increased metabolic 
demands of active skeletal muscles, i.e. cardiac output increases and blood flow from inactive 
organs and tissues must be redistributed to active skeletal muscles. In addition to these short-
term responses, the cardiovascular system undergoes structural adaptations in response to 
sustained alterations in metabolic demands, for instance after regular exercise. In case of 
hypertension, heart remodeling becomes pathological as a result of a chronically increased 
mechanical load (Hill and Olson, 2008).
 The three cell types involved in the cardiovascular response to changing metabolic 
demands are (1) ECs that regulate VSMCs contraction and barrier function in response to 
changes in blood flow; (2) VSMCs that mediate vasoconstriction in response to changes in 
intraluminal pressure and (3) cardiac myocytes, striated muscle cells that generate cardiac output. 
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These cellular responses are triggered by Ca2+ signaling events that translate environmental 
information, including mechanical cues, into cytoskeletal responses. Mechanosensitive TRP 
channels are therefore considered key regulators of vascular function (Di and Malik, 2010; 
Kwan et al., 2007). Consistent with this notion, perturbed TRP channel function has been 
associated with cardiovascular pathologies such as hypertension and pathologic cardiac 
hypertrophy (Earley and Brayden, 2010; Inoue et al., 2009; Kwan et al., 2007; Yogi et al., 
2011).
TRP channels in endothelial cells - ECs lining the blood vessels not only function as a barrier, 
but are also regulators of angiogenesis, coagulation, inflammation and VSMC contractility. 
Since ECs are in direct contact with the circulating blood, they fulfill an essential role in sensing 
changes in blood flow. ECs induce VSMC relaxation in response to increased shear stress by 
Ca2+-dependent release of vasodilators, such as nitric oxide (NO) (Vanhoutte et al., 2009), and 
by inducing hyperpolarization of the VSMC plasma membrane. Shear stress will additionally 
trigger Ca2+-mediated EC elongation and alignment in the direction of flow to reduce the effect 
of shear stress (Barbee et al., 1995; Johnson et al., 2011; Li et al., 2005b). Initially, shear stress 
induces Ca2+-dependent cell elongation and the dissolution of cell adhesions (Davies et al., 
1994; Li et al., 2005b). Later, cells will adjust to shear stress by the formation of thick stress 
fibers and reestablishment of cell adhesions, aligned in the direction of flow (Davies et al., 
1994; Li et al., 2005b).
 Several TRP channels regulate EC function (Earley and Brayden, 2010; Kwan et al., 
2007). TRP channels in ECs are activated by vasoactive agents like histamine, bradykinin as 
well as by mechanical cues (Yao and Garland, 2005). TRPP1/TRPP2, TRPV4 and TRPC1 
contribute indirectly to vasodilatation in response to changes in shear stress by modulating 
VSMC contractility (AbouAlaiwi et al., 2009; Ma et al., 2010; Mendoza et al., 2010; Nauli et 
al., 2003; Nauli et al., 2008). Upon activation, Ca2+ influx induces vasodilatation by enhancing 
the production and release of vasodilating molecules, such as NO and endothelium-derived 
hyperpolarizing factor (EDHF). Additionally, increased Ca2+ influx leads to hyperpolarization 
of the endothelial plasma membrane through the activation of Ca2+-sensitive K+ channels. 
Connected via myoendothelial gapjunctions, the underlying VSMCs become hyperpolarized, 
affecting their contractility (reviewed in (Edwards et al., 2010). TRPV4-/- mice show impaired 
vasodilatation in response to TRPV4 agonists or shear stress (Mendoza et al., 2010). TRPC1 
has recently been shown to interact and cooperate with TRPV4 in mediating shear stress-
induced Ca2+ influx (Ma et al., 2010). In addition, mechanical stimulation of the TRPP1/TRPP2 
complex in primary cilia of endothelial cells triggers the release of NO (AbouAlaiwi et al., 
2009; Hanaoka et al., 2000; Nauli et al., 2008; Nauli et al., 2006; Patel and Honore, 2010). 
This may also in part explain the increased risk of hypertension in ADPKD patients, since a 
proper response to increased shear stress is lacking (Patel and Honore, 2010). These data 
also add up to the possibility that TRPP1/TRPP2, TRPC1 and TRPV4 are part of a heteromeric 
mechanosensing complex.
 Stretch activated TRPV4 channels present at the basal membrane of ECs have been 
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implicated in mediating endothelial elongation and realignment in response to changes in blood 
flow (Thodeti et al., 2009). In addition, TRPV4 may associate with β1-integrins in EC FAs since 
local mechanical stimulation of β1-integrins leads to a very rapid (~4 ms), TRPV4-mediated 
Ca2+ influx (Alessandri-Haber et al., 2008; Matthews et al., 2010). These Ca2+ signals activate 
the small GTPase RhoA and its target ROCK, resulting in the realignment of FAs and stress 
fibers. Thus, shear stress may generate tension through stress fibers on cell-matrix adhesions 
at the basal membrane, leading to local initiation of TRPV4-mediated cytoskeletal remodeling 
(Katoh et al., 2008; Thodeti et al., 2009). A similar response has also been observed in HUVECs, 
where a transient force applied directly to FA-anchored actin filaments resulted in activation of 
mechanosensitive channels near FAs and subsequent disassembly of FAs (Hayakawa et al., 
2008; Kiyoshima et al., 2011). In conclusion, mechanosensitive TRP channels localized to EC 
FAs likely regulate Ca2+-dependent cytoskeletal remodeling in response shear stress.
TRP channels in vascular smooth muscle cells - VSMCs regulate vascular tone by Ca2+-
dependent cytoskeletal relaxation or contraction. While relaxation in response to shear stress 
is mediated indirectly by ECs (see above), changes in blood pressure are perceived by VSMCs 
themselves (Haga et al., 2007). TRP channels are known to be directly involved in translating 
fluctuations of vascular wall pressure into VSMC cytoskeletal contractility, to counteract these 
forces (Di and Malik, 2010; Earley and Brayden, 2010).
 TRPP1 and TRPP2 in VSMCs act by modulating SACs that regulate cytoskeletal 
contractility. In contrast to their complementary activities in endothelial primary cilia (see 
above), TRPP1 positively regulates SAC activation while TRPP2 overexpression inhibits 
SAC activation in response to stress. In turn, TRPP1 co-expression can reverse the inhibitory 
effect of TRPP2 (Sharif-Naeini et al., 2009). Hence, the TRPP1/TRPP2 ratio is considered to 
regulate SAC sensitivity to pressure on the vascular wall. How does this work mechanistically? 
Cortical actin filaments decrease stretch-induced membrane tension, and thereby reduce SAC 
sensitivity to mechanical stimuli (Wan et al., 1999). Since TRPP2 directly interacts with the 
actin crosslinker filamin A, TRPP2 may inhibit mechanosensitivity of VSMCs by stabilizing 
actin filaments at the cell cortex. The interaction with TRPP1 would reverse the inhibitory effect 
of TRPP2 on SAC regulation, by preventing the interaction between TRPP2 and filamin A 
(Sharif-Naeini et al., 2009).
TRP channels in cardiac myocytes - Cardiac hypertrophy, the pathological response of the 
heart to sustained hypertension, involves a disproportionate growth of cardiac myocytes. This 
physical adaptation coincides with the re-activation of a fetal gene transcription program that 
includes a shift from the expression of α-myosin heavy chain (α-MHC) towards β-myosin heavy 
chain (β-MHC) and expression of skeletal α-actin, thereby altering the contractile properties 
of the heart (Ahmad et al., 2005; Hill and Olson, 2008; Jaalouk and Lammerding, 2009). 
Pathological remodeling of the heart involves Ca2+-dependent activation of the calcineurin/NFAT 
pathway, and since TRPC channels activate this pathway in cardiac myocytes, these channels 
are considered essential players in the pathogenesis of cardiac hypertrophy (Kiyonaka et al., 
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2009; Kuwahara et al., 2006; Seth et al., 2009; Wu et al., 2010b).
 All TRPC channels, except for TRPC2, are expressed in cardiac myocytes (Eder and 
Molkentin, 2011). Moreover, cardiac hypertrophy is associated with increased expression 
levels of TRPC1, -3, -5 and -6 (Eder and Molkentin, 2011). Cardiac TRPC channels are 
indirectly gated by mechanical stress through the activation of angiotensin II type 1 receptor 
(AT1R), a G-protein coupled receptor (Fig. 1D). Mechanically induced conformational changes 
in AT1R can initiate downstream signaling which involves PIP2 hydrolysis into DAG and IP3. The 
produced DAG can activate TRPC3, -6 and -7 (Dietrich et al., 2005; Hofmann et al., 1999). 
TRPC1, -4 and -5, however, are unresponsive to DAG, but can be activated by G-protein 
coupled receptors, suggesting they might be activated downstream of IP3 signaling (Hofmann 
et al., 1999). Additionally, overexpression of AT1R in aortic smooth muscle cells renders TRPC6 
channel opening responsive to mechanical force (Mederos y Schnitzler et al., 2008).
 Direct effects of TRPC channel activation on the cardiac myocyte cytoskeleton have 
not been described to date. However, several lines of evidence indicate that cardiac TRPC 
channels modulate transcription of cytoskeletal associated genes via the calcineurin/NFAT 
pathway. For instance, overexpression of both TRPC3 and TRPC6 results in activation of the 
calcineurin/NFAT pathway, correlating with increased skeletal α-actin and β-MHC expression, 
respectively (Bush et al., 2006; Kuwahara et al., 2006). Secondly, DAG-activated TRPC3 and 
TRPC6 were shown to be essential for NFAT-mediated pathological remodeling of the heart 
(Onohara et al., 2006) while loss of TRPC1 expression protected mice from mechanical stress-
induced cardiac hypertrophy by preventing calcineurin/NFAT signaling (Seth et al., 2009). 
Thirdly, deletion of calcineurin Aβ prevented cardiac hypertrophy by TRPC3 overexpression 
(Nakayama et al., 2006). Finally, TRPC3 and TRPC6 are targets of NFAT in pathological 
growth and remodeling of mouse hearts (Bush et al., 2006; Kuwahara et al., 2006), indicating 
a regulatory feedback loop that drives cardiac hypertrophy in response to chronic pressure 
overload in the heart. Cardiac myocytes are constantly exposed to Ca2+ transients that initiate 
cardiac muscle contraction. It may therefore seem paradoxal that Ca2+ signaling through TRPC 
channels can lead to activation of a pathological gene transcription program via calcineurin/
NFAT signaling. However, it is becoming evident that the spatiotemporal characteristics of 
mechanical stimuli as well as the frequency and spatial characteristics of the resultant Ca2+ 
signals determine activation of specific downstream signaling events (Hoffman et al., 2011).
Glomerular filtration
Podocytes, highly differentiated epithelial cells, play an essential role in ultrafiltration of plasma 
that passes through the endothelium of the glomerular capillaries. Podocytes consist of a cell 
body and actin-rich protrusions, known as foot processes, which wrap around the glomerular 
capillaries and attach to the glomerular basement membrane through focal contacts. Foot 
processes from neighboring cells organize into a highly branched interdigitating, zipper-like 
network, bridged by multimolecular complexes that form the slit diaphragm, a highly specialized 
type of AJs. These AJs form a barrier that functions as a glomerular filter, allowing passage of 
small molecules, but inhibiting passage of large plasma proteins into the urinary space (Faul 
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et al., 2007). 
 Podocytes are constantly exposed to mechanical stress, generated by blood pressure 
in the glomerular capillaries, as well as shear stress resulting from fluid flow through the slit 
diaphragm and over the apical membrane of the podocyte. Ca2+-dependent remodeling of 
the actin cytoskeleton in response to mechanical load is essential to counteract these forces 
(Endlich and Endlich, 2006; Endlich et al., 2001). First of all, contractile forces generated 
by podocytes counteract capillary wall distension and prevent glomerular damage due to 
increased capillary pressure (Kriz and Endlich, 2005; Kriz et al., 1994). In addition, dynamic 
remodeling of focal contacts and AJs in response to increased fluid flow are also required to 
maintain the glomerular filtration barrier (Faul et al., 2007). Consistently, several mutations 
in key podocyte proteins that affect the organization and dynamic regulation of the highly 
specialized cytoskeleton in foot processes, such as nephrin, podocin, ACTN4 and CD2AP, 
contribute to loss of glomerular barrier function and consequently, progressive kidney failure. 
Gain-of-function mutations and increased expression of TRPC6 were shown to underlie focal 
and segmental glomerulosclerosis (FSGS) and progressive kidney failure (Moller et al., 2007; 
Reiser et al., 2005; Winn et al., 2005). However, the precise mechanism by which TRPC6 
affects podocyte function is unclear.
 TRPC6 is part of the slit diaphragm multiprotein complex and associates with nephrin 
and podocin (Reiser et al., 2005). Together, these proteins are suggested to function as a 
mechanosensing complex that triggers Ca2+ influx through the TRPC6 channel, in response to 
plasma membrane stretch at the insertion site of the slit diaphragm (Dryer and Reiser, 2010; 
Dyachenko et al., 2009). However, it is unclear whether TRPC6 in podocytes is intrinsically 
mechanosensitive since the stress induced activation of TRPC6 in podocytes depends on 
activation of AT1R (Large et al., 2009; Mederos y Schnitzler et al., 2008)(reviewed in (Patel et 
al., 2010). Interestingly, mechanical load is known to activate the angiotensin system in the 
kidney and induce protein expression of AT1R in podocytes (Durvasula et al., 2004). In CHO 
cells, however, TRPC6 could be activated by mechanical stress in the presence of an inhibitor 
phospholipase C (PLC), which is downstream of G-protein receptor activation (Spassova et 
al., 2006). Hence, the requirement of G-protein receptor activation may be cell-type specific.
Similar to the role of TRPC channels in guiding neuronal growth cone outgrowth (Li et al., 
2005a), Ca2+ influx through TRPC6 may regulate Ca2+-dependent cytoskeletal components.  
 Although downstream targets of TRPC6-mediated Ca2+ influx remain to be identified, 
the close association of TRPC6 and the actomyosin cytoskeleton is apparent from pull down 
experiments, revealing a TRPC6 signalplex. This complex contains several cytoskeletal 
proteins such as actin, myosin, α-actinin and drebrin (Goel et al., 2005). Hypothetically, TRPC6 
mediates its effect on the cytoskeleton through activation of the Ca2+-dependent phosphatase 
calcineurin (Kuwahara et al., 2006). Increased TRPC6 channel activity results in cytoskeletal 
rearrangements, characterized by a loss of actin stress fibers (Moller et al., 2007). Interestingly, 
calcineurin is known to dephosphorylate and destabilize synaptopodin, a scaffolding protein 
required for stress-fiber formation (Asanuma et al., 2006; Faul et al., 2008). Thus, TRPC6-
induced Ca2+ influx may render podocytes unable to respond properly to mechanical cues 
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through calcineurin-mediated dissolution of actin fibers.
 Additionally, TRPC6 Ca2+ influx was shown to modulate gene expression, through the 
calcineurin/NFAT pathway (Kuwahara et al., 2006; Schlondorff et al., 2009; Wang et al., 2010). 
Consistently, conditional activation of NFATc1 in a murine model resulted in proteinuria and 
glomerulosclerosis, although transcriptional targets that directly affect cytoskeletal organization 
and slit diaphragm formation were not identified (Wang et al., 2010). By analogy to cardiac 
myocytes, angiotensin was shown to induce TRPC6 expression in podocytes by activation 
of the calcineurin/NFAT pathway in a TRPC6 dependent manner, resulting in proteinuria in 
mice (Nijenhuis et al., 2011). Together these results suggest that, similar to the cardiovascular 
system, activation of the calcineurin/NFAT pathway downstream of TRP channel activation, 
acts to sustain cytoskeletal responses in glomerular foot processes.
Concluding remarks
In addition to their well-established role as sensors of heat, taste and light, TRP channels are 
considered important sensors of mechanical cues in many different organ systems. Consistent 
with this notion, perturbed TRP channel function in mechano-regulated processes contributes 
to a variety of pathologies. However, in most mechanically regulated processes, it remains to 
be established whether TRP channels act as the primary mechanosensor. 
 Activation of TRP channels initiates short-term and long-term cytoskeletal adaptations 
to changes in mechanical load. Direct regulation of cytoskeletal dynamics include the activation 
of cytoskeletal remodelers, such as calpain or MLCK, or the secretion of soluble compounds, 
such as NO, that manipulate cytoskeletal organization of neighboring cells. TRP channel-
induced Ca2+ signaling may additionally regulate cytoskeletal gene expression by activation of 
Ca2+-dependent transcription factors, such as NFAT. Although transcriptional regulation by TRP 
channels has mostly been established for mechanically activated TRPC channels, it raises the 
possibility that this is a more general feature of TRP channels.
 In most mechanosensory processes, the direct downstream targets of TRP channel 
signaling remain elusive. Since TRP channels generally organize into multiprotein signalplexes, 
knowing the precise composition of these cytoskeletal complexes will provide important clues 
on how these ion channels affect cell behavior in response to mechanical cues. In addition, 
more insight is needed into what determines the spatiotemporal characteristics of the Ca2+ 
signal. These properties may be determined by heteromerization of different TRP channel 
subunits, or association with other calcium channels, such as ORAI and STIM. Establishing 
the exact roles of these mechano-complexes will improve our understanding of pathologies in 
which physical properties of the environment are altered, such as during cancer, atherosclerosis 
and hypertension.
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Abstract
TRPM7 encodes a Ca2+-permeable non-selective cation channel with kinase activity. TRPM7 
has been implicated in control of cell adhesion and migration, but whether TRPM7 activity 
contributes to cancer progression has not been established. Here we report that high levels of 
TRPM7 expression independently predict poor outcome in breast cancer patients and that it 
is functionally required for metastasis formation in a mouse xenograft model of human breast 
cancer. Mechanistic investigation revealed that TRPM7 regulated myosin II-based cellular 
tension, thereby modifying focal adhesion number, cell-cell adhesion and polarized cell 
movement. Our findings therefore suggest that TRPM7 is part of a mechanosensory complex 
adopted by cancer cells to drive metastasis formation.
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Introduction
Metastasis formation is a complicated multi-step process involving tumor cell dissemination 
from the primary tumor, matrix invasion, entry into the circulatory system, extravasation through 
capillary endothelium, and finally the outgrowth of secondary tumors in distant organs. Each of 
these events requires extensive and continuous Ca2+-dependent remodeling of the actomyosin 
cytoskeleton as well as close interactions with the cell’s surroundings, mediated by dynamic 
adhesive structures such as focal adhesions and adherens junctions. These specialized cell 
adhesion sites convey mechanical cues across the plasma membrane, affecting both the 
physical properties of their surroundings as well as intracellular cytoskeletal dynamics. As 
the formation and maturation of focal adhesions and adherens junctions is dependent on the 
applied mechanical forces, these structures are considered to function as mechanosensors 
that integrate mechanical cues from inside and outside the cell (Bidwell and Pavalko, 2010; 
Chen et al., 2004; Geiger and Bershadsky, 2002; Liu et al., 2010; Parsons et al., 2010). The 
complex protein-protein interactions within these adhesion sites significantly contribute to 
tumor progression and metastasis formation. Hence, proteins that regulate adhesion formation 
or turnover represent interesting therapeutic targets to limit the metastatic potential of cancer 
cells (Paszek et al., 2005).
 Members of the mammalian Transient Receptor Potential (TRP) cation channel family 
are considered key players in mechanosensory signaling (Clark et al., 2008b; Lin and Corey, 
2005; Numata et al., 2007; Oancea et al., 2006; Orr et al., 2006). TRP channels organize into 
large macromolecular complexes linked to the actomyosin cytoskeleton, which may serve to 
localize signal transduction pathways and/or enhance the rate of signal transmission (Clark 
et al., 2008a; Clark et al., 2008b; Goswami et al., 2010). Tethered to the cytoskeleton, their 
ion conducting properties can be modulated by different stimuli, including mechanical cues, 
resulting in a variety of cellular responses. In earlier work, we and others identified TRPM7, a 
Ca2+-permeable non-selective cation channel with kinase activity, as a regulator of actomyosin 
contractility, cell adhesion, and directed cell migration (Clark et al., 2006; Su et al., 2006; Wei 
et al., 2009). However, a role for this bifunctional channel in cancer progression has not been 
examined. Here we show that high TRPM7 expression, at the time of diagnosis, predicts poor 
therapy outcome in a large cohort of breast cancer patients. Moreover, TRPM7 is a critical 
determinant of breast cancer cell migration in vitro and metastasis formation in vivo.
Results and discussion
TRPM7 mRNA expression levels in primary tumors are associated with breast cancer 
progression and metastasis formation, independent from standard clinical parameters
Immunohistochemistry on primary breast cancer tissue samples showed that TRPM7 protein is 
expressed by epithelial cells that align mammary glands and by breast tumor cells. Perinuclear 
staining of breast carcinoma cells was observed with accentuation of the nuclear membrane, 
with or without diffuse staining of the cytoplasm (Fig. 1A). We explored the prognostic value 
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of TRPM7 mRNA levels in breast cancer, using microarray based gene expression data from 
breast cancer specimens, obtained by resection of the primary tumor at diagnosis (discovery 
cohort; n = 368) (Table S1) (Loi et al., 2007). After dichotomization based on the median 
TRPM7 expression level, the TRPM7-high group (n = 184) was found to exhibit a significantly 
shorter recurrence-free survival as compared to the TRPM7-low group (n = 184) (hazard ratio 
(HR) = 1.42, 95% CI = 1.01 to 2.01, p = 0.042) (Fig. 1B). Even stronger was the association 
of TRPM7 with distant metastasis-free survival interval (HR = 1.85, 95% CI = 1.22 to 2.81, p = 
0.003) (Fig. 1B).
 In three additional breast cancer cohorts (n=190, n=244 and n=216), we did not detect 
a significant association of TRPM7 with disease outcome. Discordances between microarray-
based datasets remain a serious problem, often reflecting differences in patient populations, 
probe selection, and mRNA abundance. We therefore sought for independent validation by 
performing quantitative real-time PCR (q-PCR) experiments in a highly similar, independent 
breast cancer patient cohort (validation cohort; n = 144) (Table S1). TRPM7 mRNA expression 
was associated with disease recurrence (HR = 1.88, 95% CI = 1.06 to 3.33, p = 0.029) and 
occurrence of distant metastases. Although the HR was similar as in the discovery cohort, the 
latter association did not reach statistical significance (HR = 1.84, 95% CI = 0.91 to 3.71, p = 
0.085), possibly due to a lower number of events (Fig. 1C).
 We next assessed the association between TRPM7 expression and standard clinical 
parameters using the combined discovery and validation cohorts (n = 512). In support of 
its association with disease progression, TRPM7 was found enriched in high grade primary 
tumors (p = 0.02) (Table S2A). Other prognostic parameters, including tumor size and ER-
status, were not associated with TRPM7 expression levels and TRPM7 expression was similar 
between breast cancer subtypes (p = 0.28) (Table S2B & C). However, since the dominant 
prognostic feature in all microarray studies of ER-positive breast cancer is proliferation, we 
cannot exclude that TRPM7 is an indirect indicator of proliferation in the ER-positive subgroup 
of tumors.
 Univariate Cox regression analysis indicated that histological grade, tumor size and 
TRPM7 expression levels are strong predictors of both disease recurrence and the occurrence 
of distant metastases (Table 1) (p < 0.01). Importantly, multivariate analysis revealed that 
TRPM7 mRNA expression is an independent prognostic marker for both disease recurrence 
(p = 0.02) and occurrence of metastases at distant sites (p = 0.01) (Table 1), after correction 
for standard clinical parameters. While future research must address to what extent TRPM7 
levels indeed have prognostic value, our results indicate a strong and independent association 
between TRPM7 expression levels and breast cancer progression.
TRPM7 knockdown interferes with the metastatic potential, but not proliferation, of invasive, 
triple-negative breast cancer cells in vivo
To establish a causal relation between TRPM7 expression levels and metastasis formation, 
shRNA-mediated knockdown was performed by lentiviral transduction of invasive, triple-
negative MDA-MB-231 breast cancer cells. Knockdown efficiency was about 80%, as
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of TRPM7 mRNA levels in breast cancer, using microarray based gene expression data from 
breast cancer specimens, obtained by resection of the primary tumor at diagnosis (discovery 
cohort; n = 368) (Table S1) (Loi et al., 2007). After dichotomization based on the median 
TRPM7 expression level, the TRPM7-high group (n = 184) was found to exhibit a significantly 
shorter recurrence-free survival as compared to the TRPM7-low group (n = 184) (hazard ratio 
(HR) = 1.42, 95% CI = 1.01 to 2.01, p = 0.042) (Fig. 1B). Even stronger was the association 
of TRPM7 with distant metastasis-free survival interval (HR = 1.85, 95% CI = 1.22 to 2.81, p = 
0.003) (Fig. 1B).
 In three additional breast cancer cohorts (n=190, n=244 and n=216), we did not detect 
a significant association of TRPM7 with disease outcome. Discordances between microarray-
based datasets remain a serious problem, often reflecting differences in patient populations, 
probe selection, and mRNA abundance. We therefore sought for independent validation by 
performing quantitative real-time PCR (q-PCR) experiments in a highly similar, independent 
breast cancer patient cohort (validation cohort; n = 144) (Table S1). TRPM7 mRNA expression 
was associated with disease recurrence (HR = 1.88, 95% CI = 1.06 to 3.33, p = 0.029) and 
occurrence of distant metastases. Although the HR was similar as in the discovery cohort, the 
latter association did not reach statistical significance (HR = 1.84, 95% CI = 0.91 to 3.71, p = 
0.085), possibly due to a lower number of events (Fig. 1C).
 We next assessed the association between TRPM7 expression and standard clinical 
parameters using the combined discovery and validation cohorts (n = 512). In support of 
its association with disease progression, TRPM7 was found enriched in high grade primary 
tumors (p = 0.02) (Table S2A). Other prognostic parameters, including tumor size and ER-
status, were not associated with TRPM7 expression levels and TRPM7 expression was similar 
between breast cancer subtypes (p = 0.28) (Table S2B & C). However, since the dominant 
prognostic feature in all microarray studies of ER-positive breast cancer is proliferation, we 
cannot exclude that TRPM7 is an indirect indicator of proliferation in the ER-positive subgroup 
of tumors.
 Univariate Cox regression analysis indicated that histological grade, tumor size and 
TRPM7 expression levels are strong predictors of both disease recurrence and the occurrence 
of distant metastases (Table 1) (p < 0.01). Importantly, multivariate analysis revealed that 
TRPM7 mRNA expression is an independent prognostic marker for both disease recurrence 
(p = 0.02) and occurrence of metastases at distant sites (p = 0.01) (Table 1), after correction 
for standard clinical parameters. While future research must address to what extent TRPM7 
levels indeed have prognostic value, our results indicate a strong and independent association 
between TRPM7 expression levels and breast cancer progression.
TRPM7 knockdown interferes with the metastatic potential, but not proliferation, of invasive, 
triple-negative breast cancer cells in vivo
To establish a causal relation between TRPM7 expression levels and metastasis formation, 
shRNA-mediated knockdown was performed by lentiviral transduction of invasive, triple-
negative MDA-MB-231 breast cancer cells. Knockdown efficiency was about 80%, as
Figure 1. TRPM7 is a strong and independent prognostic marker for breast cancer progression and 
metastasis (A) TRPM7 protein expression in a breast tumor section (brown). Nuclei are counterstained with 
hematoxylin (blue). Left panel: scale bar = 500 μm. Right panel: scale bar = 100 μm. Indicated are breast tumor cells 
and stroma. (B) Kaplan-Meier analysis of recurrence-free survival (left) and distant metastasis-free survival (right) 
according to TRPM7 mRNA expression, obtained from microarray analysis on 368 breast cancer patients (discovery 
cohort). TRPM7-low: n = 184, TRPM7-high: n = 184. P-values are based on Log Rank test. (C) Kaplan-Meier 
analysis of recurrence-free survival (left) and distant metastasis-free survival (right) according to TRPM7 mRNA 
expression, determined by quantitative real-time PCR measurements on 144 breast cancer patients (validation 
cohort). TRPM7-low: n = 72, TRPM7-high: n = 72. P-values are based on Log Rank test.
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Figure 2. Reduced TRPM7 
expression interferes with the 
metastatic potential of MDA-MB-231 
human breast cancer cells in vivo 
(A) Proliferation and overall viability of 
control and TRPM7 knockdown MDA-
MB-231 cells, determined by MTS 
assays. Measurements were performed 
at different time points, indicated on the 
x-axis. Metabolic activity is expressed 
as the amount of produced Formazan, 
determined by photospectrometry, 
and normalized to initial metabolic 
activity. Data are presented as mean 
± SEM of 2 independent experiments 
that were performed in triplicate. (B) 
Representative bioluminescence 
images of mice, 7 days after intravenous 
injections with MDA-MB-231 control or 
TRPM7 shRNA cells. (C) Quantification 
of bioluminescence in the lung region 
of mice, for up to 30 days after 
injection. Data are presented as mean 
± SEM of n= 5 mice in each group. (D) 
Bioluminescence images of mice taken 
30 days after injection. Photon fluxes 
are to the same scale. Dagger in C 
and D indicates a mouse that had to 
be euthanized 22 days after injection 
with control MDA-MB-231 cells, due 
to a large tumor in the head region. 
Bioluminescence image in C was taken at day 21. Subsequent quantifications were performed on the 9 remaining 
mice. (E) Quantification of mean lung tumor size in mice injected with MDA-MB-231 control or TRPM7 shRNA cells. 
Error bars represent SEM for n = 3 mice in each group. (F) Quantification of the number of lung tumors per mouse, 
measured in resected lung tissue from mice injected with MDA-MB-231 control or TRPM7 shRNA cells. Error 
bars represent SEM for n= 3 in each group. *** P <0.001. For size distribution, see Fig. S2B (H) Representative 
HE staining on lung tissue, collected 30 days after injection with MDA-MB-231 control or TRPM7 shRNA cells. 
Prominent tumors in lung tissue from mice injected with TRPM7 shRNA cells (bottom) are indicated by arrows. 
Scale bar = 1 mm.
determined both by q-PCR and by measuring TRPM7 autophosphorylation using an in vitro 
kinase assay (Fig. S1A & B). A number of studies has shown that TRPM7 knockdown can 
affect cell viability and proliferation in vitro (Guilbert et al., 2009; Jiang et al., 2007). However, 
we observed that MDA-MB-231 TRPM7 shRNA cells proliferated normally and showed no 
loss in cell viability (Fig. 2A & S2A). We next compared in vivo metastasis formation of MDA-
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MB-231 control and TRPM7 shRNA cells that were made to express a luciferase reporter 
gene. Following injection of cells in the tail vein of immunodeficient Rag2-/-IL2rg-/- mice, 
luciferase based non-invasive bioluminescence imaging was used to monitor dissemination 
and growth of tumor cells in vivo. Consistent with earlier reports describing this experimental 
metastasis model (Yang et al., 2009), tumor cells were initially trapped in the lungs, probably 
due to size restrictions of the mouse lung capillaries (Fig. 2B). The progressive increase of the 
bioluminescent signal in mice injected with control cells indicates that these cells effectively 
developed into pulmonary metastases (Fig. 2C). At day 30 after injection, metastatic spread 
of tumor cells throughout the body was observed in all of the control mice. One mouse had to 
be taken out of the experiment 22 days after injection due to a large tumor mass in the head 
of the animal (Fig. 2D). TRPM7 knockdown led to a strong reduction in bioluminescent signal 
intensity from day 7 onwards, which remained mostly restricted to the lungs (Fig. 2B & C). 
Similar results were obtained from an independent experiment in which an additional TRPM7 
knockdown cell line, derived using a second shRNA, was included (Fig. S1A & B, S2B & 
C). These observations suggest that TRPM7 knockdown impairs the initial establishment of 
tumors in the lung and dissemination to other parts of the body. Quantitative analysis of tumor 
size in hematoxyline-eosine (HE) stained lung sections confirmed that TRPM7 knockdown did 
not affect proliferation (mean tumor size, control: 0.045 mm2 ± 0.0047 (n = 474) vs. TRPM7 
shRNA: 0.037 mm2 ± 0.0054 (n = 131), 3 mice per group, p = 0.29) (Fig 2E, H & S2D). 
However, TRPM7 knockdown significantly reduced the number of lung tumors per mouse 
(control: 158.33 ± 11.7 vs. TRPM7 shRNA: 43.67 ± 5.33, 3 mice per group, p < 0.001) (Fig. 2F 
& H). Overall, these experiments demonstrate that a reduction of TRPM7 protein expression 
effectively interferes with the metastatic potential of invasive human breast cancer cells in vivo.
TRPM7 knockdown impairs migratory properties of invasive, triple-negative breast cancer 
cells in vitro
To examine how TRPM7 may affect the ability of tumor cells to spread to distant sites, we 
studied the consequences of TRPM7 knockdown on cytoskeletal organization and cell 
behavior. Whereas control MDA-MB-231 cells exhibited a characteristic spindle shaped 
(mesenchymal) morphology with actin-rich protrusions at the leading edge, this elongated 
morphology was lost upon TRPM7 knockdown (percentage elongated control cells: 63.3% 
± 2.8% vs. TRPM7 shRNA: 30.0% ± 2.5%, n > 400, 4 independent experiments, p < 0.001) 
(Fig. 3A & B). Moreover, loss of TRPM7 expression effectively interfered with the ability of 
these cells to migrate towards a serum gradient, as determined in a transwell migration assay 
(control: 100% vs. TRPM7 shRNA: 50.56% ± 9.15%, 5 exp, p < 0.01) (Fig. 3C). By time-lapse 
microscopy we observed that TRPM7 knockdown affected cell migration speed, resulting in 
significantly shorter migration trajectories (control: 29.7 ± 2.2 µm/hr vs. TRPM7 shRNA: 17.2 ± 
1.1 µm/hr, n > 200, 4 exp, p < 0.01) (Fig. 3D & E). 
 Similar results were obtained with the second TRPM7 knockdown cell line (Fig. S1A & 
B, S3). We additionally re-expressed a mouse TRPM7 cDNA into the TRPM7 knockdown cells, 
which contained one mismatch with respect to the (human-specific) shRNA. We confirmed by
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Table 1. TRPM7 is a predictor of breast cancer recurrence and metastasis, independent of standard clinical 
parameters. Univariate and multivariate Cox proportional hazards modeling of factors associated with recurrence-
free survival (A) and distant metastasis-free survival (B) in the combined discovery and validation cohorts (n = 512). 
TRPM7-low: n = 256, TRPM7-high: n = 256. HR = Hazard Ratio; CI = Confidence Interval.
 | 63
3
TRPM7 is required for breast cancer metastasis
q-PCR analysis as well as by in vitro kinase assays that expression of TRPM7 was restored to 
about 70% of that in the control cells (Fig. S1C & D). Re-expression of TRPM7 was sufficient 
to rescue the elongated morphology (percentage of elongated cells: 56.2% ± 4.7%, n = 400, 4 
exp, p < 0.01), and restore the migratory properties of MDA-MB-231 TRPM7 knockdown cells 
(transwell: 95.3% ± 1.2%, 2 exp., p < 0.05; single cell migration: 25.3 ± 1.6 µm/hour, n > 200, 
4 exp, p < 0.01) (Fig. 3).
Reduced TRPM7 expression levels confer a contractile phenotype onto triple-negative breast 
tumor cells and induce cell-substrate adhesion assembly
In addition to the functional changes, immunofluorescent staining of MDA-MB-231 cells 
revealed the redistribution of filamentous actin to the cell cortex and a strong increase in the 
number of focal adhesions, especially in the periphery of TRPM7 knockdown MDA-MB-231 
cells, relative to mock transduced control cells (control: 13.8 ± 0.62, TRPM7 shRNA: 29.9 
± 0.85, n > 100, p < 0.001) (Fig. 4A & B). Focal adhesions are mechanosensitive adhesion 
structures whose assembly and disassembly need to be tightly regulated by a combination of 
myosin II-based cellular tension and local Ca2+ signaling events to allow optimal cell migration 
(Aratyn-Schaus and Gardel, 2010; Barnhart et al., 2011; Chrzanowska-Wodnicka and Burridge, 
1996; Giannone et al., 2002; Gupton and Waterman-Storer, 2006; Wolfenson et al., 2011). 
Increased focal adhesion assembly is generally associated with high cytoskeletal tension, 
accompanied by tyrosine phosphorylation of focal adhesion components such as paxillin as 
well as increased myosin light chain (MLC) phosphorylation (Chrzanowska-Wodnicka and 
Burridge, 1996). Indeed, the increase in focal adhesions observed in the TRPM7 knockdown 
cells was reflected by a rise in Tyr118-phosphorylated paxillin and Ser19-phosphorylated MLC 
on a western blot (Fig. 4C & S4A). Re-expression of TRPM7 reduced focal adhesion content 
(18.2 ± 0.89, n = 45, p < 0.001), and reverted paxillin phosphorylation (Fig. 4).
ER-positive breast cancer cells exhibit reduced cell migration speed and enforced cell-cell 
adhesions upon TRPM7 knockdown
In addition to basal-like tumors, represented by the triple-negative MDA-MB-231 breast cancer 
model, a large part of the patient dataset consisted of ER-positive, luminal type breast cancer 
patients. To validate our observations in these tumors, we knocked down TRPM7 in non-
invasive, ER-positive MCF7 human breast cancer cells (Fig. S1E). This significantly reduced 
migration of MCF7 cells in gap-closure assays (control: 11.5 ± 0.5% vs. TRPM7 shRNA: 21.2 
± 1.7 % gap remaining after 24 hours, 3 exp, p < 0.01) (Fig. 5A & B). In these epithelial-
like cells, TRPM7 knockdown predominantly affected cell-cell adhesion rather than cell-
substrate adhesion. Unlike the control shRNA transduced cells, the TRPM7 knockdown cells 
were able to maintain cell-cell contacts upon serum deprivation, a condition known to induce 
scattering of epithelial cells (Chen et al., 2010) (Fig. 5C). Although increased MLC and paxillin 
phosphorylation were not observed in MCF7 TRPM7 shRNA cells (data not shown), confocal 
microscopy revealed profound effects on cytoskeletal organization and cell-cell contacts (Fig. 
5D). Similar to our observations in MDA-MB-231 cells, TRPM7 knockdown induced the 
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Figure 3. TRPM7 contributes to 
the malignant phenotype of MDA-
MB-231 breast cancer cells in vitro
(A) Representative phase-contrast 
images of control and TRPM7 shRNA 
MDA-MB-231 cells. Scale bar = 50 µm. 
(B) Quantification of elongated MDA-
MB-231 cells, TRPM7 shRNA cells and 
TRPM7 shRNA cells made to re-express 
a mouse TRPM7 cDNA (rescued cells). 
Elongation is presented as percentage 
(± SEM; 4 independent experiments, 
n > 400) of cells that have a length 
of more than twice the width. *** P < 
0.001; ** P < 0.01. (C) Quantification 
of serum induced transwell migration 
by MDA-MB-231 cells, TRPM7 
shRNA cells and the rescued cell line. 
Data, normalized to the number of 
control MDA-MB-231 cells, are from 5 
independent experiments, performed 
in duplicate, in which the rescued cell 
line was included twice, and represent 
mean ± SEM. Migration was scored 
after 8 hours. ** P < 0.01; * P < 0.05. (D) 
Representative trajectories of migrating 
control (n = 10) and TRPM7 shRNA (n 
= 10) MDA-MB-231 cells, followed for 
24 hours. (E) Quantification of single cell migration speed. Shown is migration speed (µm / hr, mean ± SEM) of 4 
independent experiments, each performed in duplicate (n > 200 per cell line). ** P < 0.01.
redistribution of filamentous actin to the cell cortex. Moreover, cell-cell interactions appeared 
to be enforced in MCF7 TRPM7 shRNA cells, evident from increased cell-cell contact area and 
enrichment of E-cadherin at these interfaces. Cadherin-containing cell-cell adhesions, known 
as adherens junctions (AJs), show functional and structural similarities to focal adhesions 
(Chen et al., 2004). Like focal adhesions, AJs are highly dynamic multiprotein complexes that 
act in close association with the actomyosin cytoskeleton to translate mechanical signals into 
cellular responses. Moreover, their formation and size are directly associated with myosin II-
based cellular tension (Liu et al., 2010).
Pharmacological inhibition of cytoskeletal tension rescues the TRPM7 knockdown phenotype
Our results indicate that TRPM7 knockdown confers a contractile phenotype onto breast 
cancer cells and consequently, impairs their migratory and metastatic properties. Consistent 
with this notion, inhibition of myosin II-based cytoskeletal tension using the Y27632 Rho-kinase 
inhibitor (Uehata et al., 1997), was sufficient to revert the phenotype of TRPM7 knockdown in
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Figure 4. Reduced TRPM7 expression increases 
cytoskeletal contractility and affects focal 
adhesion dynamics of MDA-MB-231 cells (A) 
Immunofluorescence staining of MDA-MB-231 
cells with pTyr118 paxillin antibodies to reveal focal 
adhesions, and Alexa-568 Phalloidin to visualize 
the actin cytoskeleton. Arrows indicate enrichment 
of filamentous actin at the cell cortex. Scale bar = 
10 µm. (B) Quantification of the number of focal 
adhesions per cell, carried out by automated image 
analyses as detailed in material and methods. Data 
are mean ± SEM (n > 100 for control and TRPM7 
knockdown cells, n = 45 for rescue cell line). *** P 
< 0.001. (C) Immunoblot of Triton X-100 insoluble 
fractions derived from MDA-MB-231 control, TRPM7 
shRNA and rescued cells. Antibodies against pTyr118 
paxillin were used to determine the amount of tyrosine 
phosphorylated paxillin as a measure of cytoskeletal 
contractility and focal adhesion content. Antibodies 
against γ-tubulin were used to control for loading.
MDA-MB-231 cells to the characteristic elongated morphology of control cells (Elongated cells: 
54.5% ± 3.0%, n > 100, 2 exp, p < 0.05) (Fig. 6A), while reducing MLC- and paxillin 
phosphorylation, and the number of focal adhesions back to control levels (15.7 ± 0.26, n > 
100, p < 0.001) (Fig. 6B & C, S4A & B). A similar effect was observed with the structurally 
unrelated Rho-kinase inhibitor GSK429286 (Goodman et al., 2007) (Fig. S4A & B). Strikingly, 
Rho-kinase inhibition restored serum induced transwell migration of TRPM7 knockdown cells 
(TRPM7 shRNA: 63.9% ± 7.0% vs. TRPM7 shRNA + Y27632 (5 μM): 116.6% ± 17.9%, 3 exp, 
p < 0.05) without affecting MDA-MB-231 control cell migration (Fig. 6D & S4C). Likewise, gap-
closure speed of MFC7 TRPM7 shRNA cells was rescued by Rho-kinase inhibition (Fig. 6E & 
S4D). In contrast to MDA-MB-231 cells, low concentrations of Rho-kinase inhibitors already 
significantly increased gap-closure speed of MCF7 control cells. However, much higher 
concentrations of these compounds were required to maximize gap-closure speed of MCF7 
TRPM7 shRNA cells, supporting the notion that TRPM7 knockdown increases cellular tension. 
 Although our observations are not in agreement with the general notion that increases 
in Rho-ROCK signaling positively correlate with cell migration and metastasis formation (Croft 
et al., 2004; Jiang et al., 2009; Paszek et al., 2005), it is well known that actomyosin contractility, 
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Figure 5. TRPM7 knockdown 
reduces migratory properties and 
increases cell-cell interactions of 
MCF7 cells (A) Representative images 
of gap closure assay at time points 0, 
12, 18 and 24 hours. Scale bar = 100 
μm. (B) Quantification of percentage 
gap remaining after 12, 18 and 24 
hours. Data are from 3 independent 
experiments, each performed in 
duplicate, and represent mean ± SEM. * 
P < 0.05, ** P < 0.01. (C) Representative 
images from MCF7 control and TRPM7 
knockdown cells, after 0, 2 and 4 
hours of serum deprivation. Scale bar 
= 100 μm. (D) Immunofluorescence 
detection of E-cadherin in MCF7 cells 
to reveal adherens junctions, and 
Alexa-568 Phalloidin to visualize the 
actin cytoskeleton. Arrows indicate 
enrichment of E-cadherin at cell-cell 
interfaces. Scale bar = 10 µm.
adhesion dynamics, and the mechanical properties of the substrate, have to be tightly balanced 
in order to maximize migration velocity (Barnhart et al., 2011; DiMilla et al., 1991; DiMilla et al., 
1993; Gupton and Waterman-Storer, 2006). Hence, overassembly of either focal adhesions 
or adherens junctions in the TRPM7 knockdown cells, both a consequence of increased 
cytoskeletal tension, likely interferes with optimal cell migration (Fig. S4E). Altogether, our 
results indicate that TRPM7 is part of the mechanosensory machinery that regulates cellular 
tension and steers adhesion dynamics to allow cell migration and metastasis formation.
Conclusions
TRP channels play a prominent role in translating mechanical forces into biochemical signals, 
although in most cases it remains to be established whether they are directly activated by 
mechanical stimulation. Activation of these proteins not only leads to changes in local Ca2+ 
concentrations but also triggers other signaling mechanisms that influence cell behavior and
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Figure 6. Inhibition of cytoskeletal 
contractility recovers TRPM7 
knockdown phenotype in both 
MDA-MB-231 and MCF7 cells (A) 
Quantification of elongated MDA-
MB-231 TRPM7 shRNA cells with or 
without pretreatment with 5 µM Rho-
kinase inhibitor Y27632. Elongation is 
presented as percentage (± SEM; two 
independent experiments, n > 100) 
of cells that have a length of more 
than twice the width. * P < 0.05. (B) 
Quantification of focal adhesion content 
in MDA-MB-231 TRPM7 shRNA cells, 
with or without pretreatment for 2 
hours with 5 µM Rho-kinase inhibitor 
Y27632. Data are mean ± SEM (n > 
100 cells per cell line). *** P < 0.001. 
(C) Immunofluorescence staining of 
MDA-MB-231 cells with pTyr118 paxillin 
antibodies to reveal focal adhesions, 
and Alexa-568 Phalloidin to visualize 
the actin cytoskeleton. Scale bar = 10 
µm. (D) Quantification of serum-induced 
transwell migration of MDA-MB-231 
control and TRPM7 shRNA cells, 
treated with indicated concentrations 
Y27632 Rho-kinase inhibitor. Data, 
normalized to the number of migrated 
MDA-MB-231 control cells that were 
untreated, are from three independent 
experiments, performed in duplicate, and represent mean ± SEM. Migration was scored after 8 hours. * P < 0.05. 
For data on GSK429286 treated cells, see Fig. S4C (E) Quantification of percentage gap remaining by MCF7 
control and TRPM7 shRNA cells, treated with indicated concentrations Y27632 Rho-kinase inhibitor. Data represent 
percentage gap remaining after 18 hours (mean ± SEM, 3 independent experiments, each performed in duplicate). 
** P < 0.01, *** P < 0.0001. For data on GSK429286 treated cells, see Fig. S4D.
differentiation (Pedersen and Nilius, 2007). Mice deficient in TRPM7 show widespread defects 
in early embryonic development, pointing at a non-redundant role for this channel-kinase in 
organ development (Jin et al., 2008). Defects in mechanotransduction, especially those that 
affect cellular tension, are known to contribute to disease progression (Clark et al., 2007; 
Jaalouk and Lammerding, 2009). Hence, we propose that TRPM7 guided cell adhesion and 
migration are normal attributes of epithelial and mesenchymal cells, required during organ 
development, but when spuriously activated in cancer cells contribute to metastasis formation.
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Materials and methods
TRPM7 protein expression in primary breast cancer tissue samples detected by immunohistochemistry
Formalin-fixed, paraffin embedded breast tumor tissue, derived from the tumor bank of the Department of Laboratory 
Medicine of the Radboud University Medical Centre, was probed for TRPM7 (1:400, Cayman Chemical Company, 
Ann Arbor, MI), followed by biotin conjugated donkey anti-mouse IgG and DAB, and counterstained with hematoxylin. 
TRPM7 expression measurements in patient samples
Our discovery cohort consisted of 368 early-stage breast cancer samples, described in a previous study (Loi 
et al., 2007). The validation cohort consisted of 144 patients with unilateral breast cancer who had undergone 
resection of their primary tumor between November 1987 and December 1997 (Span et al., 2004). TRPM7 
expression levels in tumor samples derived from the discovery cohort were determined by microarray analysis 
using Affymetrix U133B Genechips (Affymetrix, Santa Clara, CA). Raw data are available at the Gene Expression 
Omnibus repository database (GEO accession number: GSE6532). TRPM7 expression levels in the validation 
cohort were determined by quantitative PCR reactions on cDNA samples derived from primary tumors, using 
power SYBR-green reagent (Applied Biosystems, Carlsbad, CA) in combination with TRPM7 specific primers 
(forward: TAGCCTTTAGCCACTGGAC; reverse: GCATCTTCTCCTAGATTTGC) according to manufacturer’s 
recommendations. TRPM7 gene expression levels were normalized to the HPRT housekeeping gene (forward: 
GGTCCTTTTCACCAGCAAGCT; reverse: TGACACTGGCAAAACAATGCA) and calculated according to the cycling 
threshold method (Livak and Schmittgen, 2001). Statistical analyses were carried out using SPSS software (version 
16.0; SPSS, Chicago, IL). Discovery and validation cohorts were dichotomized using median TRPM7 expression 
as cut-off. Survival curves were visualized by Kaplan-Meier plots, using recurrence-free and distant metastasis-
free survival as endpoints, and compared using log-rank tests. Hazard ratios were estimated by univariate Cox 
regression analysis. The independent prognostic value of TRPM7 was assessed by univariate and multivariate Cox 
regression analysis on combined discovery and validation cohorts.
 
Generation and validation of cell lines
Human TRPM7 shRNAs (#1: 5-GCGCTTTCCTTATCCACTTAA-3; #2: 5-CAGCAGAGCCCGATATTATTT-3) were 
introduced in MDA-MB-231 (HTB-26, ATCC) and human TRPM7 shRNA#1 was introduced in MCF7 human 
breast cancer cells (HTB-22, ATCC), using the pLKO lentiviral expression vector according to manufacturer’s 
instructions (Sigma Aldrich, St. Louis, MO). A nonfunctional shRNA (5-GCTACAAGAGAAACCAAATCT-3) was 
used as negative control. Transduced cells were selected with 1 µg/ml puromycin. For bioluminescent imaging, 
control and TRPM7 knockdown MDA-MB-231 cells were co-transduced with a retroviral pLZRS luciferase reporter 
construct and selected with 0.5 mg/ml Zeocin. For rescue of TRPM7 expression levels, HA-tagged mouse TRPM7, 
containing one mismatch with respect to the human-specific shRNA (Clark et al., 2006), was introduced in MDA-
MB-231 TRPM7 shRNA cells. Transduced cells were selected with 1 mg/ml G418. TRPM7 mRNA expression 
levels were determined by quantitative RT-PCR with the additional use of mouse specific TRPM7 primers 
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(forward: TAGCCTTTAGCCACTGGACC; reverse: GCATCTTCTCCTAGATTGGCAG). TRPM7 protein levels were 
determined by radioactively labeling the TRPM7 kinase domain as described previously (Clark et al., 2006).
Cell viability and proliferation measurements
The effect of TRPM7 knockdown on cell viability and proliferation was assessed by MTS assays according to 
manufacturer’s instructions (Promega, Madison, WI). Cell cycle distribution of the different cell lines was determined 
by FACS analysis on cells stained with propidium iodide. Cells were harvested and the cell pellet was incubated in 
staining solution (1 mg/ml sodium citrate, 0.1 mg/ml RNAseA, 20 µg/ml propidium iodide, and 0.1% Triton X-100). 
Cells were washed and subjected to FACS analysis. Cell cycle distribution was quantified using FlowJo analysis 
software.
Mouse xenograft experiments
All animal work was performed in accordance with protocols approved by the Animal Welfare Committee (DEC-
NKI-10.034). Immunodeficient Rag2-/-IL2rg-/- mice were used for metastasis experiments. MDA-MB-231-Luc 
control and TRPM7 knockdown cells were collected and washed with PBS. Subsequently, 0.2 ml PBS containing 
5*105 cells was injected into a tail vein. Tumor growth, was monitored by bioluminescence imaging from day 7 
onwards. Beetle luciferin (Promega, Madison, WI) was dissolved at 15 mg/ml in PBS and stored at -20°C. Animals 
were anaesthetized with 2-3% isoflurane. Luciferin solution was injected intraperitonially (0.01 ml/gram body 
weight). Light emission was measured 15 minutes later, using a cooled CCD camera (IVIS; Xenogen), coupled to 
Living Image acquisition and analysis software over an integration time of 1 min. Signal intensity was expressed 
as flux (photons / second) integrated over the lung region. Lung tissue was collected at day 30 after injection. 
Tissues were fixed in EAF (ethanol-acetic acid-formol saline fixative, 40:5:10:45 % v/v) and processed for histology. 
Paraffin sections were stained with Haematoxylin and Eosin (HE). All microscopic images were acquired using IP-
Lab software (Scanalytics Inc., Fairfax, VA, USA) in combination with a monochrome CCD camera (Retiga SRV, 
1392 * 1040 pixels) and a RGB filter (Slikder Module; QImaging, Burnaby, BC, Canada) attached to a motorized 
microscope (Leica DM6000, Wetzlar, Germany). Quantification of tumor size and number was carried out by ImageJ 
image analysis software.
Cell migration, -elongation and -scatter experiments
Following overnight serum starvation, cells were harvested and resuspended in DMEM containing 0.1% FBS. 
Subsequently, 50.000 cells were applied to a transwell insert with 8 µm pore size (Corning Life Sciences, Corning, 
NY), which was incubated in DMEM supplemented with 10% FBS. Cells were allowed to migrate for 8 hours at 
37 °C. Migrated cells were fixed (75% methanol and 25% acetic acid) and stained (0.25% Coomassie Blue, 45% 
methanol, 10% acetic acid in H2O). Single cell migration on vitronectin coated (500 ng/ml) culture dishes, was 
followed for 24 hours by time lapse microscopy and analyzed using ImageJ image analysis software. Cell elongation 
was determined based on length and width ratios, measured after 24 hours. A cell was considered elongated when 
the ratio length/width was larger than 2. MCF7 cell scattering on vitronectin coated (500 ng/ml) culture dishes was 
visualized by timelapse microscopy in DMEM supplemented with 0.1% FBS. Gap closure assays were performed 
according to manufacturer’s recommendations (Applied Biophysics, Troy, NY). In short, 40.000 MCF7 cells were 
seeded per insert and cultured overnight. After removal of the insert, cells were allowed to migrate for 24 hours and 
migration was followed by time lapse microscopy. Where indicated, cells were incubated in the presence of different 
concentrations Y27632 (Sigma-Aldrich, St. Louis, MO) and GSK429286 (Seleckbio, Munich, Germany) Rho-kinase 
inhibitors.
Fluorescent staining of focal adhesions, E-cadherin and F-actin
Images were taken with a Leica TCS SP5 confocal (Leica Microsystems) equipped with a 63x water-immersion 
objective and LAS-AF acquisition software (Leica Microsystems). Cells were cultured overnight on vitronectin 
coated (500 ng/ml) glass coverslips in DMEM containing 0.1% FBS. Where indicated, cells were next incubated for 
2 hours in the presence of 5 µM Y27632 Rho-kinase inhibitor (Sigma-Aldrich, St. Louis, MO). Cells were fixed in 
3.7% formaldehyde, permeabilized in 0.1% Triton X-100 and stained for pTyr118 paxillin (1:100, Life Technologies, 
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Carlsbad, CA), E-cadherin (1:200, BD Biosciences, Franklin Lakes, NY) and actin, using Alexa-568 conjugated 
Phalloidin (1:100, Life Technologies, Carlsbad, CA). The average number of focal adhesions per cell was quantified 
using an ImageJ analysis routine (macro). Series of paxillin images (pixel size, 0.11 x 0.11 μm2) were normalized 
with respect to intensity/contrast, background was subtracted and cell boundaries were detected by manually 
setting the appropriate threshold. The original image was subjected to a rolling-ball filter of radius 10 pixels, which 
effectively suppresses staining irregularities while retaining contrast in the focal adhesions. Further thresholding 
and the ‘Analyze Particles’ plugin (settings: particle size 30-500 pixels; circularity 0.1-1.0) were used to determine 
the number of focal adhesions. Photomicrographs of at least 60 cells were analyzed for each condition.
Detection of pSer19 myosin light chain and focal adhesion associated pTyr118 paxillin on Western blot
For detection of pSer19 myosin light chain in control and TRPM7 shRNA transduced MDA-MB-231 cells, cells 
were lysed in Laemmli buffer supplemented with 1 μM MgCl2 and 1:200 Benzoase Nuclease (Merck, Darmstadt, 
Germany), and left on ice for 30 minutes. Focal adhesion associated proteins were extracted from MDA-MB-231 
cells as described previously (Putnam et al., 2003). Proteins were separated by SDS-PAGE and blotted onto a PVDF 
membrane. Blots were incubated with rabbit polyclonal anti-pTyr118 paxillin antibody (1:750, Life Technologies, 
Carlsbad, CA), or anti-pSer19 myosin light chain antibody (1:1000, Life Technologies, Carlsbad, CA) and mouse 
monoclonal γ-Tubulin (1:10000, Sigma Aldrich, St. Louis, MO) antibodies, followed by HRP-conjugated secondary 
antibodies (1:5000, DAKO, Glostrup, Denmark). Proteins were detected using ECL Western blot reagent (GE 
Healthcare, Chalfont St. Giles, UK) and exposing the blots to film.
Statistical analysis
Statistical data are expressed as mean ± standard deviation (SD) or ± standard error of the mean (SEM) as 
indicated in the text. Statistical differences were tested with two-sided, unpaired Student’s t-tests and p < 0.05 was 
considered statistically significant.
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Figure S1. TRPM7 expression measurements on TRPM7 knockdown MDA-MB-231 and MCF7 cells and 
TRPM7 rescued cells (A) Human TRPM7 mRNA expression in control and MDA-MB-231 TRPM7 knockdown 
cells, determined by quantitative real-time PCR. TRPM7 expression in the control cells is set to 1. * P < 0.05 (B) 
Autoradiogram revealing TRPM7 autophosphorylation, indicative of TRPM7 protein levels in MDA-MB-231 control 
and TRPM7 knockdown cells. Autophosphorylation of recombinant TRPM7, stably introduced in neuroblastoma 
cells (Clark. et al., 2006), serves as positive control. (C) Mouse TRPM7 mRNA expression levels in MDA-MB-231 
TRPM7 knockdown cells that were made to re-express mouse TRPM7 (rescued). Mouse TRPM7 expression in 
the rescued cells is set to 1. *** P < 0.001. (D) Top panel: Autoradiogram revealing TRPM7 autophosphorylation, 
indicative for TRPM7 protein levels in MDA-MB-231 control, TRPM7 knockdown, and rescued cells. Bottom panel: 
Quantification of TRPM7 autophosphorylation by scintillation counting. Data are mean ± SEM of two independent 
experiments. ** P < 0.01. (E) Human TRPM7 mRNA expression in MCF7 control and TRPM7 knockdown cells, 
determined by quantitative real-time PCR. TRPM7 expression in the control cells is set to 1. ** P < 0.01.
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Figure S2. TRPM7 
knockdown does not 
affect MDA-MB-231 cell 
proliferation but impairs 
metastasis formation 
in vivo. (A) Cell cycle 
distribution of control and 
TRPM7 knockdown MDA-
MB-231 cells by propidium 
iodide staining and FACS 
analysis. Histogram shows 
fluorescent intensity, 
indicative of relative 
DNA content versus cell 
number. The percentage 
of cells in phase G1 and 
G2 of the cell cycle are 
tabulated in the inset 
panel. (B) Quantification of 
bioluminescence in mice 
treated with MDA-MB-231 
control, TRPM7 shRNA or 
TRPM7 shRNA#2 cells, 
up to 35 days after injection. Data are presented as mean ± SEM of n= 4 mice in each group. (C) Representative 
bioluminescence images of mice, 35 days after intravenous injections with MDA-MB-231 control or TRPM7 shRNA 
cells. (D) Size distribution of tumors in resected long tissue from mice treated with MDA-MB-231 control cells or 
TRPM7 shRNA cells.
Figure S3. TRPM7 shRNA#2 treatment reduces malignant phenotype of MDA-MB-231 cells. (A) Quantification 
of elongated MDA-MB-231 control and TRPM7 shRNA#2 cells. Elongation is presented as percentage (± SEM; 
3 independent experiments, n > 300) of cells that have a length of more than twice the width. * P < 0.05. (B) 
Quantification of serum induced transwell migration of MDA-MB-231 control and TRPM7 shRNA#2 cells. Data, 
normalized to the number of control MDA-MB-231 cells, are from 3 independent experiments, performed in duplicate 
and represent mean ± SEM. Migration was scored after 8 hours. ** P < 0.01. (C) Quantification of single cell 
migration speed. Shown are migration speed (µm / hr, mean ± SEM) of 3 independent experiments, each performed 
in duplicate (n > 150 per cell line). ** P < 0.01.
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Table S1. Patient- and tumor characteristics in discovery and validation cohort
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Table S2. TRPM7 expression levels and clinical parameters. (A) TRPM7 is enriched in high grade primary 
breast tumors. Patients from the combined discovery and validation cohorts (n = 512), are categorized according 
to dichotomized clinical parameters and TRPM7 expression levels. P-values are based on Fisher’s Exact test. (B) 
& (C) Based on ER status and gene expression analysis, we categorized the primary tumors within the discovery 
cohort (n=368) into breast cancer subtypes (luminal, basal-like and Her2/Neu-type). Her2/Neu amplification status 
was lacking for all the samples. However, the Affimatrix Genechips featured three independent probes against Her2/
Neu. For each individual probe, tumors were ranked according to Her2/Neu expression levels. Since the Her2/Neu 
gene is reported to be amplified in ~20% of all breast cancers (Brenton et al., 2005), a tumor was assigned ‘Her2/
Neu amplified’ when Her2/Neu expression levels were in the top 20%, according to at least two out of three probes 
(probe score ≥ 2) (B). Tumors were categorized into subtypes according to the following criteria: Luminal tumors 
are predominantly estrogen receptor (ER) positive. Basal-like tumors are generally triple negative, ie. ER-negative, 
progesteron receptor (PGR) negative and exhibit normal Her2/Neu expression levels. Her2/Neu-type tumors are 
ER-negative, PGR-negative but have a positive Her2/Neu amplification status (Slamon et al., 1987). PGR-status 
was lacking for the majority of the samples. However, PGR-status is strongly associated with ER-status and was 
therefore considered to be similar to ER-status in this analysis. P-values are based on Pearson’s Chi-Square test 
(C).
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Figure S4. Rho-kinase inhibition 
rescues contractile and migratory 
phenotype of TRPM7 shRNA cells. 
(A) Immunoblots of total lysates derived 
from MDA-MB-231 control and TRPM7 
shRNA cells that were pretreated for 2 
hours with indicated concentrations of 
Y27632 (left panel) and GSK429286 
(right panel) Rho-kinase inhibitors. 
Antibodies against pSer19 myosin light 
chain (MLC) were used to determine 
the amount of phosphorylated MLC as 
a measure of cytoskeletal contractility. 
Antibodies against γ-tubulin were used 
to control for loading. (B) Immunoblot of 
Triton X-100 insoluble fractions derived 
from MDA-MB-231 TRPM7 shRNA cell 
lysates. Cells were pretreated for 2 
hours with the indicated concentrations 
of Y27632 (left panel) and GSK429286 
(right panel) Rho-kinase inhibitors. 
Phosphorylated paxillin was detected 
with an antibody against pTyr118 paxillin. 
γ-Tubulin served as a loading control.  (C) 
Quantification of serum induced transwell 
migration of MDA-MB-231 control 
and TRPM7 shRNA cells, treated with 
indicated concentrations GSK429286 
Rho-kinase inhibitor. Data, normalized 
to the number of migrated MDA-MB-231 
control cells that were untreated, are from 
3 independent experiments, performed 
in duplicate, and represent mean ± SEM. 
Migration was scored after 8 hours. * P < 0.05. (D) Quantification of percentage gap remaining by MCF7 control 
and TRPM7 shRNA cells, treated with indicated concentrations GSK429286 Rho-kinase inhibitor. Data represent 
percentage gap remaining after 18 hours (mean ± SEM, 3 independent experiments, each performed in duplicate). 
* P < 0.05, ** P < 0.01, *** P < 0.0001. (E) Hypothetical model explaining how increased cytoskeletal tension in the 
TRPM7 knockdown cells, and its reduction by Rho-kinase inhibitors, may affect migration speed. Tight regulation of 
cytoskeletal tension and cell adhesion (x-axis) is required for optimal cell migration (y-axis). TRPM7 knockdown in 
MDA-MB-231 cells promotes cytoskeletal tension and consequently, impairs cell migration. Inhibition of actomyosin 
contractility by Rho-kinase inhibitors reverts these effects. Similarly, in MCF7 cells, optimal migration requires higher 
concentrations of Rho-kinase inhibitors in the TRPM7 knockdown cells relative to control cell.
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Abstract
Epithelial tumors acquire metastatic traits through a process known as epithelial-mesenchymal 
transition (EMT), which endows tumor cells with increased migratory and invasive properties. 
We previously showed that the channel-kinase TRPM7, a regulator of cytoskeletal tension 
and implicated in mechanosensory processes, is required for breast cancer metastasis in vitro 
and in vivo. Here we show that TRPM7 contributes to a mesenchymal phenotype in breast 
cancer cells by modulating expression of the EMT transcription factor SOX4. Consistently, 
SOX4 expression levels correlate with TRPM7 in breast cancer patient datasets. Moreover, we 
show that expression of SOX4 is inversely correlated with - and regulated by – myosin II-driven 
cytoskeletal tension. Importantly, the functional consequences of TRPM7 knockdown mirror 
those produced by loss of SOX4. Hence, high TRPM7 expression or activity may contribute to 
breast cancer progression by releasing cytoskeletal tension and enhancing SOX4 expression, 
promoting EMT. Most importantly, our results identify SOX4 as an EMT transcription factor that 
is uniquely sensitive to the contractile state of cells.
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Introduction
Metastasis accounts for approximately 90% of cancer-associated mortality. Metastatic 
progression is driven by the tumor microenvironment, for instance by the presence of paracrine 
signaling molecules acting on the tumor cells (Gonzalez and Medici, 2014). In addition, 
mechanical properties of the tumor microenvironment and the cytoskeletal responses to 
these mechanical cues contribute to metastasis formation (Butcher et al., 2009). For example, 
increased stromal stiffness in tumors was shown to promote tumor progression (Paszek et al., 
2005). Moreover, activation of mechanically-regulated signaling cascades such as the YAP/
TAZ and MRTF/SRF pathways has been linked to metastatic progression (Cordenonsi et al., 
2011; Medjkane et al., 2009).
 The majority of human cancers is derived from epithelial tissues. To become metastatic, 
epithelial tumor cells need to lose cell-cell adhesions, obtain migratory and invasive properties 
as well as the ability to survive in an anchorage-independent manner (Hanahan and 
Weinberg, 2011). Epithelial tumor cells acquire these features by activation of a developmental 
transcription program known as epithelial-mesenchymal transition (EMT) (Thiery et al., 2009). 
Whereas EMT endows tumor cells with the ability to escape from the primary tumor and form 
micrometastases, the reverse process, mesenchymal-epithelial transition (MET) is thought to 
be required for the outgrowth of macrometastases (Tsai and Yang, 2013). Plasticity between 
epithelial and mesenchymal states therefore seems essential throughout the metastatic 
cascade.
 The EMT transcriptional program is activated by a number of extracellular signaling 
molecules, including TGF-β, Notch ligands, Wnt proteins and growth factors (Gonzalez and 
Medici, 2014). These proteins activate intracellular signaling molecules, such as SMADs, 
PI3K-Akt, β-catenin or STAT3 which in turn induce expression of EMT-transcription factors 
(EMT-TFs) such as SNAI1, SNAI2, TWIST1, ZEB1, ZEB2 and SOX4 (Gonzalez and Medici, 
2014; Lamouille et al., 2014). Independent of ligand-induced EMT, the mechanical properties 
of the microenvironment, and the cytoskeletal responses that follow, also play a role in EMT 
regulation (Brown et al., 2013; O’Connor and Gomez, 2014). For instance, the cytoskeleton-
regulated transcriptional regulators TAZ and SRF have been implicated in EMT (Diepenbruck 
et al., 2014; Lei et al., 2008; Zhao et al., 2014). In addition, TWIST1 was recently shown to 
translocate to the nucleus by increased matrix stiffness (Wei et al., 2015). 
 We and others have shown that the channel-kinase TRPM7, a member of the transient 
receptor potential family of cation channels, reduces myosin II-based cellular tension via Ca2+- 
and kinase-dependent interactions with the actomyosin cytoskeleton, thereby affecting cell 
adhesion and migration (Clark et al., 2006; Kuipers et al., 2012; Su et al., 2006; Visser et al., 
2013). Consistent with this notion, we demonstrated that expression of TRPM7 is required for 
breast tumor cell migration in vitro and metastasis formation in mouse xenografts (Middelbeek et 
al., 2012). In addition, high TRPM7 mRNA expression levels at time of diagnosis are correlated 
with poor outcome and metastasis formation in breast cancer patients (Middelbeek et al., 
2012). Recent reports have confirmed the association between high TRPM7 expression and 
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cancer progression in other tumor types, including pancreatic, nasopharyngeal and prostate 
cancer (Chen et al., 2014; Rybarczyk et al., 2012; Sun et al., 2013).
 In addition to regulating cellular tension, cell adhesion and motility by direct interactions 
with the actomyosin cytoskeleton, TRPM7 controls gene expression programs involved 
in cellular differentiation and embryogenesis. For instance, TRPM7 is required for proper 
embryonic development in mice, zebrafish and Xenopus (Elizondo et al., 2005; Jin et al., 2008; 
Jin et al., 2012; Liu et al., 2011). Furthermore, TRPM7 was shown to be required for TGF-β-
induced atrial fibroblast proliferation and differentiation, contributing to atrial fibrosis (Du et al., 
2010). Moreover, TRPM7 regulates protein expression of the EMT marker vimentin in MDA-
MB-468 breast cancer cells (Davis et al., 2014). Based on these findings, we hypothesized that 
TRPM7-induced changes in cytoskeletal tension may affect developmental gene expression 
programs such as those involved in cancer progression. Here, we report that TRPM7 is 
essential for the maintenance of a mesenchymal phenotype in breast cancer cell lines by 
regulating expression of the EMT transcription factor SOX4, an important regulator of EMT and 
implicated in breast cancer progression (Tiwari et al., 2013). Moreover, high TRPM7 expression 
is correlated with high SOX4 expression in published breast cancer patient datasets. Finally, we 
show that expression of SOX4 is highly sensitive to the myosin II-driven tensional state of the 
cytoskeleton, indicating that TRPM7 regulates SOX4 expression by modulating cytoskeletal 
tension.
Results
TRPM7 maintains mesenchymal phenotype of breast cancer cells
We recently showed that loss of TRPM7 affects the metastatic potential of highly invasive MDA-
MB-231 (MDA-231) mesenchymal breast cancer cells (Middelbeek et al., 2012). Knockdown 
of TRPM7 in MDA-231, using two independent shRNAs against TRPM7 that we characterized 
previously (Middelbeek et al., 2012), resulted in a loss of the typical spindle-shaped morphology 
of these cells (Figure 1A & (Middelbeek et al., 2012)). Because TRPM7 has been linked to 
the regulation of cellular differentiation and embryonic development (Du et al., 2010; Elizondo 
et al., 2005; Jin et al., 2008; Jin et al., 2012), we speculated that TRPM7 shRNA-induced loss 
of the spindle-shaped morphology of MDA-231 was in fact a MET-like process. Indeed, MDA-
231 TRPM7 shRNA cells showed increased formation of cell-cell adhesions, as observed 
by translocation of the tight junction protein ZO-1 to sites of cell-cell contacts (Figure 1B), 
while the expression of ZO-1 was not affected (Figure 1D). In contrast, TRPM7 knockdown 
markedly increased the expression of the epithelial markers and cell-cell adhesion proteins 
CDH1 (E-cadherin) and CLDN1 (claudin-1) both at the mRNA and protein level (Figure 1C-
D), whereas expression of the mesenchymal markers FN1 (fibronectin) and VIM (vimentin) 
decreased (Figure 1C-D). These observations were largely reproduced by incubating cells 
with the TRPM7-specific inhibitor Waixenicin A (Waix A) (Zierler et al., 2011), which lead to an 
increase in CLDN1 expression and a decrease in FN1 expression (Supplementary Fig. S1A). 
Unexpectedly however, CDH1 expression decreased by Waix A treatment (Supplementary 
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Figure 1. TRPM7 is necessary for maintenance of the 
mesenchymal phenotype of MDA-231 cells. (A) Phase-
contrast images showing morphology of MDA-231 shCntrl, 
shT7#1 and shT7#2. Scale bar = 50 µM. (B) Representative 
immunofluorescence staining of F-actin (cytoskeletal protein) 
and ZO-1 (tight junction protein). Red arrows in ZO-1 pictures 
indicate ZO-1 localization to cell-cell adhesions. Right panels 
are a zoom in of middle panels. Scale bars = 20 µM for left 
and middle panels, 5 µM for right panels. (C) Relative mRNA 
expression of indicated EMT markers, depicted as fold changes 
in expression over MDA-231 shCntrl as determined by q-PCR. 
(D) Protein expression of indicated EMT markers as determined 
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by western blotting. γ-tubulin was used as loading control. Representative examples of n = 3 experiments. (E) Effect 
of 4 days TGF-β stimulation (2 ng/ml) on EMT marker expression in MDA-231 shCntrl and shT7#1. TGF-β was 
replenished after 2 days of stimulation. mRNA expression is depicted as fold change over unstimulated MDA-231 
shCntrl or shT7#1. (C) + (E) mRNA expression levels were determined by q-PCR. Data are mean ± SEM of n = 3 
experiments that were performed in duplicate. Statistical significance was determined by a one-sample t-test. * = p 
< 0.05, ** = p < 0.01, *** = p < 0.001.
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Fig. S1A). Waix A treatment did not affect TRPM7 mRNA expression, pointing to specific 
effects of TRPM7 activity on gene expression (Supplementary Fig. S1B). Importantly, 
TRPM7 knockdown as well as inhibition of TRPM7 with Waix A induced a similar epithelial-like 
phenotype in the mesenchymal breast cancer cell line Hs 578T (Supplementary Fig. S2A-E). 
Subsequently, we assessed whether TRPM7 expression is required for MDA-231 shT7#1 cells 
to undergo EMT. To this end, we stimulated MDA-231 shCntrl and shT7#1 cells with TGF-β for 4 
days and observed that CDH1 and CLDN1 expression decreased and FN1 and VIM expression 
increased in shT7#1 cells to a similar extent as in shCntrl cells (Figure 1E). Taken together, 
these results indicate that TRPM7 is required for maintenance of a mesenchymal phenotype of 
breast cancer cells in the absence of EMT inducing ligands, but not in the presence of potent 
EMT inducers such as TGF-β.
TRPM7 regulates expression of the EMT transcription factor SOX4
To identify how TRPM7 modulates EMT, we performed microarray analysis on MDA-231 shCntrl 
and shT7#1 cells. From the microarray analysis, we selected a set of transcription factors 
known to regulate EMT or MET (Lamouille et al., 2014; Moustakas and Heldin, 2014). While 
MET inducers remained largely unaffected, we found that the EMT regulating transcription 
factor SOX4 was significantly downregulated in response to TRPM7 knockdown (~6x) (Figure 
2A). SOX4 has only recently been recognized as an EMT-TF (Tiwari et al., 2013; Zhang et 
al., 2012). Consistent with our previous findings on TRPM7, SOX4 expression appears to 
play a key role during tumor cell migration and metastasis in mouse experimental metastasis 
models (Tiwari et al., 2013). Moreover, similar to TRPM7 (Middelbeek et al., 2012), SOX4 
expression positively correlates with metastatic progression in breast cancer patients (Tiwari 
et al., 2013). Reduced expression of SOX4 by TRPM7 shRNA was confirmed by q-PCR and 
western blotting in both MDA-231 and Hs 578T cells (Figure 2B-C & Supplementary Fig. 
S3A-B). To further substantiate these findings, we determined the expression of the well-
established EMT-TFs SNAI1, SNAI2, ZEB1 and ZEB2 (TWIST1 expression was not detected 
by q-PCR in MDA-231). In line with the observed changes in gene expression, we found that 
only SNAI2 expression was weakly affected by TRPM7 shRNA in MDA-231 cells (Figure 2B). 
Similarly, in Hs 578T cells, SNAI1, SNAI2, TWIST1, ZEB1 and ZEB2 were not affected by 
TRPM7 knockdown (Supplementary Fig. S3A). Inhibition of TRPM7 by treating MDA-231 
and Hs 578T cells with Waix A induced a rapid decrease in SOX4 expression, indicating that 
signaling events downstream of TRPM7 activity regulate expression of SOX4 (Figure 2D & 
Supplementary Fig. S3C). In contrast, SNAI2 expression in MDA-231 cells did not follow the 
gradual decrease we observed for SOX4 expression, but only decreased slightly after 4h and 
o/n Waix A stimulation (Supplementary Fig. S3D). Similar to TRPM7 knockdown in Hs 578T, 
SNAI2 expression was unaffected by Waix A treatment, suggesting cell type specific regulation 
of SNAI2 by TRPM7 (Supplementary Fig. S3C). Together, our results show that SOX4 is a 
common downstream transcriptional target of TRPM7 signaling in mesenchymal breast cancer 
cell lines, and that its expression depends on TRPM7 expression and activity. In support of 
these observations, we observed that TRPM7 and SOX4 mRNA expression correlate in 
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primary breast tumor samples, as determined in four independent, publicly available breast 
cancer patient cohorts (R2: Genomics Analysis and Visualization Platform, http://r2.amc.nl) 
(Figure 2E-F).
SOX4 maintains mesenchymal phenotype of breast cancer cells
To test if reduced SOX4 expression induces a similar MET-like process in MDA-231 cells, 
we performed shRNA-mediated knockdown of SOX4 using two independent SOX4 targeting 
shRNAs (Supplementary Fig. S4A-B). Similar to TRPM7 shRNA MDA-231 cells (see above), 
SOX4 knockdown MDA-231 cells lost their spindle-shaped morphology and adapted a more
Figure 2. TRPM7 knockdown reduces expression of the EMT transcription factor SOX4. (A) Microarray results 
depicted in a heatmap containing log10 transformed intensity values of known EMT and MET inducers in MDA-
231 shCntrl and shT7#1 (B) Relative mRNA expression of well-established EMT-TFs, depicted as fold changes in 
expression over MDA-231 shCntrl. (C) Protein expression of SOX4 after stable knockdown of TRPM7, determined 
by western blotting. Representative example of n = 3 experiments. (D) Effect of Waix A (3.3 µM) stimulation on 
SOX4 mRNA expression in MDA-231 cells at different timepoints. Waix A activity is reduced in the presence of 
serum (Zierler et al., 2011). Therefore, stimulation was performed in serum-depleted medium. (B) and (D) mRNA 
expression levels were determined by q-PCR. Data are mean ± SEM of n = 3 experiments that were performed in 
duplicate. Statistical significance was determined by a one-sample t-test. * = p < 0.05, ** = p < 0.01. (E) Scatter plot 
showing the correlation between TRPM7 and SOX4 expression in the Bertucci dataset. (F) Correlation coefficients 
between TRPM7 and SOX4 in four breast cancer patient datasets. (E) and (F) Patient dataset analysis was 
performed using R2 microarray analysis tools (http://r2.amc.nl). Pearsons’ correlations tests were performed to test 
for statistical significance of correlation.
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epithelial-like morphology (Figure 3A). Consistently, we observed an increase in cell-cell 
adhesions as evidenced by translocation of ZO-1 to sites of cell-cell contacts (Supplementary 
Fig. S4C). In addition, the expression of the cell-cell adhesion proteins E-cadherin and 
claudin-1 was strongly induced in MDA-231 shSOX4#1, both at the mRNA and protein level 
(Figure 3B-C). MDA-231 shSOX4#2 cells showed a similar but less pronounced increase in 
E-cadherin and claudin-1, probably a reflection of the less efficient SOX4 knockdown in these 
cells (Figure 3B-C & Supplementary Fig. S4A-B). Fibronectin decreased to a similar extent 
in both SOX4 shRNA MDA-231 cell lines (Figure 3B-C). No decrease in vimentin expression 
was observed (Figure 3B-C). Expression of other EMT-TFs was unaffected by knockdown of 
SOX4 in MDA-231 with the exception of ZEB2, which increased in SOX4 shRNA MDA-231 
cells (Supplementary Fig. S4D).
 To assess if MDA-231 shSOX4#1 can still undergo EMT, we stimulated cells with 
TGF-β for 4 days and observed decreased CDH1 expression and increased FN1 expression 
(Supplementary Fig. S4E). Hence, similar to what we observed in the TRPM7 knockdown 
cells, in the presence of a potent EMT inducer such as TGF-β, loss of SOX4 expression alone 
does not appear to be sufficient to block EMT transcriptional programs.
 To determine to what extent SOX4 mediates the effects on gene expression that we 
observed in response to TRPM7 knockdown, we performed microarray analysis on MDA-231 
shCntrl and shSOX4#1 cells, and compared the up- and downregulated genes between MDA-
231 shT7#1 and shSOX4#1. Using a fold change cut-off ≥ |2|, we found a highly significant 
overlap in up- and downregulated genes between MDA-231 shT7#1 and shSOX4#1 (135 
upregulated genes, p = 1.70e-97 and 84 downregulated genes, p = 5.01e-40) (Figure 3D & 
Supplementary Table S1). Hence, these data identify SOX4 as a key determinant of TRPM7 
gene expression signature. Moreover, our results indicate that activation of the TRPM7-SOX4 
axis acts to preserve the mesenchymal state of breast cancer cells.
SOX4 expression is inversely correlated with cellular tension 
We previously showed that activation of TRPM7 reduces cytoskeletal tension while knockdown 
of TRPM7 increases cytoskeletal tension (Clark et al., 2006; Middelbeek et al., 2012). Since 
cytoskeletal tension was shown to have an effect on gene expression regulation (Halder et al., 
2012; Mammoto et al., 2012; Posern and Treisman, 2006), we hypothesized that TRPM7 may 
regulate SOX4 expression by modulating cytoskeletal tension. To assess if and how increased 
cytoskeletal tension would affect SOX4 expression, we stimulated MDA-231 shCntrl cells with 
lysophosphatidic acid (LPA), a potent activator of RhoA, leading to increased actomoysin-based 
contraction in most cell types (Moolenaar et al., 2004). Alternatively, we stably transduced 
MDA-231 cells with constitutive active V14RhoA. Similar to inhibition of TRPM7, LPA caused 
a rapid decrease in SOX4 expression that was sustained o/n (Figure 4A), whereas V14RhoA 
stably reduced SOX4 expression (Figure 4B). At the same time, expression of the EMT-TF 
SNAI2 remained largely unaffected by increased cytoskeletal tension (Supplementary Fig. 
S5A-B).
 We next determined whether the expression of epithelial and mesenchymal markers 
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Figure 3. SOX4 knockdown MDA-231 phenotypically mimic TRPM7 knockdown MDA-231. (A) Phase-contrast 
images showing morphology of MDA shCntrl, shSOX4#1 and shSOX4#2. Scale bar = 50 µM. (B) Relative mRNA 
expression of EMT markers, depicted as fold changes in expression over MDA-231 shCntrl as determined by 
q-PCR. Data are mean ± SEM of n = 3 experiments that were performed in duplicate. Statistical significance was 
determined by a one-sample t-test. * = p < 0.05, ** = p < 0.01. (C) Protein expression of EMT markers as determined 
by western blotting. γ-tubulin was used as loading control. Representative examples of n = 3 experiments. (D) 
Overlapping up- and downregulated genes in shSOX4#1 (total up: 457; total down: 445) and shT7#1 (total up: 
661; total down: 727) microarray. A fold-change ≥ |2| was used as cut-off. p-values were determined by means of a 
hypergeometric distribution test.
was also affected by increases in cytoskeletal tension. Indeed, CLDN1 expression increased 
rapidly both after LPA stimulation as well as in V14RhoA expressing cells, relative to MDA-
231 EV control cells (Figure 4C-D). Conversely, FN1 expression was reduced both by LPA 
stimulation and V14RhoA expression (Figure 4E-F). Unexpectedly, but similar to what was 
seen after Waix A treatment (Supplementary Fig. S1A), CDH1 expression decreased after 
8h and o/n stimulation with LPA, as well as in MDA-231 V14RhoA cells (Supplementary Fig. 
S5C-D), which differs from the increase in CDH1 expression seen in response to TRPM7 and 
SOX4 knockdown (Figure 1C & 3B). TRPM7 expression was not significantly affected by either 
LPA or V14RhoA, ruling out the possibility that LPA and V14RhoA act by expression regulation 
of TRPM7 (Supplementary Fig. S5E-F). Together, these results indicate that increasing 
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Figure 4. Increasing cytoskeletal tension decreases SOX4 expression in MDA-231. (A) + (C) + (E) Effect of 
LPA stimulation on SOX4, CLDN1 and FN1 expression. To sensitize MDA-231 for LPA stimulation, cells were serum 
starved o/n. Cells were subsequently stimulated with 10 µM LPA (in serum-depleted medium) for the indicated 
time points. (B) + (D) + (F) Effect of stable overexpression of V14RhoA on SOX4, CLDN1 and FN1 expression. 
(B) Overexpression of myc-tagged V14RhoA in MDA-231 shCntrl was verified by western blot using an anti-myc 
antibody. (A) – (F) mRNA expression levels were determined by q-PCR. Data are mean ± SEM of n = 3 experiments 
that were performed in duplicate. Statistical significance was determined by a one-sample t-test. * = p < 0.05, ** = 
p < 0.01, *** = p < 0.001.
cytoskeletal tension induces a partial MET response which appears to involve a reduction in 
SOX4 expression.
 To the converse, reducing RhoA signaling, either by serum starvation or inhibition of 
Rho kinase, using increasing concentrations of the Rho kinase inhibitor Y-27632, led to a robust 
increase in SOX4 expression (Figure 5A-B). Similarly, direct inhibition of actomyosin-based 
contractility, using increasing concentrations of the myosin II ATPase inhibitor blebbistatin, 
caused a gradual increase in SOX4 expression in both MDA-231 and Hs 578T shCntrl cells,
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Figure 5. Reducing cytoskeletal tension increases SOX4 expression in MDA-231. (A) + (D) + (G) Effect of 
serum starvation on SOX4, CLDN1 and FN1 expression. MDA-231 shCntrl cells were serum starved o/n. (B) + (E) 
+ (H) Effect of Rho-kinase inhibition on SOX4, CLDN1 and FN1 expression. MDA-231 were stimulated with either 5 
µM or 15 µM Y-27632 for 4 days in normal culture medium. Y-27632 stimulation was replenished every day. (C) + (F) 
+ (I) Effect of myosin II inhibition on SOX4, CLDN1 and FN1 expression. MDA-231 were stimulated o/n with either 
DMSO, 2.5 µM, 5 µM or 10 µM blebbistatin. (A) – (I) mRNA expression levels were determined by q-PCR. Data are 
mean ± SEM of n = 3 experiments that were performed in duplicate. Statistical significance was determined by a 
one-sample t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
confirming that SOX4 expression is indeed sensitive to myosin II-driven cytoskeletal tension 
(Figure 5C & Supplementary Fig. S6A). In contrast, SNAI2 expression remained largely 
unaffected by reduced cytoskeletal tension (Supplementary Fig. S6B & 7A-C). Expression 
of the EMT-TF target CLDN1 was decreased, while that of FN1 was increased, consistent 
with the induction of a mesenchymal phenotype in response to reduced cytoskeletal tension 
(Figure 5D-I & Supplementary Fig. S6C-D). CDH1 expression remained largely unaffected by 
reduced cytoskeletal tension (Supplementary Fig. S7D-F). It should be noted that none of the 
approaches used to reduce cytoskeletal tension affected TRPM7 expression (Supplementary 
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Fig. S6E & 7G-I). Taken together, our findings firmly establish that myosin II-based cytoskeletal 
tension controls the expression of SOX4 to affect downstream EMT markers. Moreover, 
we conclude that TRPM7-mediated cytoskeletal relaxation skews (breast cancer) cells to a 
mesenchymal state, by elevating expression of SOX4 (Figure 6).
Discussion
The mechanical properties of the tumor microenvironment are important contributors to 
metastatic progression. The downstream cytoskeletal responses not only regulate invasion and 
migration, but can also exert control over transcription, affecting gene expression programs that 
may promote metastasis (Mammoto et al., 2012). There is growing recognition that TRPM7, a 
cation channel implicated in mechanosensory processes, is an important determinant of tumor 
metastasis formation (reviewed in (Visser et al., 2014)). We and others showed that TRPM7 
controls cell adhesion and migration through regulation of cytoskeletal tension (Clark et al., 
2006; Middelbeek et al., 2012; Su et al., 2006). In addition, TRPM7 was found to be required 
for the activation of transcriptional programs that control embryonic development and cellular 
differentiation (Du et al., 2010; Elizondo et al., 2005; Jin et al., 2008; Jin et al., 2012; Liu et al., 
2011). These developmental programs are often usurped by tumor cells to enhance their ability 
to metastasize. Indeed, our study provides evidence that TRPM7 regulates EMT in breast 
cancer cells, a transcriptional program that is normally active during embryonic development. 
Our results are in accordance with recent findings showing that TRPM7 is able to regulate 
protein expression of the EMT marker vimentin in MDA-MB-468 breast cancer cells (Davis et 
al., 2014). Moreover, we recently showed that TRPM7 regulates expression of the EMT-TF 
SNAI2 in neuroblastoma cells, maintaining progenitor-like features of these cells (Middelbeek 
et al., 2015). More specifically, our findings indicate that TRPM7 maintains the mesenchymal 
state of breast cancer cells, rather than being required for the initiation of EMT, since TGF-β 
was still able to evoke EMT in the epithelial-like MDA-231 shT7#1 cells. Maintenance of the 
mesenchymal state by TRPM7 involves the regulation of SOX4 expression, a recently identified 
EMT-TF and a promotor of tumor progression in various cancer types, including breast cancer 
(Tiwari et al., 2013; Vervoort et al., 2013; Zhang et al., 2012). This intimate association between 
TRPM7 expression and SOX4 regulation, as we observed in our breast cancer models, is also 
seen in primary breast cancer, as we observed that expression of TRPM7 mRNA is positively 
correlated with that of SOX4 in a number of independent breast cancer patient datasets. 
SOX4 expression is subject to regulation by different signal transduction pathways, including 
TGF-β and controlled by several microRNAs (Vervoort et al., 2013). Here, we identify SOX4 
as a mechanically regulated EMT-transcription factor. We show that expression of SOX4, but 
not other EMT-TFs tested, is inversely correlated with cytoskeletal tension. Consistently, we 
observed that the epithelial marker CLDN1 is upregulated in response to TRPM7 knockdown, 
SOX4 knockdown and increased cellular tension. Reciprocally, we found that the mesenchymal 
marker FN1 is downregulated under these conditions. Although expression of CDH1, an 
epithelial marker, was upregulated both in TRPM7 shRNA and SOX4 shRNA cells, CDH1 
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was downregulated upon temporary inhibition 
of TRPM7 or the induction of cellular tension. 
As yet, we cannot explain this discrepancy. 
However, the fact that we observe an increase 
in CDH1 expression in response to TRPM7 
knockdown, suggests that under a regime 
of sustained cytoskeletal tension, prolonged 
MET-inducing signals are dominant, leading to 
an increase in CDH1 expression. Although our 
results indicate that SOX4 acts downstream of 
TRPM7, we were unable to rescue the TRPM7 
knockdown phenotype by reintroduction of a 
SOX4 cDNA (data not shown). This suggests 
that, in addition to SOX4, other (tension-
sensitive) co-factors may be required to 
reverse the TRPM7 knockdown phenotype. 
Taken together, our results indicate that 
TRPM7-induced cytoskeletal relaxation in 
mesenchymal breast cancer cells acts to 
maintain a mesenchymal state.
 How cytoskeletal relaxation regulates 
SOX4 expression remains to be established. 
Possibly, cytoskeletal relaxation maintains 
and/or enhances nuclear localization of a yet 
to be determined transcriptional regulator. A 
similar mechanism has been described for 
the transcriptional regulators YAP and TAZ, 
which translocate to the nucleus in response 
to increased cytoskeletal tension (Dupont et 
al., 2011). Alternatively, cytoskeletal tension 
may be transmitted directly to the nucleus, 
affecting tension on the nuclear membrane and 
consequently chromatin organization, which 
in turn may affect transcription (Mammoto et 
al., 2012).
 The mechanical properties of the 
tumor microenvironment affect the metastatic 
capablities of tumor cells (Butcher et al., 2009; 
Paszek et al., 2005). Since TRPM7 can be 
activated by mechanical cues (Kuipers et al., 
2012; Wei et al., 2009) our results suggest a 
TRPM7
Tension
SOX4
?
Epithelial
Mesenchymal
Figure 6. TRPM7-induced cytoskeletal relaxation 
maintains a mesenchymal phenotype by regulating 
SOX4 expression. Model describing the correlation 
of TRPM7-induced cytoskeletal relaxation with SOX4 
expression. Activation of TRPM7 induces cytoskeletal 
relaxation which in turn enhances SOX4 expression 
through an unidentified mechanism, thereby maintaining 
a mesenchymal state.
92 |
Chapter 4
model in which TRPM7 interprets mechanical cues from the tumor microenvironment to affect 
EMT. Several studies have shown that increased stiffness drives tumor progression (Butcher et 
al., 2009; Provenzano et al., 2009) and, very recently, EMT (Wei et al., 2015). Our observation 
that reduced cytoskeletal tension maintains the metastatic potential of tumor cells may seem 
to be at odds with these findings. However, other studies indicate that reduced matrix stiffness 
and, as a result, reduced cytoskeletal tension, can similarly enhance metastatic properties of 
tumor cells (McGrail et al., 2014; Plodinec et al., 2012; Tan et al., 2014), suggesting that the 
tumor promoting effects of matrix stiffness are highly dependent on the context, i.e. tumor 
(sub)type, cell or origin or stage of the disease. For instance, it was shown in late-stage 
breast tumors that, although the periphery of primary tumors is stiffer than healthy breast 
tissue, cells in the hypoxic core are in fact softer than healthy counterparts (Plodinec et al., 
2012). Moreover, migration and metastatic spreading were correlated with the low stiffness 
of hypoxia-associated cells (Plodinec et al., 2012). In addition, other reports found that more 
invasive or metastatic cells show reduced cellular tension relative to benign or less metastatic 
cells (Corbin et al., 2015; Cross et al., 2007; Li et al., 2008; Swaminathan et al., 2011). 
 In conclusion, our results indicate that the channel-kinase TRPM7 maintains a 
mesenchymal state in breast cancer cells by tensional regulation of the EMT-transcription 
factor SOX4. Together these data imply that breast cancer-associated EMT and MET are 
dependent on the tensional state of tumor cells, and regulated by activity and expression of the 
TRPM7-SOX4 axis.
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Materials and methods
Antibodies and reagents
Reagents: Waixenicin A was a kind gift from David Horgen (Hawaii Pacific University, Kaneohe, U.S.A.). From 
R&D Systems: Recombinant human TGF-β (#240-B-002). From Sigma-Aldrich: LPA (#L7260), Y-27632 (#Y0503), 
blebbistatin (#B0560).
Antibodies: From Cell Signaling Technology: claudin-1 (#4933, WB 1:1000), E-cadherin (#3195, WB 1:2000), ZO-1 
(#8193, WB 1:2000; IF 1:200). From BD Biosciences: fibronectin (#610077, WB 1:5000), vimentin (#550513, WB 
1:5000). From Sigma-Aldrich: γ-tubulin (#T6557, WB 1:10000). From Diagenode: SOX4 (#C15310129, WB 1:4000). 
From Life Technologies -- Molecular Probes: phalloidin-Alexa-568 (#A12380, IF 1:200).
Cell culture
MDA-MB-231 and Hs 578T (American Type Culture Collection) were cultured in Dulbecco’s Modified Eagle Medium 
+ Glutamax (Life Technologies, Gibco, #31966), supplemented with 10% fetal bovine serum and 1% pen/strep (Life 
Technologies, Invitrogen, #15140). Cells were cultured in a humidified incubator at 37 °C and 5% CO2.
Generation of cell lines
To generate knockdown cell lines scrambled, TRPM7 (Middelbeek et al., 2012) or SOX4 shRNAs (obtained from 
Dr. R. Beijersbergen at The Netherlands Cancer Institute - Screening and Robotics Facility) (see Supplementary 
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Table S2 for sequences) were transduced into MDA-MB-231 or Hs 578T using the pLKO lentiviral expression vector 
according to manufacturer’s protocol (Sigma-Aldrich). Cells were selected using 1 µg/ml puromycin. To generate 
a stable constitutively active RhoA overexpressing cell line, MDA-231 shCntrl cells were transduced with pLZRS-
mycV14RhoA or an empty vector control. Cells were selected with 2 mg/ml G418.
Immunofluorescence
Cells were cultured o/n on glass coverslips and were subsequently fixed in 4% paraformaldehyde and permeabilized 
in 0.1% Triton-X 100. Non-specific binding was blocked with 3% BSA. Cells were incubated with ZO-1 antibodies 
diluted in 3% BSA. Cells were then incubated with phalloidin-Alexa 568 and anti-rabbit Alexa 647 conjugated 
antibodies diluted in 3% BSA and kept in the dark. Images (2048x2048 resolution, with 6x line averaging) were 
taken on a Leica TCS SP5 (Leica Microsystems) equipped with a 63x water-immersion objective and LAS-AF 
acquisition software (Leica Microsystems). Images were processed for publication using ImageJ 1.48.
Quantitative real-time PCR
mRNA was isolated using an RNeasy minikit (Qiagen, #74106) and DNAse-treated on column (Qiagen, #79254). 
cDNA was synthesized using an iScript cDNA synthesis kit according to manufacturer’s protocol (Bio-Rad, #170-
8891). q-PCRs were performed using Power SYBR green mix (Life Technologies, Applied Biosystems, #4368708) 
on a CFX96 Touch™ Real-Time System (Bio-Rad) using PCR conditions as supplied by Applied Biosystems. Gene 
expression levels were normalized against the GAPDH housekeeping gene and calculated according to the 2-ΔΔCt 
method. For q-PCR primer sequences see Supplementary Table S2.
Western blotting
Cells were lysed in RIPA lysisbuffer (150 mM NaCl, 1% NP40, 5 mM EDTA, 50 mM Tris pH 8.0, 0.5% deoxycholate, 
0.1% SDS) supplemented with complete protease inhibitor cocktail (Roche). After clarification, lysates were diluted 
in Laemlli’s buffer (0.25 M Tris pH 6.8, 10% glycerol, 2% SDS and 0.02% bromophenol blue), supplemented with 
10% β-mercaptoethanol and incubated at 95 °C for 5 min. Proteins were separated by SDS-PAGE and subsequently 
blotted onto PVDF membranes. Non-specific binding was blocked with 5% BSA or 4% skim milk (for SOX4 blots) 
diluted in TBS + 0.1% Tween-20 (TBST). Blots were then incubated with primary antibodies, followed by HRP-
conjugated secondary antibodies, both diluted TBST + 5% BSA or 0.8% skim milk (for SOX4 blots). Proteins were 
detected using ECL detection agent (Amersham GE Healthcare #RPN2232) and imaged on a Fluorchem E Digital 
Darkroom (Proteinsimple).
Microarray analysis
MDA-231 shCntrl, shT7#1 and shSOX4#1 were subjected to microarray analysis (GEO accession number: 
GSE63958), which was performed at ServiceXS B.V. (Leiden, The Netherlands). RNA concentrations were 
measured using the Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies). RNA quality and integrity 
were determined using Lab-on-Chip analysis on the Agilent 2100 Bioanalyzer (Agilent Technologies). Biotinylated 
cRNA was prepared using the Illumina TotalPrep RNA Amplification Kit (Ambion Inc.) according to manufacturer’s 
specifications with an input of 200 ng total RNA. Per sample, 750 ng of the obtained biotinylated cRNA samples was 
hybridized onto the Illumina HumanHT-12 v4 (Illumina Inc.). Hybridization and washing were performed according 
to the Illumina Manual ‘Direct Hybridization Assay Guide’. Scanning was performed on the Illumina iScan (Illumina 
Inc.). Image analysis and extraction of raw expression data was performed with Illumina GenomeStudio v2011.1 
Gene Expression software. Arrays were normalized in Arraystar (v. 4.03), using Robust-Multi-Array normalization. 
For visualization of selected EMT/MET inducers in a heatmap (Multi Experiment Viewer v 4.8.1), normalized linear 
intensity values were log10 transformed. Statistical significance of overlapping up- and downregulated in MDA-231 
shT7#1 and shSOX4#1 was determined by means of a hypergeometric distribution test. To this end, normalized 
linear intensity values were log2 transformed. Log2 values < 2.5 were considered background and a fold change of 
≥ |2| was used as cut-off. The amount of background corrected gene products (n = 22278) was used as total gene 
set for the hypergeometric distribution test.
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Statistical analysis
Statistics on q-PCR data were performed using a one-sample t-test, comparing fold changes in expression to 
control levels that were set to 1 in each independent experiment. Data are represented as mean ± SEM. P-values 
< 0.05 were considered statistically significant.
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Supplementary Fig S1. Effect of Waix A on gene expression in MDA-231. (A) + (B) Effect of o/n Waix A (3.3 μM) 
stimulation on (A) CDH1, CLDN1, FN1 and (B) TRPM7 expression in MDA-231 cells. mRNA expression levels were 
determined by q-PCR. Data are mean ± SEM of n = 3 (B) or n = 4 (A) experiments that were performed in duplicate. 
Statistical significance was determined by a one-sample t-test. * = p < 0.05.
Supplementary Fig S2. TRPM7 is required for maintenance of mesenchymal phenotype of Hs 578T cells. (A) 
Knockdown efficiency of shT7#1 in Hs 578T cells. (B) Phase contrast images showing effect of TRPM7 knockdown 
on cell morphology in Hs 578T cells. Note the loss of long cell protrusions (indicated by white arrows in shCntrl) in 
shT7#1. Scale bars = 50 µM. (C) Effect of TRPM7 knockdown on EMT marker expression, depicted as fold changes 
over shCntrl. CDH1 expression was not detectable by q-PCR in both shCntrl and shT7#1. (D) Effect of TRPM7 
knockdown on EMT marker expression as determined by western blotting. Black arrow indicates correct claudin-1 
band (claudin-1 is only weakly expressed in Hs 578T). γ-tubulin was used as loading control. (E) Effect of o/n Waix 
A (4 µM) stimulation on CLDN1 and FN1 expression in Hs 578T cells. (A) + (C) + (E) mRNA expression levels were 
determined by q-PCR. Data are mean ± SEM of n = 3 experiments that were performed in duplicate. Statistical 
significance was determined by a one-sample t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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Supplementary Fig S3. Effect of TRPM7 knockdown or inhibition on EMT-TF expression in Hs 578T & MDA-
231. (A) Effect of TRPM7 knockdown on EMT-TF expression in Hs 578T, depicted as fold changes over shCntrl. 
(B) Effect of TRPM7 knockdown on SOX4 protein expression as determined by western blotting. Representative 
example of n = 3 experiments. (C) Effect of o/n Waix A (4 µM) stimulation on SOX4 and SNAI2 expression in Hs 
578T cells. (D) Effect of Waix A (3.3 μM) stimulation on SNAI2 expression in time. mRNA expression levels were 
determined by q-PCR. (A) + (C) + (D) mRNA expression levels were determined by q-PCR. Data are mean ± SEM 
of n = 3 experiments that were performed in duplicate. Statistical significance was determined by a one-sample 
t-test. * = p < 0.05.
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Supplementary Fig S4. SOX4 knockdown in MDA-231. (A) Knockdown efficiency of shSOX4#1 and shSOX4#2 
in MDA-231 as determined by q-PCR. (B) Knockdown efficiency of shSOX4#1 and shSOX4#2 as determined by 
western blotting. Representative example of n = 3 experiments. (C) Representative immunofluorescence staining 
of F-actin and ZO-1 in MDA-231 shCntrl and MDA-231 shSOX4#2. Red arrows in ZO-1 pictures indicate ZO-1 
localization to cell-cell adhesions. Scale bars = 20 µM. (D) Effect of SOX4 knockdown in MDA-231 on EMT-
TF mRNA expression. (E) Effect of 4 days TGF-β stimulation (2 ng/ml) on EMT marker expression in MDA-231 
shSOX4#1, depicted as fold changes over unstimulated MDA-231 shSOX4#1. TGF-β was replenished after 2 days 
of stimulation. (A) + (D) + (E) mRNA expression levels were determined by q-PCR. Data are mean ± SEM of n = 3 
experiments that were performed in duplicate. Statistical significance was determined by a one-sample t-test. * = p 
< 0.05, ** = p < 0.01.
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Supplementary Fig S5. Effect of increased cytoskeletal contractility on SNAI2, CDH1 and TRPM7 expression. 
(A) + (C) + (E) Effect of LPA stimulation on SNAI2, CDH1 and TRPM7 expression. To sensitize MDA-231 for LPA 
stimulation, cells were serum starved o/n. Cells were subsequently stimulated with 10 µM LPA (in serum-depleted 
medium) for the indicated time points. (B) + (D) + (F) Effect of stable overexpression of V14RhoA on SNAI2, CDH1 
and TRPM7 expression (A) – (F) mRNA expression levels were determined by q-PCR. Data are mean ± SEM of n 
= 3 experiments that were performed in duplicate. Statistical significance was determined by a one-sample t-test. * 
= p < 0.05, ** = p < 0.01.
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Supplementary Fig S6. Effect of myosin II inhibition on gene expression in Hs 578T shCntrl. Effect of myosin 
II inhibition in Hs 578T shCntrl on SOX4 (A), SNAI2 (B), CLDN1 (C), FN1 (D), CLDN1 (E), and TRPM7 (F). Cells 
were stimulated o/n with either DMSO, 5 µM or 10 µM blebbistatin. mRNA expression levels were determined by 
q-PCR. Data are mean ± SEM of n = 3 experiments that were performed in duplicate. Statistical significance was 
determined by a one-sample t-test. * = p < 0.05.
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Supplementary Fig S7. Effect of reduced cytoskeletal contractility on SNAI2, CDH1 and TRPM7 expression. 
(A) + (D) + (G) Effect of serum starvation on SNAI2, CDH1 and TRPM7 expression. MDA-231 shCntrl cells were 
serum starved o/n. (B) + (E) + (H) Effect of Rho kinase inhibition on SNAI2, CDH1 and TRPM7 expression. MDA-
231 were stimulated with either 5 µM or 15 µM Y-27632 for 4 days in normal culture medium. Y-27632 stimulation 
was replenished every day. (C) + (F) + (I) Effect of myosin II inhibition on SOX4, CLDN1 and FN1 expression. MDA-
231 were stimulated o/n with either DMSO, 2.5 µM, 5 µM or 10 µM blebbistatin. (A) – (I) mRNA expression levels 
were determined by q-PCR. Data are mean ± SEM of n = 3 experiments that were performed in duplicate. Statistical 
significance was determined by a one-sample t-test. * = p < 0.05.
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Supplementary Table 1
Overlapping up- and downregulated genes in shT7#1 and shSOX4#1 microarray
Upregulated in both shT7#1 and shSOX4#1
ADA HS.4892 OLR1
ADAMTS9 HS.566661 OSBP2
AIF1L HS.582338 PI16
ARHGEF16 HSD11B1 PLAC1
ATP8B1 ICAM1 PLCG2
BATF ICAM2 PTX3
BIK IFIH1 RAB15
BIRC3 IL1A RAB3IL1
C10ORF35 IL1B RELB
C15ORF48 IL23A RNY4
C4BPB IL24 RRAD
C4ORF26 IL32 RSAD2
C6ORF132 IL6 SAA1
C9ORF58 IL7R SAA2
CCL3L1 IL8 SAA4
CCL3L3 ISG20 SDC4
CCL4L1 ISL1 SEMA4D
CD83 KRT17 SLC43A2
CDC42EP5 LAMC2 ST6GALNAC5
CEACAM1 LCN2 TGFB2
CGN LOC100129022 THBD
CH25H LOC100129637 TIFA
CHST4 LOC100132240 TMEM132A
CITED4 LOC100133572 TMPRSS2
CLDN1 LOC339799 TNFAIP2
CLDN11 LOC392145 TNFAIP3
COL17A1 LOC441395 TNFRSF1B
COL6A2 LOC644760 TNFRSF9
CSF2 LOC645249 TRAF1
CX3CL1 LOC645638 TRIM29
CXCL1 LOC649174 TUBAL3
CXCL10 LOC651876 UCA1
CXCL2 LOC728463 VNN1
CYP24A1 LOC729642 VSTM1
DENND2A LOC730833 WT1
DHX58 LOC732419 XYLB
EBI3 LTA ZC3H12A
ECSCR LTB ZC3H12C
EDN2 MAP3K8 ZNF114
EFNA1 MATN2
ERCC6 MMP9
FAM23B NCF2
FLG NFKBIA
FLI1 NFKBIE
GAL NLK
GATA2 NOSTRIN
GBP4 NUAK2
HKDC1 NUP210
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Supplementary Table 1
Overlapping up- and downregulated genes in shT7#1 and shSOX4#1 microarray
Downregulated in both shT7#1 and shSOX4#1
ANKHD1-EIF4EBP3 LOC730525
ANKRD37 MARCKSL1
ANXA10 MEX3B
ARMCX2 MGC42630
AXIN2 MGC4294
B3GN-T6 MIR637
C13ORF15 MNDA
C16ORF45 NINJ2
C5ORF46 NUDT7
C6ORF105 ODZ3
C6ORF141 OPN3
CA9 PDE1C
CCNG2 PFKFB4
CHN2 PFTK1
CITED1 PKIA
CLEC2B PMEPA1
CNPY4 PSKH1
DIS3 RASD1
DKFZP451M2119 REEP1
FBXL17 RHOJ
FILIP1L RUNDC3B
FLJ44790 SLITRK5
FLRT2 SNTB1
GOLSYN SPANXA2
HCG3 SPANXB2
HIST1H3H SPANXC
HS.133324 SPANXE
HS.146586 SPDEF
HS.453381 SPOCK1
HS.569175 SPRY1
HTRA1 SPSB1
IRX5 SSBP2
KAL1 STS-1
KCNS3 TBXAS1
KLHL3 TMEM163
KRT81 WDR72
LDOC1
LOC100131471
LOC100133171
LOC100134073
LOC100134370
LOC100216001
LOC643296
LOC643938
LOC652683
LOC653366
LOC653580
LOC727958
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Supplementary Table 2 - shRNA & primer sequences
shRNAs Sequence (5' - 3')
shCntrl (scrambled shRNA) GCTACAAGAGAAACCAAATCT
shT7#1 (TRPM7 shRNA) GCGCTTTCCTTATCCACTTAA
shT7#2 (TRPM7 shRNA) GCCCGATATTATTTCCACTAT
shSOX4#1 (SOX4 shRNA) CCTTTCTACTTGTCGCTAAAT
shSOX4#2 (SOX4 shRNA) TGGGCACATCAAGCGACCCAT
Primers q-PCR Sequence (5' - 3')
CDH1 Fwd TCCTGGGCAGAGTGAATTTT
CDH1 Rev GGCGTAGACCAAGAAATGGA
CLDN1 Fwd GGCAGATCCAGTGCAAAGTC
CLDN1 Rev TCATCTTCTGCACCTCATCG
FN1 Fwd TGGCACCCCACGCTCAGATACA
FN1 Rev CTCGCCAGGCAGGTTGACGG
GAPDH Fwd CTCCTCCACCTTTGACGCTG
GAPDH Rev TCCACCACCCTGTTGCTGTA
SNAI1 Fwd TCGGAAGCCTAACTACAGCGA
SNAI1 Rev AGATGAGCATTGGCAGCGAG
SNAI2 Fwd AAGCATTTCAACGCCTCCAAA
SNAI2 Rev GGATCTCTGGTTGTGGTATGACA
SOX4 Fwd GGCCTCGAGCTGGGAATCGC
SOX4 Rev GCCCACTCGGGGTCTTGCAC
TRPM7 Fwd TAGCCTTTAGCCACTGGAC
TRPM7 Rev GCATCTTCTCCTAGATTTGC
TWIST1 Fwd GTCCGCAGTCTTACGAGGAG
TWIST1 Rev GCTTGAGGGTCTGAATCTTGCT
VIM Fwd GAGAACTTTGCCGTTGAAGC
VIM Rev GCTTCCTGTAGGTGGCAATC
ZEB1 Fwd TTACACCTTTGCATACAGAACCC
ZEB1 Rev TTTACGATTACACCCAGACTGC
ZEB2 Fwd GACAGATCAGCACCAAATGC
ZEB2 Rev GCTGATGTGCGAACTGTAGG
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Abstract
Neuroblastoma is an embryonal tumor derived from poorly differentiated neural crest 
cells. Current research is aimed at identifying the molecular mechanisms that maintain the 
progenitor state of neuroblastoma cells and to develop novel therapeutic strategies that induce 
neuroblastoma cell differentiation. Mechanisms controlling neural crest development are 
typically dysregulated during neuroblastoma progression, and provide an appealing starting 
point for drug target discovery. Transcriptional programs involved in neural crest development 
act as a context dependent gene regulatory network. In addition to BMP, Wnt and Notch 
signaling, activation of developmental gene expression programs depends on the physical 
characteristics of the tissue microenvironment. TRPM7, a mechanically regulated TRP channel 
with kinase activity, was previously found essential for embryogenesis and the maintenance of 
undifferentiated neural crest progenitors. Hence, we hypothesized that TRPM7 may preserve 
progenitor-like, metastatic features of neuroblastoma cells.
 Using multiple neuroblastoma cell models, we demonstrate that TRPM7 expression 
closely associates with the migratory and metastatic properties of neuroblastoma cells in vitro 
and in vivo. Moreover, microarray-based expression profiling on control and TRPM7 shRNA 
transduced neuroblastoma cells indicates that TRPM7 controls a developmental transcriptional 
program involving the transcription factor SNAI2. Overall, our data indicate that TRPM7 
contributes to neuroblastoma progression by maintaining progenitor-like features.
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Introduction
Neuroblastoma is an embryonic tumor derived from cells of the neural crest. Survival rates 
are excellent for patients with low- and intermediate risk neuroblastomas. In contrast, patients 
with high-risk neuroblastomas present with metastatic disease at diagnosis and require 
intensive treatment regimens. Although virtually all patients initially respond to treatment, a 
therapy resistant pool of poorly differentiated cells may arise that leads to refractory disease 
for which no treatment options are currently available (Maris, 2010; Morgenstern et al., 2013). 
To develop more effective treatment strategies for these patients, there is an urgent need 
to understand the molecular mechanisms that control the progenitor state of neuroblastoma 
cells. The similarities between neural crest development and neuroblastoma progression have 
previously been recognized (Cheung and Dyer, 2013; Jiang et al., 2011; Mohlin et al., 2011) 
and provide an appealing starting point for drug target discovery.
 The neural crest is a population of cells that arises at the borders of the neuroectoderm 
during early embryogenesis, spreads to different parts of the embryo and gives rise to a multitude 
of cell types, including the peripheral sympathetic neurons (Prasad et al., 2012). Mechanisms 
controlling migration and differentiation of neural crest cells are typically dysregulated during 
neuroblastoma development and progression. For instance genes that maintain the balance 
between proliferation and differentiation of neural crest cells, such as MYCN, ALK and 
PHOX2B, are often found mutated or overexpressed in high-risk neuroblastomas (Cheung 
and Dyer, 2013; Jiang et al., 2011). Additionally, metastatic neuroblastoma cells adopt a pro-
migratory developmental program known as epithelial-to-mesenchymal transition (EMT), which 
allows neural crest cells to delaminate from the neural plate borders and spread throughout 
the embryo (Ferronha et al., 2013; Nozato et al., 2013; Thiery et al., 2009; van Nes et al., 
2013). Consistently, in vitro evidence indicates that genes involved in EMT of neural crest cells, 
including transcription factors such as SNAI2, are misregulated in metastatic neuroblastomas 
(Ferronha et al., 2013; Jiang et al., 2011; Vitali et al., 2008).
 BMP, Wnt and Notch mediated signal transduction pathways act in concert to control 
neural crest formation, migration and maturation (Prasad et al., 2012). Additionally, mechanical 
input from the cellular environment drives neural crest maturation (Carmona-Fontaine et al., 
2008; Li et al., 2011; Perris and Perissinotto, 2000; Theveneau et al., 2010; Theveneau and 
Mayor, 2012). As these signals are essential for proper tissue development and maintenance 
of cellular quiescence, perturbed mechanical signaling can propagate de-differentiation, 
uncontrolled cell proliferation, tissue invasion and therapy resistance in solid tumors, including 
neuroblastoma (Eke et al., 2012; Feduska et al., 2013; Kim et al., 2012b; Lee et al., 2012; 
Matsushima and Bogenmann, 1992; Megison et al., 2013; Meyer et al., 2004; Molenaar et 
al., 2012; Ou et al., 2012; Sloan et al., 2006; White et al., 2006; Wirtz et al., 2011; Yoon 
and Danks, 2009). Members of the mammalian Transient Receptor Potential (TRP) cation 
channel family are considered key regulators of the mechanical interactions between the cell 
and its microenvironment. Tethered to the cytoskeleton, their ion conducting properties can be 
modulated by different stimuli, including mechanical cues, resulting in responses that range 
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from adhesion remodeling to cellular differentiation (Kuipers et al., 2012; Lin and Corey, 2005; 
Orr et al., 2006). Indeed, we showed that TRPM7, a TRP-cation channel with kinase activity, 
directly interacts with the actomyosin cytoskeleton and controls cell-matrix interactions in breast 
cancer cells as well as in neuroblastoma cells (Clark et al., 2006; Middelbeek et al., 2012). 
Moreover, we and others showed that TRPM7 functionally contributes to the progression of a 
number of malignancies in vitro and in vivo (reviewed in (Visser et al., 2014)). However, the 
mechanisms by which TRPM7 drives tumor progression remain poorly understood.
 Studies using TRPM7 conditional knockouts demonstrate that TRPM7 expression is 
required during early stages of embryogenesis (Jin et al., 2008; Jin et al., 2012). Moreover, 
TRPM7 appears to be essential for the maintenance of multi-potent neural crest cells (Jin et 
al., 2012). Hence, we hypothesize that TRPM7 expression and/or activity may contribute to 
neuroblastoma progression by disrupting normal neural crest cell maturation and preserving 
progenitor-like features in tumor cells. Consistent with this notion, we show here that 
TRPM7 overexpression confers a metastatic phenotype onto an otherwise poorly metastatic 
neuroblastoma cell line, while shRNA-mediated knockdown of TRPM7 reduces the migratory 
properties of neuroblastoma cells. In addition, by gene expression profiling we demonstrate 
that TRPM7 is required for the maintenance of a progenitor-like gene expression program in 
human neuroblastoma cell lines.
Results
TRPM7 confers a malignant phenotype onto poorly metastatic neuroblastoma cells. 
To address if TRPM7 contributes to the malignant properties of neuroblastoma cells, we 
assessed whether TRPM7 overexpression promotes metastasis formation of poorly metastatic 
murine N1E-115 neuroblastoma cells in vivo. To this end, we intravenously injected luciferase 
expressing neuroblastoma cells that were previously generated to either overexpress mouse 
TRPM7 (mTRPM7) or an empty vector control (Control) (Fig. S1A) (Clark et al., 2006), into 
Rag2-/-Il2rg-/- immunodeficient mice. Non-invasive bioluminescence imaging was used 
to monitor tumor cell dissemination and growth. Bioluminescence signals were observed 
at day 7 post-injection and progressively increased over time (Fig. 1A & B), showing that 
injected cells survived, proliferated and formed metastasis. In good agreement with earlier 
reports on metastasis of neuroblastoma cells in mice (Bogenmann, 1996), bioluminescence 
originated predominantly from the abdominal region. Strikingly, the abdominal signal in N1E-
115 mTRPM7 injected mice was much higher at all time points (day 7: control = 5.41 x 104 ± 
9.92 x 103 photons/s, n = 9; mTRPM7 = 9.75 x 105 ± 1.63 x 105 photons/s, n = 9). Note that 
the progressive increase in bioluminescence was comparable in both groups, suggesting that 
the in vivo proliferation rate of neuroblastoma cells was not affected by TRPM7 expression 
levels (Fig. 1B). Indeed, MTS assays indicated that mTRPM7 overexpression did not affect in 
vitro proliferation rates (Fig. 1C).
TRPM7 promotes metastatic spread to liver and bone marrow, but not in vivo proliferation
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Figure 1. TRPM7 increases the metastatic potential of 
N1E-115 cells (A) Representative bioluminescent images of 
mice, 7 and 20 days after intravenous injections with N1E-115 
control or mTRPM7 overexpressing cells (n = 9 mice in each 
group). Photon fluxes are set to the same scale (photons / s). 
Asterix indicates an example of bioluminescence observed in 
a limb. (B) Quantification of bioluminescence in the abdominal 
region between day 7 and day 20 post-injection. Data are 
mean ± SEM of n = 9 mice per group. Data presented are 
from 1 out of 2 independent experiments that show highly 
reproducible results. (C) Quantification of cell proliferation, 
determined by MTS assays. Data are mean extinction at 492 
nm ± SEM of n = 3 experiments.
As the proliferation rate of N1E-115 mTRPM7 cells did not differ from control cells in vitro, the 
increased abdominal signals of mice injected with these cells suggest that dissemination is 
more widespread. Histopathological analysis showed that the dissemination pattern was similar 
in both groups, with metastases predominantly present in the liver (Fig. 2A & B). However, 
image analysis of liver paraffin sections demonstrated that much more tumors were present 
in mice injected with N1E-115 mTRPM7 cells (control = 9.5 ± 3.3 tumors per liver section; 
mTRPM7 = 79.7 ± 13.4 tumors per liver section; p < 0.01, n = 9) (Fig. 2A & C). Consistent with 
the observation that TRPM7 does not affect proliferation in vitro, mTRPM7 overexpression had 
no effect on mean tumor size (control = 0.35 ± 0.13 mm2, n = 118 tumors; mTRPM7 = 0.26 ± 
0.03 mm2, p = 0.23, n = 786 tumors) (Fig. 2D & E).
 In addition to the liver, bone and bone marrow metastases are commonly observed 
in neuroblastoma patients (DuBois et al., 1999). We therefore isolated bone marrow content 
from each limb and analyzed luciferase activity. Limbs were considered positive when 
bioluminescence was five times above background. Strikingly, only one limb from a single 
N1E-115 control injected mouse met this criterion, whereas all mice injected with N1E-115 
mTRPM7 cells scored positive with an average of 3 affected legs per mouse (control = 1 limb 
in 1 out of 9 mice; mTRPM7 = 9 out of 9 mice affected with 27 out of 36 limbs scoring positive, 
p < 0.01) (Fig. 2F). Hence, we conclude that TRPM7 enhances the metastatic potential, but 
not proliferation rate, of N1E-115 neuroblastoma cells in vivo.
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Figure 2. TRPM7 promotes metastatic spread to liver and bone marrow. (A) Representative H&E staining on 
liver tissue, collected 20 days after injection with N1E-115 cells. Prominent tumors in the liver indicate that both N1E-
115 control and mTRPM7 overexpressing cells metastasize to the liver. (B) Histopathological analysis of mouse 
tissue sections, collected 20 days after injection with either N1E-115 control or mTRPM7 overexpressing cells. 
Mouse tissues were scored for the presence of tumor cells. Adrenal glands of 5 mice were scored for presence of 
tumor cells, whereas 9 mice were dissected for other tissues. (C) Quantification of the number of liver tumors per 
mouse, measured in resected liver tissue from mice injected with N1E-115 control or mTRPM7 overexpressing 
cells. Data are mean ± SEM of n = 9 mice in each group. ** p < 0.01, two-tailed unpaired t-test with Welch correction. 
(D) Quantification of mean liver tumor size in mice injected with N1E-115 control and mTRPM7 overexpressing 
cells. Data are mean ± SEM of n = 9 mice in each group. (E) Size distribution of tumors in liver sections emphasizes 
similar growth rates for both cell lines. (F) Percentage of mice (left panel) and limbs (right panel) with bone marrow 
metastases. Data are mean ± SEM of n = 9 mice in each group. ** p < 0.01, two-tailed unpaired t-test with Welch 
correction.
TRPM7 expression does not affect viability and proliferation of human neuroblastoma cells
Although TRPM7 overexpression did not affect proliferation of mouse N1E-115 neuroblastoma 
cells, others have suggested a role for TRPM7 in neuroblastoma cell proliferation, specifically 
in a MYCN-amplified context (Zhang et al., 2014). SH-EP2 is a non-neuronal (S-type) subclone 
of the SK-N-SH human neuroblastoma cell line with no expression of MYCN. In turn, MYCN is 
amplified in the neuroblastic (N-type) subclone of SK-N-SH cells, named SH-SY5Y (Cohen et 
al., 2003). As MYCN was essential for proliferation of these cells (Huang et al., 2011b), the SH-
SY5Y neuroblastoma model provides a physiological relevant model to study the functional 
interactions between TRPM7 and MYCN in cell proliferation. 
 To see if and how TRPM7 affects viability and proliferation of MYCN-negative and 
-positive neuroblastoma cells, we generated stable TRPM7 knockdown SH-EP2 and SH-
SY5Y cells using a previously characterized lentiviral shRNA construct (Middelbeek et al., 
2012) (Fig. S1B & D). TRPM7 knockdown did not markedly affect viability and proliferation 
of MYCN-negative SH-EP2 cells, as we assessed by MTS-assays (Fig. 3A & B, S2A & B). 
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In contrast to previous reports (Zhang et al., 2014), however, stable knockdown of TRPM7 
did not affect viability and proliferation of MYCN-amplified SH-SY5Y cells (Fig. 3C & D). To 
exclude the possibility that endogenous TRPM7 expression levels were limiting MYCN-induced 
proliferation, we overexpressed mTRPM7 in SH-SY5Y cells (Fig. S1C) and subsequently 
assayed viability and proliferation. Again, no effects of TRPM7 expression levels were observed 
(Fig. 3E & F). From these experiments, we conclude that in our hands, stable knockdown or 
overexpression of TRPM7 does not affect viability and proliferation of both MYCN-negative 
and MYCN-amplified neuroblastoma cell lines.
Figure 3. Manipulation of TRPM7 expression does not affect neuroblastoma cell viability and proliferation. 
Quantification of cell viability and proliferation, determined by MTS assays. Viability was assessed over 4 hours, 
proliferation was assessed over 4 days. Data represents normalized mean extinction at 492 nm mean ±  SEM of  n 
> 2 experiments performed in triplo. (A - D) Effects of TRPM7 shRNA on viability and proliferation of SH-EP2 cells 
and SH-SH-5Y human neuroblastoma cells. (E & F) Effects of mTRPM7 overexpression on viability and proliferation 
of SH-SY5Y human neuroblastoma cells.
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Figure 4. TRPM7 drives mouse and 
human neuroblastoma cell migration 
(A) & (B) Transwell migration of N1E-
115 (n = 6) and SH-SY5Y (n = 3) control 
and mTRPM7 overexpressing cells. 
Equal numbers of cells were allowed 
to migrate towards a serum gradient 
for 48 hours. Data are normalized to 
control and represent mean ± SEM of n 
> 3 independent experiments performed 
in duplicate. (C) & (D) Transwell 
migration of SH-SH5Y and SH-EP2 
control and TRPM7 shRNA cells. Equal 
numbers of SH-SY5Y and SH-EP2 
cells were allowed to migrate towards 
a serum gradient for 48 and 24 hours 
respectively. Data are normalized to 
control and represent mean ± SEM of n 
= 3 independent experiments performed 
in duplicate. (E) Representative images 
of gap closure by SH-EP2 control and 
TRPM7 shRNA cells at time points 0, 10 
and 20 hours. (F) Gap closure over time, 
presented as percentage of gap size at 
time point 0 hours. (G) Quantification 
of time to 50% gap closure. Data in 
(F) and (G) represent mean from n 
= 3 independent experiments, each 
performed in duplicate. * p < 0.05, ** p < 
0.01, two-tailed unpaired t-test.
TRPM7 promotes neuroblastoma cell migration
We previously showed that TRPM7 is required for breast cancer cell migration (Middelbeek et 
al., 2012). Since metastatic neuroblastoma cells adopt the migratory potential of disseminating 
neural crest cells, we set out to evaluate the effects of TRPM7 expression on neuroblastoma 
cell migration. We first compared the migratory properties of N1E-115 control and mTRPM7 
cells by assaying migration towards a serum gradient in Boyden chambers. Whereas control 
cells remained immobile during 48 hours, mTRPM7 overexpression enhanced the ability of 
neuroblastoma cells to cross the transwell membrane (191.5 ± 72 fold mTRPM7 cells relative 
to control cells, p = 0.05, n = 6) (Fig. 4A). Similarly, mTRPM7 overexpression promoted 
transwell migration of human SH-SY5Y cells (1.5 ± 0.078 fold mTRPM7 cells relative to control 
cells, p = 0.026, n = 3) (Fig. 4B). In reciprocal experiments, TRPM7 knockdown limited serum 
induced transwell migration of SH-SY5Y cells (0.56 ± 0.049 fold TRPM7 shRNA cells relative to 
control cells, p = 0.012, n = 3), as well as SH-EP2 cells (0.36 ± 0.15 fold TRPM7 shRNA cells 
relative to control cells, p = 0.049, n = 3) (Fig. 4C & D). The substrate adhesive characteristics 
of SH-EP2 cells allowed us to assess cell migration in gap closure assays. Consistent with 
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serum induced transwell migration, reduced TRPM7 expression levels significantly reduced 
gap closure speed (control = 5.4 ± 0.3 hrs; TRPM7 shRNA = 7.7 ± 0.26 hrs to 50% closure, p = 
0.005, n = 3) (Fig. 4E - G). To control for off-target effects of the TRPM7 shRNA, we confirmed 
the effect of TRPM7 knockdown on SH-EP2 cell migration using cells that were transduced 
with a second, independent TRPM7 targeting shRNA (Fig. S1D, S2C-E). Overall, we conclude 
that TRPM7 drives neuroblastoma cell migration.
TRPM7 maintains neuroblastoma cells in a progenitor state
Since TRPM7 was shown to be required for the development of neural crest derived tissues 
by maintaining the pool of pluripotent progenitor cells (Jin et al., 2012), we hypothesized that 
TRPM7 may contribute to neuroblastoma metastasis by preserving progenitor-like, migratory 
neural crest cell features. We performed microarray-based gene expression profiling and 
identified 3015 genes that were significantly (p < 0,05) up (1418 genes) or down (1597 genes) 
regulated in neuroblastic SH-SY5Y TRPM7 shRNA cells, when compared to control cells (www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64000). Subsequent Gene Ontology (GO)-
term analysis revealed 40 GO categories within the ‘Biological Process’ subroot that were 
significantly enriched (p < 0.01, > 10 genes per category) (Table S1). Consistent with a role for 
TRPM7 in embryonic development (Jin et al., 2008; Jin et al., 2012), GO categories comprising 
organism and cellular development were most significantly enriched (Fig. 5A). Moreover, a 
simplified graphical representation of relationships between all 40 enriched GO-terms based 
on the directed acyclic graph as presented by Webgestalt, clearly indicates that genes affected 
by TRPM7 shRNA are involved in neuronal differentiation (Fig. 5B). Within the GO category 
’Cell Differentiation’, we found many genes that are well established to control neural crest 
development as well as neuroblastoma progression. In view of the complex crosstalk between 
these genes and the different roles they play at distinct stages of development,  it is difficult 
to define in detail how the observed changes in gene expression affect neuroblastoma 
progression. In general, genes that promote neural crest development, such as DLX5, LEF1 
and MSX1 were upregulated, whereas genes that are expressed by precursor cells or suppress 
differentiation, including ASCL1, ID3, SNAI2 and STAT3, were down regulated (Fig. 5C & 
Table 1). Hence, TRPM7 expression appears to be inversely associated with neural crest 
differentiation. Moreover, genes that have previously been established to drive neuroblastoma 
progression and migration, including DBH, NOTCH1, RET and WNT1, were down regulated 
in response to TRPM7 knockdown  (Fig. 5C & Table 1). Combined with our in vitro and in vivo 
data, these data support the notion that shRNA-mediated knockdown of TRPM7 impairs the 
malignant potential of human SH-SY5Y neuroblastoma cells at the gene expression level, by 
reducing a progenitor-like state. 
 It seems plausible that TRPM7 shRNA impairs migration of neuroblastic SH-SY5Y by 
affecting genes that control neuronal precursor characteristics. Despite the lack of neuronal 
features, TRPM7 shRNA similarly impaired migration of epithelial-like SH-EP2 cells (Fig. 4). 
This suggests that TRPM7-mediated effects on gene expression are not restricted to neuronal 
cells. We set out to define the transcriptional program controlled by TRPM7 in SH-EP2 cells
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Figure 5. TRPM7 controls progenitor-
like features of neuroblastic 
neuroblastoma cells on the gene 
expression level (A) TRPM7 controls 
developmental gene expression 
programs. GO-term analysis was 
performed on genes that were 
differentially expressed (p < 0.05) 
in SH-SY5Y TRPM7 shRNA cells, 
when compared to SH-SY5Y control 
cells. Presented are the 10 most 
significantly enriched (P) GO-terms 
within the subroot ‘Biological Process’. 
Fold enrichment is the ratio between 
observed and expected genes within 
a category. Number of expected genes 
is based on the number of protein 
encoding genes within a category. 
(B) TRPM7 shRNA affects genes 
that control neuronal differentiation. 
Simplified representation of GO-term 
relationships involved in neuronal 
differentiation, and the number of genes 
observed per category. (C) TRPM7 
shRNA impairs progenitor-status and 
tumorigenicity of neuroblastic SH-
SY5Y neuroblastoma cells. Selection of 
differentially regulated genes within the 
‘Cell Differentiation’ category that are 
known to control neural crest formation, 
delamination and differentiation, and 
neuroblastoma progression (Table 1). 
X-axis represents fold difference in 
normalized expression levels between control and TRPM7 shRNA SH-SY5Y cells. (D) TRPM7 drives expression of 
SNAI2 transcription factor in human and mouse neuroblastoma cell lines. SNAI2 expression levels were determined 
by quantitative RT-PCR in SH-SY5Y and SH-EP2 control and TRPM7 shRNA cells. Additionally, SNAI2 expression 
levels were quantified in N1E-115 mouse neuroblastoma control and TRPM7 overexpressing cells. Data represents 
mean expression levels ± SEM (n = 3) that are normalized to GAPDH housekeeping gene expression. SNAI2 
expression in control cells is set to 1. * p < 0.05, ** p < 0.01, *** p < 0.001. 
using a similar approach as described for SH-SY5Y cells. We identified a set of 3322 genes 
that was differentially expressed by SH-EP2 cells upon TRPM7 knockdown (1664 up, 1658 
down, p < 0.05). Consistent with the large differences between neuroblastic and epithelial-like 
neuroblastoma cells, this set of genes showed only modest overlap with the genes that were 
up or down regulated by TRPM7 shRNA in SH-SY5Y cells (5.6% up, 7.1% down) (Fig. 3B). 
GO-term analysis yielded 40 significantly enriched categories within the ‘Biological Process’ 
subroot (p < 0.01, > 10 genes per category), comprising a number of developmental categories 
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that were similar to those identified in SH-SY5Y cells (Table S2). However, unlike in the SH-
SY5Y cells, neurogenesis-related categories were not found enriched in the SH-EP2 cells. 
Instead, many GO-terms linked to cell migration were enriched in these cells. Moreover, 
shRNA-mediated knockdown of TRPM7 in SH-EP2 cells affected expression of genes involved 
in EMT, a developmental transcription program that allows epithelial cells to become migratory 
(Fig S3A). Transcriptional activators that contribute to EMT, including SNAI1, SNAI2, TWIST1, 
HIF1A and LEF1, were significantly down regulated by TRPM7 knockdown, consistent with 
reduced migration of SH-EP2 TRPM7 shRNA cells. Despite the up regulation of some other 
EMT inducers such as SOX9 and EOMES upon TRPM7 knockdown, these results suggest 
that TRPM7 maintains epithelial-like neuroblastoma cells in a progenitor-like migratory state. 
 In search of transcription factors that are directly controlled by TRPM7, we screened for 
transcriptional regulators that were affected in both SH-EP2 and SH-SY5Y TRPM7 shRNA cells 
(Fig. S3C). In addition to LIN28B, POU4F1, ID3 and SNAI1, SNAI2 was of particular interest 
since its expression was most strongly reduced in both cell lines upon TRPM7 knockdown. 
Indeed, we confirmed by quantitative RT-PCR that expression of SNAI2 was reduced upon 
TRPM7 knockdown in both SH-SY5Y and SH-EP2 neuroblastoma cells (Fig. 5D & Fig. S2F). 
Moreover, overexpression of TRPM7 in the SNAI2 negative N1E-115 mouse neuroblastoma 
cell line induced expression of SNAI2. Since SNAI2 is not only an important driver of neural 
crest formation and migration (Ferronha et al., 2013; Prasad et al., 2012; Taneyhill et al., 2007), 
but also a determinant of cancer stemness, migration and metastasis (Cobaleda et al., 2007; 
Ferronha et al., 2013; Jiang et al., 2011; Vitali et al., 2008), our results indicate that TRPM7 
maintains progenitor features of neuroblastoma cells by controlling gene expression programs 
that involve the transcription factor SNAI2.
Discussion
Studies using in vitro and in vivo approaches have identified TRPM7 as a critical regulator of 
embryogenesis and tissue homeostasis. Deregulation or dysfunction of TRPM7 is associated 
with a number of pathologies, including cancer (Visser et al., 2014; Yee et al., 2014). Despite 
the increasing number of studies on the role of TRPM7 in cancer, data that support the 
association between TRPM7 expression levels and disease progression in patients are 
limited. TRPM7 expression levels are increased in nasopharyngeal carcinomas (Chen et 
al., 2014) and pancreatic ductal adenocarcinomas (Rybarczyk et al., 2012), and we showed 
in two independent cohorts that high TRPM7 expression associates with poor prognosis of 
breast cancer patients at time of diagnosis (Middelbeek et al., 2012). In a recent publication, 
Zhang et. al. observed a strong correlation between TRPM7 and MYCN expression levels in 
a large neuroblastoma patient cohort (Kocak, n = 649) (Zhang et al., 2014). We were able to 
confirm a positive association between TRPM7 and MYCN mRNA expression in two out of five 
additional neuroblastoma patients datasets that are publically available (Table S3). However, 
neither in the Kocak dataset nor in the other datasets did TRPM7 expression associate with 
neuroblastoma disease stage, an important prognostic marker. In only one of the datasets we 
found TRPM7 to be associated with relapse, but not with overall survival. Thus, increased
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TRPM7 expression may correlate with MYCN expression, but whether TRPM7 mRNA 
expression associates with disease progression in neuroblastoma patients remains to be 
established.
 In this study, we show that TRPM7 overexpression confers a malignant phenotype 
onto poorly metastatic neuroblastoma cells in vivo. This is in close agreement with our recent 
observations in breast cancer cells, showing that TRPM7 shRNA-mediated knockdown impairs 
breast cancer metastasis formation in a mouse model (Middelbeek et al., 2012). Together, these 
experiments indicate that high TRPM7 expression levels promote tumor metastasis formation 
in vivo. A number of studies have suggested that TRPM7 contributes to tumor progression by 
enhancing cell proliferation (Guilbert et al., 2009; Jiang et al., 2007; Yee et al., 2012; Zhang 
et al., 2014; Zierler et al., 2011). Using neuroblastoma cells that are made to express high 
levels of MYCN, experiments by Penner and colleagues suggest that TRPM7 expression 
is required for MYCN-enhanced proliferation of neuroblastoma cells (Zhang et al., 2014). 
However, using neuroblastoma cells that express more physiological levels of MYCN, we find 
that TRPM7 knockdown and overexpression do not affect proliferation in vitro, irrespective of 
MYCN amplification status. Moreover, we find an increased number of tumors in mice injected 
with mouse neuroblastoma cells that overexpress TRPM7, rather than increased tumor size. 
Differences in experimental approach may explain the discordance between our observation 
and those reported in literature. Whereas we stably overexpressed mTRPM7 or TRPM7 
shRNAs by retro- and lentiviral transductions, and subsequently selected viable cells, others 
manipulated TRPM7 protein levels by transient expression of siRNA oligos. In our hands, 
transient knockdown as well as overexpression of TRPM7 induces cell death within 48 hours 
after transfection (data not shown). In agreement, long term exposure to high concentrations of 
TRPM7 channel blockers reduces cell viability (Chubanov et al., 2012; Kim et al., 2012a; Zierler 
et al., 2011). We propose that by generating stable TRPM7 overexpression and knockdown 
cell lines, we have modulated TRPM7 expression levels within a range compatible with normal 
cell viability and proliferation. 
 High-risk metastatic neuroblastoma cells adopt features used by neural crest progenitor 
cells to delaminate from the neural border and to colonize different parts of the embryo 
(Jiang et al., 2011). Using conditional knockout mice, TRPM7 was found to be required for 
the maintenance of multi-potent neural crest cells during embryogenesis (Jin et al., 2012). 
Hence, TRPM7 may drive neuroblastoma metastasis by preserving neural crest-like progenitor 
features. Indeed, we observed that TRPM7 expression is required for migration of neuroblastic 
(N-type) and epithelial-like (S-type) neuroblastoma cells, resembling the migratory potential of 
neural crest cells (Thiery et al., 2009). Using microarray-based expression profiling, we show 
that TRPM7 controls expression of genes that regulate neural crest development (Fig. 5 & S3). 
Gene ontology analysis suggests that TRPM7 maintains an undifferentiated state in N-type 
SH-SY5Y cells by controlling the expression of neural plate border and neural crest specifiers, 
whereas it preserves a motile phenotype in S-type SH-EP2 cells by controlling genes that drive 
the epithelial-to-mesenchymal transition. It should be noted, however, that genes controlling 
neural crest development play distinct roles at different stages of development. Attributing 
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genes a specific role in neural crest development, i.e. neural plate border and neural crest 
specification, induction of migration (EMT) and late differentiation, is an oversimplification of 
the complex crosstalk between genes during development (Prasad et al., 2012). However, 
based on an extensive literature search (Table 1), we postulate that TRPM7 knockdown 
redirects neuroblastoma gene expression by reducing stemness and motility, and promoting 
differentiation. 
 The limited overlap in genes that are controlled by TRPM7 in the two  cell models is 
reminiscent of the concept that signaling inputs and transcription factors involved in neural 
crest development act as time and context dependent gene regulatory networks (Prasad et al., 
2012). Since SNAI2 function is crucial to early neural crest specification, as well as EMT-driven 
delamination and survival of neural crest cells outside of the niche, down regulation of SNAI2 
expression may underlie the distinct effects on developmental gene expression programs upon 
TRPM7 shRNA in N-type and S-type neuroblastoma cells (Cobaleda et al., 2007; Ferronha et 
al., 2013; Prasad et al., 2012; Taneyhill et al., 2007; Tribulo et al., 2004). 
 Consistent with its function in neural crest development (Cobaleda et al., 2007), SNAI2 
is an important driver of cancer progression. SNAI2 expression is suggested to maintain the 
pool of cancer stem cells, allowing tumor cells to leave the primary tumor, colonize ectopic 
tissues, and induce therapy resistance (Cobaleda et al., 2007; Come et al., 2006; Shih and 
Yang, 2011). Moreover, SNAI2 drives EMT in neuroblastoma cells (Ferronha et al., 2013), and, 
reciprocally, SNAI2 knockdown increases the sensitivity to apoptosis-inducing compounds and 
impairs the metastatic potential of neuroblastoma cells in vitro and in vivo (Vitali et al., 2008). 
Hence, our results strongly suggest that TRPM7 maintains stem cell features of neuroblastoma 
cells by expression regulation of SNAI2. 
 Although the findings presented in this study are in line with the accumulating 
evidence that TRPM7 plays a crucial role during embryogenesis, cellular differentiation 
and overall tissue homeostasis (Visser et al., 2014; Yee et al., 2014), the precise signaling 
mechanisms and transcriptional regulators involved remain largely elusive. Supporting the 
idea that developmental processes are controlled in a context-dependent manner, TRPM7 
activity is responsive to the physical characteristics of the microenvironment (Oancea et al., 
2006; Wei et al., 2009) and modulates mesenchymal stem cell differentiation upon mechanical 
stimulation (Xiao et al., 2014). In addition to activating Ca2+-dependent transcription factors 
upon mechanical stimulation, including STAT3 and NFATC1 (Davis et al., 2013; Jin et al., 
2012; Liu et al., 2014; Xiao et al., 2014), TRPM7 may translate mechanical cues from the 
microenvironment into gene expression alternations by modulating cytoskeletal tension. 
Actomyosin-driven cytoskeletal tension is an important determinant of neural crest formation 
(Kim et al., 2014). For instance, reduced cytoskeletal tension promotes the expression of neural 
crest specifiers including SNAI2. Consistent with the association between TRPM7 and SNAI2 
expression levels in our neuroblastoma cell models, we previously showed that TRPM7 activity 
induces cytoskeletal relaxation in breast cancer cells as well as in neuroblastoma cells (Clark 
et al., 2006; Middelbeek et al., 2012). Although the mechanism by which TRPM7 affects gene 
expression remains to be explored, our results suggest a model in which context dependent 
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activation of TRPM7 reduces cytoskeletal tension, and through activation of transcriptional 
regulators that respond to cytoskeletal dynamics, such as YAP/TAZ and SRF (Dupont et al., 
2011; Posern and Treisman, 2006), controls the malignant features of neuroblastoma cells 
by promoting neural crest stem cell properties. Future studies will determine how alterations 
in cytoskeletal dynamics affect the expression of SNAI2, and whether TRPM7-driven SNAI2 
expression contributes to neuroblastoma progenitor-like features. Ultimately, specific TRPM7 
inhibitors such as Waixenicin A (Zierler et al., 2011), could potentially be used to induce 
neuroblastoma differentiation, and may prove useful in treatment of neuroblastoma in future 
(pre-) clinical studies. 
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Materials and methods
Constructs and cell lines
N1E-115 and SH-EP2 cells were cultured in DMEM supplemented with 10% FCS and 1% penicillin-streptomycin, at 
37˚C and 5% CO2. SH-SY5Y were maintained in DMEM/F12 medium supplemented with 10% FCS, 1% penicillin-
streptomycin, 1% non-essential amino acids and 1% L-glutamine.
 Cloning of full length TRPM7-HA cDNA into LZRS-neo was previously described (Clark et al., 2006). 
Luciferase cDNA was isolated from pMX-luciferase-YFP-neo and subcloned into a retroviral pLZRS-IRES-zeocin 
vector. N1E-115 mouse and SH-SY5Y human neuroblastoma cells stably overexpressing TRPM7-HA and empty 
vector control were generated by retroviral transductions. Transduced cells were selected by the addition of 1 
mg/ml G418. For bioluminescent imaging, control and TRPM7 overexpressing N1E-115 cells were co-transduced 
with a retroviral pLZRS luciferase reporter construct and selected with 0.5 mg/ml Zeocin. Human TRPM7 
shRNA (5-GCGCTTTCCTTATCCACTTAA-3) was introduced in SH-SY5Y (CRL-2266, ATCC) and SH-EP2 (J. 
Molenaar, AMC, Amsterdam, The Netherlands) cells, using the pLKO lentiviral expression vector according to 
manufacturer’s instructions (Sigma Aldrich, St. Louis, MO). An independent TRPM7 shRNA was introduced in SH-
EP2 to control for off-target effects (TRPM7 shRNA#2: 5-TTGCCTGTAAGATCTATCGTT-3). A nonfunctional shRNA 
(5-GCTACAAGAGAAACCAAATCT-3) was introduced in SH-SY5Y and SH-EP2 cells to serve as negative control. 
Transduced cells were selected with 1 µg/ml puromycin. 
 The effect of TRPM7 overexpression and knockdown on cell viability and proliferation was assessed by 
MTS assays according to manufacturer’s instructions (Promega, Madison, WI).
Quantitative RT-PCR
Total mRNA isolation (Qiagen, Valencia, CA) was followed by SuperScript cDNA synthesis (Life Technologies, 
Carlsbad, CA), according to manufacturer’s protocols. TRPM7 mRNA expression levels in N1E-115, SH-EP2 
and SH-SY5Y cells were determined by quantitative PCR reactions using power SYBR-green reagent (Applied 
Biosystems, Carlsbad, CA) in combination with mouse specific (forward: TAGCCTTTAGCCACTGGACC; 
reverse: GCATCTTCTCCTAGATTGGCAG) or human specific (forward: TAGCCTTTAGCCACTGGAC; reverse: 
GCATCTTCTCCTAGATTTGC) TRPM7 primers according to manufacturer’s recommendations. Using the 
similar approach, SNAI2 levels were determined using mouse specific (forward: GGCTGCTTCAAGGACACATT; 
reverse: GGTTTTGGAGCAGTTTTTGC) and human specific (forward: AGATGAGCATTGGCAGCGAG; reverse: 
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AAGCATTTCAACGCCTCCAAA) SNAI2 primers. Mouse and human TRPM7 and SNAI2 mRNA expression levels 
were normalized to the mouse (forward: GCCAAGGTCATCCATGACAAC; reverse: GAGGGGCCATCCACAGTCTT) 
or human (forward: CTCCTCCACCTTTGACGCTG; reverse: TCCACCACCCTGTTGCTGTA)  GAPDH housekeeping 
genes respectively, and calculated according to the cycling threshold method (Livak and Schmittgen, 2001).
Cell migration assays
Following overnight serum starvation, cells were harvested and resuspended in DMEM containing 0.1% FBS. 
Subsequently, 50.000 cells were applied to a transwell insert with 8 µm pore size (Corning Life Sciences, Corning, 
NY), which was incubated in DMEM supplemented with 10% FBS. N1E-115 and SH-SY5Y cells were allowed to 
migrate for 48 hours at 37 °C towards a serum gradient. SH-EP2 cells were allowed to migrate for 24 hours. Migrated 
cells were fixed (75% methanol and 25% acetic acid) and stained (0.25% Coomassie Blue, 45% methanol, 10% 
acetic acid in H2O). Gap closure assays were performed according to manufacturer’s recommendations (Applied 
Biophysics, Troy, NY). In short, 50.000 SH-EP2 cells were seeded per insert and cultured overnight. After removal 
of the insert, cells were allowed to migrate for 24 hours and migration was followed by time lapse microscopy for 24 
hours. Gap closure speed was quantified using ImageJ (version 1.48)  image analysis software.
Mouse xenograft experiments
All animal work was performed in accordance with protocols approved by the Animal Welfare Committee (DEC-
NKI-10.034). Rag2-/-Il2rg-/- immunodeficient mice, backcrossed on a Balb/c background, were used for metastasis 
experiments at 5-8 weeks old. N1E-115 mouse neuroblastoma cells were trypsinized and washed 3 times with 
PBS. Subsequently, 0.2 ml PBS containing 5*105 cells was injected into a tail vein. Tumor growth was monitored 
by bioluminescence imaging from day 7 onwards. Beetle luciferin (Promega, Fitchburg, WI, USA) was dissolved at 
15 mg/ml in sterile PBS and stored at -20°C. Animals were anaesthetized with 2-3% isoflurane. Luciferin solution 
was injected i.p. (0.01 ml per gram body weight). Light emission was measured 15 min later, using a cooled CCD 
camera (IVIS; Xenogen), coupled to Living Image acquisition and analysis software over an integration time of 1 
min. Signal intensity was quantified as the Flux (photons / s) measured over the abdominal region. Organs and 
tissues were collected at day 20 after injection, fixed in EAF (ethanol-acetic acid-formol saline fixative, 40:5:10:45 
v/v) and processed routinely for histology preparations. The paraffin sections were stained with Haematoxylin and 
Eosin (H&E). For quantitative analysis of the neoplastic lesions, liver sections (9 sections from each liver) were 
stained with Haematoxylin and Eosin. Liver tumors were quantified under a microscope and the data were further 
processed by Image J (version 1.48).
Microarray
Microarray-based gene expression profiling on SH-SY5Y and SH-EP2 control and shTRPM7 cells was performed 
by ServiceXS B.V. (Leiden, The Netherlands). Samples were prepared and analyzed in duplo. mRNA was purified 
from cell cultures and treated with DNAse (Qiagen, Valencia, CA). RNA concentrations were measured using the 
Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE. U.S.A). RNA quality and integrity 
were determined using Lab-on-Chip analysis on the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa 
Clara, CA, U.S.A). Biotinylated cRNA was prepared using the Illumina TotalPrep RNA Amplification Kit (Ambion, 
Inc., Austin, TX, U.S.A) according to manufacturer’s specifications with an input of 200 ng total RNA. Per sample, 
750 ng of the obtained biotinylated cRNA samples was hybridized onto the Illumina HumanHT-12 v4 (Illumina, 
Inc., San Diego, CA, U.S.A). Hybridization and washing were performed according to the Illumina Manual ‘Direct 
Hybridization Assay Guide’. Scanning was performed on the Illumina iScan (Illumina, Inc., San Diego, CA, U.S.A). 
Image analysis and extraction of raw expression data was performed with Illumina GenomeStudio v2011.1 Gene 
Expression software. Arrays were normalized in Arraystar (v. 4.03), using Robust-Multi-Array normalization. Fold 
difference and P-values were calculated using Multi Experiment Viewer (v. 4.8.1). GO-term analysis was performed 
using Webgestalt (http://bioinfo.vanderbilt.edu/webgestalt/) on genes that were significantly (p < 0.05) up or down 
regulated. Vennmaster (http://sysbio.uni-ulm.de/?Software:VennMaster) was used to determined the overlap in 
genes that were significantly up or down regulated in SH-SY5Y and SH-EP2 TRPM7 shRNA cells.
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Figure S1. Manipulation of TRPM7 expression in mouse N1E-115 
cells, and human SH-SY5Y and SH-EP2 cells (A) Mouse TRPM7 mRNA 
expression in mouse N1E-115 control and mTRPM7 overexpressing cells, 
determined by quantitative RT-PCR. Mouse TRPM7 expression in the control 
cells is set to one. Data is mean ± SEM of n = 2 independent experiments. (B) 
Human TRPM7 mRNA expression in human SH-SY5Y control and TRPM7 
shRNA cells, determined by quantitative RT-PCR. Human TRPM7 expression 
in the control cells is set to one. Data is mean ± SEM of n = 6 independent 
experiments. (C) Mouse TRPM7 mRNA expression in human SH-SY5Y 
control and mTRPM7 overexpressing cells, determined by quantitative RT-
PCR. Mouse TRPM7 expression in the control cells is set to one. Data is 
mean ± SEM of n = 3 independent experiments. (D) Human TRPM7 mRNA 
expression in human SH-EP2 control, TRPM7 shRNA and TRPM7 shRNA#2 
cells, determined by quantitative RT-PCR. Human TRPM7 expression in 
the control cells is set to one. Data is mean ± SEM of n = 2 independent 
experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure S2. TRPM7 shRNA#2 reduces SH-EP2 cell migration and SNAI2 mRNA expression, but not cell 
viability and proliferation. (A) & (B) Effect of TRPM7 shRNA#2 on viability and proliferation of SH-EP2 cells. 
Quantification of cell viability and proliferation, determined by MTS assays. Viability was assessed over 4 hours, 
proliferation was assessed over 4 days. Data represents normalized mean extinction at 492 nm mean ±  SEM of n 
= 2 experiments performed in triplo. (C) Transwell migration of SH-EP2 control and TRPM7 shRNA#2 cells. Equal 
numbers of cells were allowed to migrate towards a serum gradient for 24 hours. Data are normalized to control 
and represent mean ± SEM of n = 3 independent experiments performed in duplicate. (D) Gap closure over time, 
presented as percentage of gap size at time point 0 hours. (E) Quantification of time to 50% gap closure. Data in 
(D) and (E) represent mean ± SEM from n = 3 independent experiments, each performed in duplicate. (F) TRPM7 
shRNA#2 reduces SNAI2 mRNA expression levels in SH-EP2 cells, as determined by quantitative RT-PCR. Data 
represents mean expression levels ± SEM (n = 3) that are normalized to GAPDH housekeeping gene expression. 
SNAI2 expression in control cells is set to one. * p < 0.05, ** p < 0.01, two-tailed unpaired t-test.
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Figure S3. TRPM7 shRNA reduces expression of EMT transcription factors in SH-EP2 cells (A) TRPM7 
shRNA induces a partial mesenchymal to epithelial transition in SH-EP2 human neuroblastoma cells. Selection of 
differentially regulated genes within the ‘Epithelial to mesenchymal transition’ category, that are known to positively 
(+) or negatively (-) associate with epithelial to mesenchymal transition in neural crest and neuroblastoma cells. X-axis 
represents fold difference in normalized expression levels between control and TRPM7 shRNA cells. (B) Overlap 
in differentially expressed genes in neuroblastic SH-SY5Y and epithelial-like SH-EP2 cells. (C) Transcriptional 
regulators that are up or down regulated in both neuroblastic SH-SY5Y and epithelial-like SH-EP2 cells. X-axis 
represents fold difference in normalized expression levels between control and TRPM7 shRNA cells.
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Observed Expected
Fold 
Enrichment P
multicellular organismal development 476 378.16 1.26 8.44e-07
developmental process 523 424.07 1.23 8.44e-07
system development 416 326.59 1.27 1.56e-06
anatomical structure development 463 373.80 1.24 4.61e-06
multicellular organismal process 613 523.51 1.17 2.55e-05
single-multicellular organism process 610 520.54 1.17 2.55e-05
nervous system development 217 159.91 1.36 0.0001
cell morphogenesis involved in differentiation 104 65.30 1.59 0.0002
anatomical structure morphogenesis 247 190.61 1.30 0.0005
glycosaminoglycan biosynthetic process 25 9.28 2.70 0.0005
aminoglycan biosynthetic process 25 9.37 2.67 0.0005
blood vessel development 76 45.64 1.67 0.0006
tissue development 182 134.40 1.35 0.0007
chondroitin sulfate proteoglycan metabolic process 17 5.19 3.27 0.0007
neuron projection morphogenesis 86 54.08 1.59 0.0008
anatomical structure formation involved in morphogenesis 196 147.85 1.33 0.0011
neuron differentiation 131 91.83 1.43 0.0011
cell morphogenesis involved in neuron differentiation 84 53.33 1.57 0.0012
chondroitin sulfate metabolic process 16 5.01 3.19 0.0013
cell proliferation 190 143.58 1.32 0.0013
cell adhesion 126 88.49 1.42 0.0014
biological adhesion 126 88.67 1.42 0.0015
cell-cell adhesion 63 37.47 1.68 0.0015
neuron projection development 98 65.30 1.50 0.0015
vasculature development 76 47.95 1.58 0.0017
axonogenesis 77 48.79 1.58 0.0017
organ development 291 236.71 1.23 0.0019
cell differentiation 302 247.19 1.22 0.0020
response to chemical stimulus 310 254.70 1.22 0.0020
cell-cell junction organization 26 11.50 2.26 0.0025
spinal cord motor neuron differentiation 10 2.41 4.15 0.0026
cell morphogenesis 122 87.65 1.39 0.0030
cell projection organization 120 86.63 1.39 0.0030
negative regulation of developmental process 76 49.99 1.52 0.0030
cellular developmental process 314 262.40 1.20 0.0030
cell differentiation in spinal cord 13 3.99 3.26 0.0030
cell part morphogenesis 93 64.09 1.45 0.0030
cell development 176 135.51 1.30 0.0030
neurogenesis 142 105.74 1.34 0.0030
glycosaminoglycan metabolic process 29 13.82 2.10 0.0030
Table S1
GO-term
Table S1. GO-term analysis on TRPM7 shRNA affected genes in SH-SY5Y cells. GO-term analysis using 
Webgestalt yields 40 significantly enriched categories (P). Fold enrichment is the ratio between observed and 
expected genes within a category. Number of expected genes is based on the number of protein encoding genes 
within a category.
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Table S2. GO-term analysis on TRPM7 shRNA affected genes in SH-EP2 cells. GO-term analysis using 
Webgestalt yields 40 significantly enriched categories (P). Fold enrichment is the ratio between observed and 
expected genes within a category. Number of expected genes is based on the number of protein encoding genes 
within a category. Categories that were also found enriched in SH-SY5Y TRPM7 shRNA cells (Table S1) are 
indicated in grey.
Observed Expected
Fold 
Enrichment P
Table S2
GO-term
response to wounding 183 118.47 1.54 2.59e-07
circulatory system development 135 80.62 1.67 2.59e-07
vasculature development 103 55.28 1.86 2.59e-07
cardiovascular system development 135 80.62 1.67 2.59e-07
cellular component movement 192 126.81 1.51 3.04e-07
blood vessel development 96 52.60 1.82 7.05e-07
blood vessel morphogenesis 86 46.30 1.86 1.74e-06
response to external stimulus 204 141.46 1.44 3.28e-06
renal system development 57 26.94 2.12 4.77e-06
single-multicellular organism process 696 598.64 1.16 8.11e-06
multicellular organismal process 699 602.07 1.16 8.58e-06
response to lipid 104 62.23 1.67 9.64e-06
urogenital system development 62 31.22 1.99 9.89e-06
regulation of response to external stimulus 74 40.20 1.84 1.42e-05
angiogenesis 71 38.17 1.86 1.56e-05
cell migration 137 89.81 1.53 1.94e-05
wound healing 108 66.93 1.61 2.41e-05
locomotion 188 133.01 1.41 2.49e-05
cell motility 145 97.19 1.49 2.62e-05
localization of cell 145 97.19 1.49 2.62e-05
system development 456 376.04 1.21 3.59e-05
anatomical structure morphogenesis 285 219.61 1.30 4.32e-05
response to organic cyclic compound 100 61.91 1.62 4.74e-05
single-organism process 904 815.69 1.11 6.43e-05
kidney development 46 22.24 2.07 7.23e-05
developmental process 570 487.66 1.17 8.14e-05
response to molecule of bacterial origin 48 24.06 2.00 9.64e-05
regulation of cell motility 76 44.59 1.70 9.64e-05
cell adhesion 147 101.68 1.45 9.64e-05
circulatory system process 64 35.50 1.80 9.64e-05
biological adhesion 147 101.89 1.44 9.64e-05
regulation of localization 194 141.78 1.37 9.64e-05
regulation of cell migration 73 42.23 1.73 9.64e-05
epithelial to mesenchymal transition 23 8.13 2.83 0.0001
ERK1 and ERK2 cascade 32 13.79 2.32 0.0001
system process 237 180.91 1.31 0.0001
anatomical structure development 507 430.25 1.18 0.0001
regulation of locomotion 80 47.90 1.67 0.0001
regulation of body fluid levels 100 63.72 1.57 0.0001
blood circulation 63 35.39 1.78 0.0001
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Table S3. TRPM7 does not correlate with disease stage and progression in neuroblastoma patients. R 
indicates correlation coefficient. P indicates significance of correlations. Statistical significant correlations (p < 0.05 
), are indicated in red. Analysis on patient datasets were performed using R2 (http://r2.amc.nl).
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The small GTPase RhoJ is regulated by the 
TRPM7-SOX4 axis and affects focal adhesion 
dynamics and cell migration
Arthur J. Kuipers,  Veerle Geurts, Erik van Buijtenen, Tanya Smeets, 
Jeroen Middelbeek & Frank N. van Leeuwen
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Abstract
Breast cancer metastasis is driven by the developmental transcriptional program epithelial-
mesenchymal transition (EMT), which endows tumor cells with invasive and migratory 
properties. EMT is accompanied by large-scale cytoskeletal rearrangements. We recently 
showed that the channel-kinase TRPM7 maintains the mesenchymal phenotype of breast 
cancer cells by regulating expression of the transcription factor SOX4, an important mediator 
of EMT in breast cancer cells. We speculated that the TRPM7-SOX4 axis may contribute 
to dynamic regulation of the cytoskeleton by controlling the expression of genes important 
for cytoskeletal regulation. Here, we show that expression of RhoJ, a member of the Cdc42 
subfamily of Rho GTPases, is regulated by the TRPM7-SOX4 signaling axis. In addition, 
RhoJ knockdown in MDA-231 breast cancer cells increases the number of focal adhesions, 
reminiscent of TRPM7 knockdown in MDA-231. Moreover, migratory properties of MDA-231 
are decreased in response to RhoJ knockdown, without affecting cell proliferation or viability, 
which also mirrors the effects of TRPM7 knockdown in MDA-231 cells. Combined, these results 
identify RhoJ as a common downstream effector of TRPM7 and SOX4 in breast cancer cells 
and suggest that RhoJ contributes to TRPM7-regulated adhesion dynamics.
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Introduction
Tumor metastasis is the leading cause of cancer-associated mortality. Signaling pathways 
that regulate cytoskeletal dynamics play an important role during metastatic progression 
by driving invasion and migration of tumor cells (Friedl and Alexander, 2011). Consistently, 
aberrant expression or activation of cytoskeletal proteins and cytoskeletal regulators including 
Rho GTPases have been shown to enhance metastatic properties of tumor cells (Alan and 
Lundquist, 2013). In addition, cytoskeletal tension is able to activate metastatic transcriptional 
pathways such as YAP/TAZ, MRTF/SRF, and EMT (Chapter 4 and (Cordenonsi et al., 2011; 
Medjkane et al., 2009).
 We and others previously showed that the channel-kinase TRPM7, a member of the 
transient receptor potential family of cation channels, affects cell adhesion and migration by 
reducing myosin II-based cellular tension through Ca2+- and kinase-dependent interactions with 
the actomyosin cytoskeleton (Clark et al., 2006; Middelbeek et al., 2012; Su et al., 2006; Su et 
al., 2011; Visser et al., 2013). In addition, we found that TRPM7 is required for breast cancer 
cell metastasis in mouse xenografts (Middelbeek et al., 2012). Moreover, we showed that high 
TRPM7 mRNA expression levels predict poor disease outcome and metastasis formation in 
breast cancer patients at time of diagnosis (Middelbeek et al., 2012).
Figure 1. RhoJ is a TRPM7 and SOX4 target gene, but not regulated by TGF-β signaling. Effect of TRPM7 (A) 
or SOX4 (B) knockdown in MDA-231 cells on RHOJ expression levels. (C) Effect of TRPM7 knockdown in 4T07 
cells on Rhoj expression levels. (D) Effect of TRPM7 wildtype (T7 wt) or kinase dead (T7 kd) overexpression in 
N1E-115 cells on Rhoj mRNA expression levels. mRNA expression levels were determined by q-PCR. Data are 
mean ± SEM of n = 3 experiments that were performed in duplicate. Statistical significance was determined by a 
one-sample t-test. * = p < 0.05, ** = p < 0.01.
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 In addition to directly regulating cytoskeletal organization and adhesion dynamics, 
TRPM7 affects gene expression programs involved in differentiation and developmental 
processes (Du et al., 2010; Jin et al., 2008; Jin et al., 2012). For instance, we found that 
TRPM7-induced cytoskeletal relaxation maintains the migratory state of breast cancer cells by 
activating a developmental transcriptional program known as epithelial-mesenchymal transition 
(EMT) (Chapter 3 & 4). Maintenance of a mesenchymal state by TRPM7 involves regulation 
of the EMT transcription factor SOX4 (Chapter 4) and requires large-scale cytoskeletal 
rearrangements (Gonzalez and Medici, 2014). Here, we show that both TRPM7 and SOX4 
regulate expression of RhoJ, a member of the Cdc42 subfamily of Rho GTPases, a protein 
family known for its role in cytoskeletal dynamics. Moreover, we find that RhoJ knockdown in 
MDA-MB-231 (MDA-231) breast cancer cells, similar to loss of TRPM7, reduces cell adhesion 
dynamics and cell migration, suggesting a role for RhoJ in mediating EMT downstream of 
SOX4. 
Figure 2. Trpm7 shRNA 4T07 and 
RHOJ shRNA MDA-231. Knockdown 
efficiency of Trpm7 shRNAs (A) or 
RHOJ shRNAs (B) in 4T07 or MDA231 
cells, respectively, as determined by 
q-PCR. mRNA expression levels were 
determined by q-PCR. Data are mean 
± SEM of n = 3 experiments that were 
performed in duplicate. Statistical 
significance was determined by a one-
sample t-test. * = p < 0.05, ** = p < 0.01.
Results & Discussion
To identify transcriptional targets acting downstream of TRPM7 and SOX4 that can be linked 
to cytoskeletal remodeling, we queried gene expression arrays of MDA-231 TRPM7 and SOX4 
knockdown cells (Chapter 4). We found that expression of RhoJ, a member of the Cdc42 
subfamily of Rho GTPases was suppressed both in TRPM7 as well as SOX4 knockdown 
MDA-231 cells (2.8 fold, and 2.4 fold respectively). RhoJ knockdown was previously shown 
to increase the number of focal adhesions and cytoskeletal tension in endothelial cells (Ho et 
al., 2013; Kaur et al., 2011; Wilson et al., 2014; Yuan et al., 2011). In addition, RhoJ regulates 
melanoma migration and invasion and tumor progression in vivo (Ho et al., 2013). Consistent with 
these findings, we observed increased formation of focal adhesions and reduced cell migration 
upon TRPM7 knockdown in our MDA-231 breast cancer cells (Chapter 3 & (Middelbeek et al., 
2012)). Reduced RHOJ expression was confirmed by q-PCR in both MDA-231 TRPM7 and 
SOX4 shRNA cells (Fig 1A-B; knockdown cells were characterized in Chapter 3 and Chapter 
4). In addition, TRPM7 knockdown reduced Rhoj expression in the mesenchymal-like mouse 
breast cancer cell line 4T07 (Fig 1C & Fig 2A for TRPM7 knockdown levels), confirming 
Figure 2
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Figure 3. Reduced RhoJ 
expression increases the 
number of focal adhesion 
and decreases migratory 
properties of MDA-231 cells. 
(A) Immunofluorescence 
staining of MDA-231 cells with 
phalloidin to visualize the actin 
cytoskeleton pTyr118 paxillin 
antibodies to reveal focal 
adhesion. Scale bar = 20 µm. 
(B) Western blot of Triton X-100 
insoluble fractions derived from 
MDA-231 shCntrl, shRHOJ#1 
and shRHOJ#1 cells. Antibodies 
against pTyr118 paxilling were 
used to determine the amount of 
tyrosine phosphorylated paxillin 
as measure of cytoskeletal 
contractility and focal adhesion 
content. Y-tubulin antibodies 
were used a loading control. 
(C) Quantification of migratory 
trajectories over 24 h of 
migration on vitronectin-coated 
culture dishes, expressed as in 
arbitrary units.
RhoJ as a TRPM7 target gene in mesenchymal breast cancer cells. Furthermore, overexpression 
of TRPM7 in the mouse N1E-115 neuroblastoma cell line (characterized in (Clark et al., 2006)) 
increased Rhoj expression in a kinase-dependent manner (Fig 1D). The fact that RhoJ is 
regulated by both TRPM7 and SOX4 suggests it could be part of an EMT gene expression 
program. Indeed, RhoJ was found to be expressed in mesenchymal-like circulating tumor cells 
(CTCs), whereas its expression was lacking in epithelial-like CTCs (Yu et al., 2013). However, 
the fact that TGF-β stimulation of MDA-231 cells did not increase RHOJ expression (Fig 1E), 
whereas other TRPM7/SOX4/EMT targets such as CDH1, CLDN1, FN1 and VIM did respond 
to TGF-β stimulation (Chapter 4, Fig 1D), suggests that RhoJ may not be a universal marker 
of EMT. 
 To test whether loss of RhoJ contributes to TRPM7 knockdown-induced cytoskeletal 
rearrangements (Middelbeek et al., 2012), we generated shRNA-mediated knockdown of RhoJ 
in MDA-231 (MDA-231 shRHOJ#1 and shRHOJ#2). Although we were able to detect RhoJ 
protein expression in the endothelial cell line EA.hy926, in which RhoJ is highly expressed
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 (~200x MDA-231 expression levels on mRNA level), RhoJ protein expression was undetectable 
at the protein level in MDA-231 cells (data not shown). Therefore, RhoJ knockdown efficiency 
could only be validated at the mRNA level (Fig 2B). Similar to TRPM7 knockdown in MDA-
231 (Middelbeek et al., 2012), shRNA mediated depletion of RhoJ in MDA-231 cells led to an 
increase in the number of focal adhesions (Fig 3A), which could be confirmed by an increase 
in Tyr118-paxillin phosphorylation, as dettermined by western blotting (Fig 3B). Consistently, 
migratory properties of MDA-231 decreased upon RhoJ knockdown (Fig 3C). Although in 
human melanoma cells, RhoJ expression was shown to suppress proliferation (Ho et al., 
2012), we did not observe any effects of RhoJ knockdown on proliferation or viability in our 
MDA-231 breast cancer model (Fig 4). Together, these data indicate that knockdown of RhoJ 
induces cytoskeletal rearrangements in MDA-231 cells that are highly similar to the effects 
seen in response to TRPM7 knockdown, consistent with the notion that RhoJ is a common 
effector of the TRPM7-SOX4 axis. 
Figure 4. Reduced RhoJ expression in MDA-231 does not affect cell proliferation or viability. (A) + (B) 
Proliferation and overall viability of shCntrl, shRHOJ#1 and shRHOJ#2 MDA-231 cells as determined by MTS 
assays. Measurements were performed at different time points, indicated on the x-axis. Metabolic activity is 
expressed as the amount of Formazan produced as determined by photospectrometry. Metabolic activity was 
normalized to initial metabolic activity. Data are represented as mean ± SEM of 3 independent experiments that 
were carried out in triplicate.
Concluding remarks
The effects of the cytoskeleton on transcriptional programs have been well documented and 
are likely to play an important role during cancer progression. We have previously shown that 
activation of TRPM7 leads to cytoskeletal relaxation by direct inhibition of myosin II function 
(Clark et al., 2006; Middelbeek et al., 2012). In addition, we observed that TRPM7-mediated 
cytoskeletal relaxation maintains the mesenchymal phenotype of breast cancer cells by 
preserving expression of the EMT transcription factor SOX4 (Chapter 4). Here, we provide 
evidence, that, in addition to its effects on cellular tension, TRPM7 promotes focal adhesion 
formation (or reduces turnover) by enhancing expression of distinct cytoskeletal regulators, 
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such as RhoJ. Therefore, we propose that the effects of TRPM7 on cell adhesion and migration 
are maintained by a regulatory loop involving changes in actomyosin based tension, increased 
expression of SOX4 and its downstream effector, RhoJ, which together may either maintain or 
enhance the malignant properties of tumor cells. (Figure 5).
Figure 5. Model describing a TRPM7-induced cytoskeletal dynamics regulatory loop. TRPM7-induced 
changes in cytoskeletal dynamics increase expression of SOX4. In turn, SOX4 enhances expression of RhoJ, 
which controls cytoskeletal dynamics and focal adhesion formation. This suggests that the effects of TRPM7 on 
cell adhesion and migration are maintained by regulatory loop involving changes in expression of the cytoskeletal 
regulator RhoJ.
Materials and methods
Cell culture
MDA-MB-231 and N1E-115 (American Type Culture Collection) were cultured in Dulbecco’s Modified Eagle Medium 
+ Glutamax (Life Technologies, Gibco, #31966), supplemented with 10% fetal bovine serum and 1% pen/strep 
(Life Technologies, Invitrogen, #15140). 4T07 (a kind gift from M. Zeegers, Radboudumc) were cultured in RPMI 
+ Glutamax (#72400), supplemented with 10% fetal bovine serum, 1% pyruvate (Life Technologies, Invitrogen, 
#11360) and 1% pen/strep. Cells were cultured in a humidified incubator at 37 °C and 5% CO2.
Generation of cell lines
To generate knockdown cell lines scrambled, human TRPM7, SOX4, RHOJ or mouse Trpm7 shRNAs (obtained 
from Dr. R. Beijersbergen at The Netherlands Cancer Institute - Screening and Robotics Facility) (see Table 1 for 
sequences) were transduced into cells using the pLKO lentiviral expression vector according to manufacturer’s 
protocol (Sigma-Aldrich). Cells were selected using 1 µg/ml (MDA-231) or 10 µg/ml (4T07) puromycin.
Quantitative real-time PCR
mRNA was isolated using an RNeasy minikit (Qiagen, #74106) and DNAse-treated on column (Qiagen, #79254). 
cDNA was synthesized using an iScript cDNA synthesis kit according to manufacturer’s protocol (Bio-Rad, #170-
TRPM7 SOX4
RhoJ
Migration
Cytoskeletal
dynamics
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8891). q-PCRs were performed using Power SYBR green mix (Life Technologies, Applied Biosystems, #4368708) 
on a CFX96 Touch™ Real-Time System (Bio-Rad) using PCR conditions as supplied by Applied Biosystems. Gene 
expression levels were normalized against the GAPDH housekeeping gene and calculated according to the 2-ΔΔCt 
method. See Table 1 for sequences. 
Table 1. shRNA & primer sequences.
Immunofluorescence
Cells were cultured o/n on glass coverslips and were subsequently fixed in 4% paraformaldehyde and permeabilized 
in 0.1% Triton-X 100. Non-specific binding was blocked with 3% BSA. Cells were incubated with anti pTyr118-
paxillin antibodies (1:200, Life Technologies) diluted in 3% BSA. Cells were then incubated with phalloidin-Alexa 
568 (1:100, Life Technologies-Molecular Probes) and anti-rabbit Alexa 647 conjugated antibodies diluted in 3% 
BSA and kept in the dark. Images (2048x2048 resolution, with 6x line averaging) were taken on a Leica TCS 
SP5 (Leica Microsystems) equipped with a 63x water-immersion objective and LAS-AF acquisition software (Leica 
Microsystems). Images were processed for publication using ImageJ 1.48.
Detection of focal adhesion-associated pTyr-118 paxillin
Focal adhesion–associated proteins were extracted from MDA-MB-231 cells, as described previously (Putnam et al., 
2003). Proteins were separated by SDS-PAGE and blotted onto PVDF. Blots were incubated with rabbit polyclonal 
anti-pTyr118 paxillin antibody (1:750) and mouse monoclonal γ-tubulin (1:10000; Sigma Aldrich) antibodies, followed 
by horseradish peroxidase–conjugated secondary antibodies (1:5000; Dako). Proteins were detected using ECL 
Western blot reagent (GE Healthcare) and imaged on a Fluorchem E Digital Darkroom (Proteinsimple).
shRNAs Sequence (5’ - 3’)
shCntrl (scrambled shRNA) GCTACAAGAGAAACCAAATCT
shT7#1 (TRPM7 shRNA) human GCGCTTTCCTTATCCACTTAA
shT7#2 (TRPM7 shRNA) human GCCCGATATTATTTCCACTAT
shSOX4#1 (SOX4 shRNA) human CCTTTCTACTTGTCGCTAAAT
shSOX4#2 (SOX4 shRNA) human TGGGCACATCAAGCGACCCAT
shRHOJ#1 (RHOJ shRNA) human GTCTTGCCATGAAATACTC
shRHOJ#2 (RHOJ shRNA) human GCGCTTTCCTTATCCACTTAA
shT7#1 (Trpm7 shRNA) mouse GGATGCATCTATGGAAGAAGG
shT7#2 (Trpm7 shRNA) mouse CCTTATCAAACCCTATTGAAT
Primers q-PCR Sequence (5’ - 3’)
human RHOJ Fwd GCTACGCCAACGACGCCTTC
human RHOJ Rev TTGAGCTCGGGACCCATTC
mouse RhoJ Fwd CGGCTGCAATGGACATGAG
mouse RhoJ Rev GGCACGTATTCCTCTGGGAAG
human TRPM7 Fwd TAGCCTTTAGCCACTGGAC
human TRPM7 Rev GCATCTTCTCCTAGATTTGC
mouse Trpm7 Fwd TAGCCTTTAGCCACTGGACC
mousee Trpm7 Rev GCATCTTCTCCTAGATTGGCAG
human GAPDH Fwd CTCCTCCACCTTTGACGCTG
human GAPDH Rev TCCACCACCCTGTTGCTGTA
mouse Gapdh Fwd GCCTTCCGTGTTCCTACCCC
mouse Gapdh Rev GAGTTGCTGTTGAAGTCGC
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Cell viability and proliferation measurements
The effect of RhoJ knockdown on cell viability and proliferation was assessed by MTS assays according to 
manufacturer’s instructions (Promega, Madison, WI).
Statistical analysis
Statistics on q-PCR data were performed using a one-sample t-test, comparing fold changes in expression to 
control levels that were set to 1 in each independent experiment. Statistics on migration data were performed using 
a two-sided, unpaired t-test. Data are represented as mean ± SEM. P-values < 0.05 were considered statistically 
significant.
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Tumor metastasis is the leading cause of cancer-associated mortality, causing roughly 
90% of cancer deaths. To acquire metastatic properties, tumor cells adopt a developmental 
transcriptional program termed epithelial-mesenchymal transition (EMT) (Kalluri and Weinberg, 
2009; Thiery et al., 2009). A diverse set of signaling molecules from the tumor microenvironment, 
such as TGF-β, other growth factors and cytokines, can induce EMT (Gonzalez and Medici, 
2014). In addition to these biochemically-induced signaling pathways, mechanically-induced 
signaling pathways are known to regulate developmental gene expression programs (Butcher 
et al., 2009; Cordenonsi et al., 2011; Dupont et al., 2011; Medjkane et al., 2009; Paszek et al., 
2005). The mechanical properties of the cell and its surroundings can affect gene expression 
by regulating nuclear localization of transcription factors or affecting tension on the nuclear 
membrane and consequently chromatin organization (Brown et al., 2013; Mammoto et al., 2012; 
O’Connor and Gomez, 2014; Wei et al., 2015). Understanding these mechanotransduction 
pathways, for instance by interfering with extracellular matrix (ECM) remodeling or inhibiting 
mechanosensitive proteins, may help to identify novel drug targets that may be able to stabilize 
metastatic cancers (Bonnans et al., 2014; Goodman and Picard, 2012; Harisi and Jeney, 2015; 
Nilius and Szallasi, 2014).
 The transient receptor potential (TRP) family of cation channels is a family of proteins 
implicated in sensory processes including mechanotransduction (Plant, 2014). For instance, 
a number of TRP channels, including TRPM7, is activated by mechanical stimuli and interacts 
with the actomyosin cytoskeleton to control many cellular processes, including adhesion, 
migration and transcription (Chapter 2 & (Fiorio Pla and Gkika, 2013; Kuipers et al., 2012; 
Prevarskaya et al., 2011). TRPM7 is a unique TRP channel harboring a C-terminal kinase and 
is required for proper embryonic development (Jin et al., 2008; Jin et al., 2012). Through direct 
interactions with the actomyosin cytoskeleton, TRPM7 decreases cytoskeletal tension (Visser 
et al., 2014). Based on these properties we proposed that TRPM7 may contribute to tumor 
progression.
 In this thesis we show that TRPM7 is required for efficient cancer metastasis formation. 
TRPM7 expression levels significantly associate with disease outcome in large breast cancer 
patient datasets. Moreover, we show that TRPM7 driven cytoskeletal relaxation promotes 
the metastatic properties of tumor cells involving immediate effects on actomyosin based 
contractility and cell adhesion dynamics, as well as long-term effects on developmental gene 
expression programs.
TRPM7 and tumor progression
Is TRPM7 of prognostic value for cancer patients?
In Chapter 3 we showed in two independent breast cancer patient cohorts, one microarray, 
one q-PCR based, that TRPM7 expression levels at the time of diagnosis correlate with patient 
survival and distant metastasis formation, independent of other common clinical parameters 
such as histological grade or tumor size. Other studies have found similar correlations of 
TRPM7 with breast and other types of cancer, such as ovarian and nasopharyngeal cancer 
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(Chen et al., 2015; Guilbert et al., 2009; Guilbert et al., 2013; Rybarczyk et al., 2012; Sun et 
al., 2013). Although these data support the prognostic value of TRPM7 expression levels, we 
did not find a correlation of TRPM7 expression with cancer progression in three additional 
breast cancer cohorts (Chapter 3) or in a neuroblastoma patient data set (Chapter 5). Such 
discordances may be explained by differences patient populations, probe selection and mRNA 
abundance. Future studies must therefore address to what extent TRPM7 has prognostic 
value during tumor progression and in which tumor types (see also Box I).
Box I -  A specific role for the TRPM7-SOX4 axis in distinct breast cancer subtypes?
In addition to our in vitro data showing that TRPM7 regulates SOX4 expression, we found 
significant expression correlations between SOX4 and TRPM7 in four breast cancer patient 
data sets (Chapter 4). Since we found expression regulation of SOX4 by TRPM7 in the MDA-
231 and Hs 578T breast cancer cell lines, which are considered claudin-low breast cancer cell 
lines, we wondered if expression correlations between SOX4 and TRPM7 would be enhanced 
in claudin-low breast cancer subtypes. Unfortunately, none of the datasets included claudin-
low specification. Interestingly however, when we examined the correlations between SOX4 
and TRPM7 in other subtypes we found a strong increase in the correlation coefficient in the 
luminal B subtype (Bertucci dataset, from r = 0.386 to r = 0.630, Figure 1). At the same time, 
no correlation was found in luminal A or Her2 positive subtypes (data not shown), whereas a 
trend was observed in basal type breast cancers (p = 0.07, probably reflecting the low number 
of patients; Figure 1). What are the implications of these findings? Although preliminary, these 
findings could implicate that the importance of the TRPM7-SOX4 signaling axis (i.e. sensitivity of 
cells to TRPM7-imposed changes in cytoskeletal tension) differs among the different subtypes 
of breast cancer. The cell of origin (e.g. luminal vs basal) or the differentiation grade may 
underlie such differences. Clearly future studies should focus on defining the role of TRPM7 
and SOX4 in these distinct breast cancer subtypes.
Figure 1. Correlation coefficients between 
TRPM7 and SOX4 in luminal B and basal 
subtype breast cancer patients. Patient 
dataset analysis was performed using 
R2 microarray analysis tools using the 
Bertucci dataset (http://r2.amc.nl). Pearsons’ 
correlations tests were performed to test for 
statistical significance of correlation.
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TRPM7 promotes metastasis formation in vivo
Our studies in breast cancer (Chapter 3) and neuroblastoma (Chapter 5) are the first to provide 
evidence that TRPM7 is required for metastasis formation in vivo. By intravenous injections of 
tumor cells into immuno-compromised mice we showed that knockdown of TRPM7 in breast 
cancer cells impairs metastasis formation, whereas overexpression in neuroblastoma cells 
enhances metastasis formation. We found that the number of lesions, rather than tumor size, 
was reduced or enhanced by TRPM7 knockdown or overexpression, respectively, indicating 
that proliferation of seeded tumor cells was unaffected. This is in agreement with our in 
vitro findings showing that TRPM7 does not affect proliferation or viability (Chapter 3 and 
Chapter 5). However, TRPM7 may be required for anoikis resistance, i.e. the ability of cells 
to survive in an anchorage independent manner. The effect of TRPM7 on cell survival in the 
circulation, a condition that requires anoikis resistance, has not been examined. This could 
be tested in vitro using assays such as a soft agar assay or an anoikis resistance assay 
in ultra-low adhesion plates. Furthermore, orthotopic injections of breast tumor cells in the 
mammary gland or neuroblastoma cells in the adrenal gland, will allow studying the effect of 
TRPM7 knockdown and overexpression on early metastatic events, such as tissue invasion 
and extravasation. Even more informative would be the use of a conditional TRPM7 knockout 
mouse model, which could be crossed with a spontaneous mouse model of (breast) cancer, 
such as the PyMT-MMTV mouse, allowing close examination of the role of TRPM7 in growth 
and metastasis as well as tumor initiation.
 Together, the patient dataset analysis and mice xenograft experiments clearly indicate 
that high TRPM7 expression levels in tumors associate with metastatic disease and poor 
disease outcome. What are the underlying molecular mechanisms? We found that there 
are two possible mechanisms that contribute to TRPM7-controlled metastasis. One involves 
regulation of adhesion and migration by TRPM7-mediated cytoskeletal relaxation. The other 
involves cytoskeletal tension-mediated control of EMT by TRPM7.
TRPM7 drives cell migration by reducing cellular tension
Cellular invasion and migration are dependent on the spatiotemporal regulation of cytoskeletal 
dynamics and adhesion structures such as matrix-degrading invadosomes and focal adhesions. 
Earlier studies in our lab showed that overexpression of TRPM7 in N1E-115 neuroblastoma 
cells induces cell spreading and adhesion and the formation of invadosomes by inducing 
cytoskeletal relaxation (Clark et al., 2006; Visser et al., 2013). In this thesis we showed that 
TRPM7 knockdown in breast cancer cells increases the formation of focal adhesions and 
cell-cell adhesions by increasing cytoskeletal tension (Chapter 3). Moreover, we found that 
TRPM7-mediated cytoskeletal relaxation is required for the migratory properties of breast 
cancer cells (Chapter 3). These findings are in agreement with other studies showing that 
TRPM7 controls adhesion and migration (Su et al., 2006; Su et al., 2011; Wei et al., 2009).
 How TRPM7 signals to control cytoskeletal tension, adhesion and migration is not 
completely understood. TRP channels have been shown to interact with macromolecular 
complexes that comprise cytoskeletal (regulatory) proteins (Goel et al., 2005; Goswami and 
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Hucho, 2008; Montell, 2005), which could facilitate processes involved in cytoskeletal and 
adhesion regulation. Consistently, TRPM7 was found to directly interact with the actomyosin 
cytoskeleton (Clark et al., 2006). The interaction of TRPM7 with the cytoskeleton is Ca2+- and 
kinase-dependent (Clark et al., 2006) and phosphorylation of substrates is Ca2+-dependent 
(Dorovkov and Ryazanov, 2004; Ryazanova et al., 2004; Schmitz et al., 2003). It is therefore 
likely that Ca2+ influx and substrate phosphorylation act in concert to reduce cytoskeletal 
tension and increase adhesion dynamics and migration.
Role of Ca2+ in adhesion and migration regulation
We did not specifically address the role of TRPM7-mediated Ca2+ influx in adhesion and 
migration regulation. However, Ca2+ is known to regulate cytoskeletal proteins, adhesion 
dynamics and migration (Prevarskaya et al., 2011; Ridley et al., 2003). For instance, Ca2+-
mediated contraction at the rear end of migrating cells induces release of focal adhesion-
mediated adhesion, thereby allowing forward migration of cells (Ridley et al., 2003). Moreover, 
Ca2+ entry through Orai1/Stim1 channels is required for focal adhesion turnover, migration and 
metastasis formation in mouse xenografts (Yang et al., 2009). Ca2+ signals can also activate the 
calpain family of proteases, which cleave adhesion-associated proteins such as talin, vinculin 
and paxillin, thereby regulating adhesion dynamics (Wells et al., 2005). Indeed, TRPM7-
mediated Ca2+ influx activates m-calpain thereby regulating cell adhesion (Su et al., 2006; Su 
et al., 2010). In addition, TRPM7-induced ‘Ca2+-flickers’ at the leading edge of migrating cells 
were suggested to steer cell polarization and migration (Wei et al., 2009). Based on these 
data it seemed plausible that TRPM7-mediated Ca2+-influx controls adhesion and migration. 
However, we showed that TRPM7-induced Ca2+ hotspots in N1E-115 were not found to co-
localize with invadosomes (Visser et al., 2013). Moreover, removing extracellular Ca2+ did not 
affect invadosome dynamics or migration (Visser et al., 2013). In addition, in breast cancer cells 
TRPM7 was shown to regulate migration independent of Ca2+ influx (Guilbert 2013). Although 
these data would argue against a role for TRPM7-mediated Ca2+ signals in localized regulation 
of adhesion dynamics it cannot be excluded that these Ca2+ signals have more subtle effects 
within the adhesion complexes that TRPM7 is part of.
Role of kinase-domain in adhesion and migration regulation
Interactions between TRPM7 and the actomyosin cytoskeleton depend on a functional kinase 
domain (Clark et al., 2006). In addition, TRPM7-induced podosomes in N1E-115 cells appear to 
be kinase-dependent and enhanced by cytoskeletal relaxation (Clark et al., 2006). Consistently, 
the TRPM7 kinase domain was shown to phosphorylate the myosin heavy chain (MHC) in 
vitro, leading to the disassembly of bipolar myosin fibers and cytoskeletal relaxation (Clark 
et al., 2006; Clark et al., 2008). Reciprocally, we showed in this thesis that phosphorylation 
of the myosin light chain increases upon TRPM7 knockdown in MDA-231 cells (Chapter 3). 
These results were further substantiated by findings in MDA-231 cells showing that MHC 
phosphorylation decreased upon TRPM7 knockdown (Guilbert et al., 2013). In contrast to 
these reports, two publications showed that introducing a kinase-dead mutant of TRPM7 was 
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sufficient to rescue cytoskeletal alterations induced by loss of TRPM7 (Liu et al., 2011; Su et 
al., 2011). Hence, these reports argue for different mechanisms by which TRPM7 regulates 
cytoskeletal tension. To differentiate between TRPM7’s channel and kinase function it would 
be required to generate channel- and kinase-dead TRPM7 mutants, which could be achieved 
by using CRISPR/CAS9-mediated mutation, as this will allow targeted mutation of endogenous 
TRPM7 DNA, which would allow studying the effects of these mutants  at physiological TRPM7 
protein levels.
TRPM7 and gene expression regulation
TRPM7 controls developmental processes that affect metastatic properties
Developmental programs such as EMT are often exploited by cancer cells to enhance their 
metastatic properties. In this thesis we showed that loss of TRPM7 in mesenchymal breast 
cancer cells confers epithelial properties to these cells (Chapter 4). Moreover, we showed 
that this is largely mediated by a reduction in expression of the transcription factor SOX4 
(Chapter 4), a recently identified EMT regulating transcription factor required for metastasis 
formation in mouse xenografts (Tiwari et al., 2013; Vervoort et al., 2013; Zhang et al., 2012). 
On the other hand, in neuroblastoma cells TRPM7 maintains progenitor-like features by 
regulating expression of the well-established EMT-TF SNAI2 (Chapter 5), showing cell type or 
cancer specific regulation of EMT-TFs by TRPM7. The acquisition of mesenchymal traits has 
been linked to enhanced anoikis resistance, i.e. the ability of cells to survive in an adhesion 
independent manner (Kumar et al., 2011; Smit and Peeper, 2011). This could in part explain 
why we observe fewer metastases in mice injected with TRPM7 knockdown MDA-231 cells, 
as survival of these knockdown cells in the circulation may be reduced. Together, our data 
show that TRPM7 controls metastatic properties of cells both directly, by regulation of cellular 
tension, as well as by reactivation of developmental programs such as EMT.
Tensional control of SOX4 expression
We showed that expression of the TRPM7 target gene SOX4 is uniquely sensitive to changes 
in cytoskeletal tension (Chapter 4). More specifically, SOX4 expression is inversely correlated 
with cytoskeletal tension, indicating that a TRPM7-maintained ‘relaxed’ cytoskeleton acts to 
preserve SOX4 expression, thereby maintaining the mesenchymal state. Whether a similar 
mechanism is responsible for TRPM7-mediated SNAI2 regulation in neuroblastoma cells 
remains to be determined. 
 How does TRPM7-imposed cytoskeletal relaxation drive SOX4 expression? One 
option is that cytoskeletal relaxation affects nuclear localization of transcriptional regulators. 
For instance, upon increased tension, YAP and TAZ translocate to the nucleus via an as 
yet undetermined mechanism (Dupont et al., 2011). In addition, a reduction in the amount 
of monomeric actin (G-actin) in response to increased cytoskeletal tension causes MRTF to 
translocate to the nucleus and by interacting with SRF affects transcription (Miralles et al., 
2003; Posern and Treisman, 2006). However, tension-induced increases in YAP/TAZ and 
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MRTF/SRF activity have been associated with enhanced metastasis formation as opposed 
to our findings that show that reduced tension preserves metastatic traits, making it unlikely 
that these pathways act downstream of TRPM7. Up to date, no transcriptional regulator known 
to be involved in enhancing metastasis has been shown to translocate to the nucleus upon 
cytoskeletal relaxation (or vice versa a tumor suppressing transcriptional regulator to the 
cytosol). However, we cannot exclude that such a mechanism acts downstream of TRPM7.
 Another option is that TRPM7-imposed changes in cytoskeletal tension are transmitted 
to the nuclear membrane thereby affecting nuclear stiffness and chromatin organization 
(Mammoto et al., 2012). In addition to the data on the modulation of cytoskeletal tension as 
described in Chapter 4 (increasing tension by LPA and constitutive active RhoA; decreasing 
tension by serum starvation, Rho kinase inhibition and myosin II inhibition), we also tested 
the effect of two other actin modulatory compounds on SOX4 expression: cytochalasin 
D and jasplakinolide. These compounds act on actin dynamics in seemingly opposing 
ways. Cytochalasin D impairs actin polymerization whereas jasplakinolide stabilizes actin 
polymerization in vitro (Olson and Nordheim, 2010). Surprisingly, both compounds cause an 
increase in SOX4 expression in MDA-231 cells (see Figure 2). A possible explanation for this 
finding can be sought in the fact that both compounds cause disruption of actin filaments in 
vivo (Bubb et al., 2000; Mazumder and Shivashankar, 2010). Interestingly, disruption of actin 
filaments by cytochalasin D and blebbistatin (myosin II ATPase inhibitor), which both increase 
SOX4 expression in the mesenchymal breast cancer cell models we use, were shown to cause 
a decrease in nuclear size (Mazumder and Shivashankar, 2010). The decrease in nuclear 
size was likely caused by a disruption in actomyosin-mediated pulling forces on the nucleus. 
Consequently, the decrease in nuclear size might have affected chromatin organization and as 
a result transcription of SOX4. On the other hand, nocodazole, a microtubule depolymerizing 
drug, was shown to cause an increase in nuclear size, likely through a disruption in compressing 
force on the nucleus exerted by the microtubule network (Mazumder and Shivashankar, 2010). 
As a consequence, an increase in nuclear size could have had an opposing effect on SOX4 
expression. Indeed, our preliminary data show that nocodazole causes a decrease in SOX4 
expression in MDA-231 (data not shown). It has to be mentioned however that nocodazole 
may also induce RhoA activation (Chang et al., 2008), which also reduces SOX4 expression in 
MDA-231 (see Chapter 4, Figure 4B). 
Figure 1. Effect of cytochalasin D and jasplakinolide on SOX4 
expression in MDA-231 cells. MDA-231 shCntrl were stimulated o/n 
with 5 µM cytochalasin D (CytoD) or 5 nM jasplakinolide (jasplak). mRNA 
expression levels were determined by q-PCR. Data are mean ± SEM of n 
= 3 experiments that were performed in duplicate. Statistical significance 
was determined by a one-sample t-test. * = p < 0.05.
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 Different results were found for the tension-sensitive transcriptional regulator YAP. 
For instance, cytochalasin D and jasplakinolide do have opposing effects on YAP nuclear 
localization (prevents versus enhances, respectively) (Johnson and Halder, 2014; Reddy et 
al., 2013), whereas nocodazole does not impose any effect on nuclear localization of YAP 
(Dupont et al., 2011). These data argue against the option that TRPM7-imposed changes in 
cytoskeletal tension cause nuclear translocation of a transcriptional regulator, such as YAP or 
TAZ. To further test the hypothesis that TRPM7 affects nuclear mechanics, the effect of both 
TRPM7 knockdown and actin modulators on nuclear stiffness, size and/or shape will have to be 
determined. Together, these data could lead to a model in which TRPM7-induced cytoskeletal 
relaxation is transmitted to the nucleus to affect chromatin organization and to subsequently 
maintain a mesenchymal (or progenitor-like) state via the regulation of SOX4 expression.
RhoJ is regulated by a TRPM7-SOX4 axis to contribute to TRPM7-mediated cytoskeletal 
dynamics
EMT is accompanied by large-scale cytoskeletal rearrangements, that contribute to the malignant 
phenotype of this process (Gonzalez and Medici, 2014). In search of transcriptional targets 
downstream of TRPM7 and SOX4 that could underlie these cytoskeletal rearrangements, we 
found that RhoJ, a member of the Cdc42 subfamily of Rho GTPases, is regulated by both 
TRPM7 and SOX4 (Chapter 6). RhoJ was shown to control cell migration and metastasis 
formation in a mouse model of melanoma (Ho et al., 2013). Interestingly, knockdown of RhoJ in 
MDA-231 cells closely follows the cytoskeletal rearrangements and the decrease in migration 
observed upon TRPM7 knockdown in MDA-231 (Chapter 6). These results are in agreement 
with a number of reports showing that knockdown of RhoJ increases cytoskeletal tension and 
the number of focal adhesions and decreased migratory properties of cells such as, HUVECs 
and melanoma cells (Ho et al., 2013; Kaur et al., 2011; Wilson et al., 2014; Yuan et al., 2011). 
Loss of RhoJ may therefore contribute to the TRPM7 and SOX4 knockdown phenotype. 
However, whether re-expressing RhoJ cDNA into TRPM7 knockdown cells reduces focal 
adhesion numbers and increases migration remains to be established.
 Since RhoJ is regulated by both TRPM7 and SOX4, both implicated in EMT regulation, 
it is tempting to speculate that it represents a novel marker for EMT. Indeed, RhoJ is expressed 
in mesenchymal-like circulating tumor cells (CTCs), and not in epithelial-like CTCs (Yu et al., 
2013). However, TGF-β stimulation did not increase RHOJ expression in MDA-231 (Chapter 
6). Since TGF-β was able to regulate other EMT markers such as CDH1, CLDN1, FN1 and 
VIM in MDA-231 (Chapter 4), these results indicate that RhoJ is not a universal EMT marker, 
but rather a TRPM7 and SOX4 target gene.
The stiffness vs pliability ‘discrepancy’
Our results favor a model in which TRPM7-imposed cytoskeletal relaxation maintains a 
mesenchymal phenotype. However, in general increased stromal stiffness is considered to 
promote tumor progression (Butcher et al., 2009). For instance, tumor tissue is generally 
stiffer compared to healthy tissue. Moreover, increased mammographic density, associated 
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with increased stromal collagen deposition, poses a risk factor for breast cancer development 
(Boyd et al., 2007). A number of studies have shown that increased matrix stiffness drives 
tumor progression and EMT (Provenzano et al., 2009; Wei et al., 2015). Our results may 
therefore seem to be add odds with these reports. However, other studies show that reduced 
matrix stiffness, and, as a result, reduced cytoskeletal tension can also enhance metastatic 
properties of cells. For instance, several reports show that more invasive or metastatic cells 
are less stiff than benign or less metastatic cells (Corbin et al., 2015; Cross et al., 2007; Li 
et al., 2008; Swaminathan et al., 2011). In addition, the hypoxic region of late-stage breast 
tumors was found to be less stiff when compared to healthy breast tissue (Plodinec et al., 
2012). Importantly, migration and metastatic spreading were correlated with reduced stiffness 
in hypoxia-associated cells (Plodinec et al., 2012). Interestingly, hypoxia is associated with 
the induction or maintenance of cancer stem cells (Mujcic et al., 2014; van den Beucken 
et al., 2014), which in turn is associated with EMT (Guo et al., 2012; Singh and Settleman, 
2010). Moreover, nuclear stiffness is lowest in embryonic stem cells and increases during stem 
cell differentiation (Swift and Discher, 2014). This may indicate that reduced cellular tension 
favors the maintenance of stem cell like features in tumor cells. By decreasing cytoskeletal 
tension, TRPM7 may well contribute to maintaining such a pliable state. Combined, these 
data could imply that tumor initiation may be enhanced by increased matrix stiffness, but 
as a tumor progresses, low tension in hypoxic regions may favor the induction of TRPM7-
maintained highly metastatic cells. Obviously these findings warrant caution with respect to 
the development of therapeutic targets interfering with the mechanical properties of the ECM 
(Bonnans et al., 2014).
Does TRPM7 signaling affect Ca2+-sensitive TFs?
In addition to transcriptional regulation via the modulation of cytoskeletal tension, TRPM7 may 
also exert control over transcription by regulation of Ca2+-sensitive transcription factors. For 
instance, STAT3 was shown to be activated in a Ca2+- and TRPM7-dependent manner to 
regulate EGF-induced EMT in MDA-MB-468 breast cancer cells (Davis et al., 2014). However, 
we did not find an effect on STAT3 phosphorylation upon TRPM7 knockdown in MDA-MB-231 
cells (data not shown). Members of the NFAT family of Ca2+-sensitive transcription factors may 
act downstream of TRPM7. However, inhibiting calcineurin, an upstream regulator of NFATs, 
using two independent inhibitors (cyclosporine A and FK506) did not affect SOX4 expression 
(data not shown). We can however not exclude that TRPM7-mediated Ca2+ influx affects 
transcription through the regulation of yet unidentified transcription factors.
Concluding remarks
TRPM7 can be (indirectly) activated by mechanical cues (Kim et al., 2015; Numata et al., 2007; 
Oancea et al., 2006; Song et al., 2014; Wei et al., 2009; Xiao et al., 2015). Combined with the 
results in this thesis, we propose a model in which TRPM7 relays mechanical cues from the 
microenvironment to control cytoskeletal tension, adhesion dynamics and developmental gene 
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Figure 3. Model of the diverse metastasis-regulating functions of TRPM7. Mechanical stimuli from the tumor 
microenvironment may directly or indirectly activate or enhance TRPM7 signaling. Ca2+ influx through TRPM7 
pores may induce cytoskeletal remodeling through the activation of proteins such as m-calpain. In addition, 
TRPM7-mediated Ca2+ influx could activate Ca2+-sensitive transcription factors that may regulate transcriptional 
programs involved in metastasis formation. Ca2+ influx furthermore promotes association of the kinase domain with 
its substrates. The TRPM7 kinase domain can phosphorylate the myosin heavy chain, leading to dissociation of 
myosin molecules from F-actin, in turn causing cytoskeletal relaxation. This affects migratory properties of tumor 
cells. In addition, these changes in cytoskeletal tension can affect transcription (in breast cancer transcription of the 
EMT-TF SOX4) through regulation of nuclear localization of TFs or by changing nuclear membrane tension, which 
in turn can change chromatin organization leading to changes in transcriptional programs.
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expression programs in tumor cells (Figure 3). Future studies should aim at unraveling the 
mechanism by which TRPM7 controls expression of EMT transcription factors such as SOX4 
and SNAI2. In addition, it would be worthwhile to investigate the discrepancy between stiffness 
and pliability in tumors and the role of TRPM7 in this process. Do tumor cells transit into more 
pliable metastatic tumor cells during tumor progression or EMT? Or do tumors comprise a 
mixture of intrinsically stiff and pliable tumor cells? Is the role of TRPM7 in these pliable cells 
more prominent than in stiffer cells? With regards to potential therapeutic targeting of TRPM7 
it is worthwhile to investigate the two potent TRPM7 inhibitory compounds, Waixenicin A and 
NS8593. It will be crucial to test in detail if these or derivative molecules are suitable for use in 
a clinical setting.
 In conclusion, TRPM7 takes a central role in the metastatic cascade by controlling 
the tensional state of metastatic tumor cells to regulate adhesion dynamics, migration and 
developmental gene expression programs, thereby enhancing metastasic properties of tumor 
cells. Combined, the results in this thesis further our understanding of cancer’s diverse biology 
and suggest that TRPM7 could possibly be used as a therapeutic target, eventually contributing 
to the war against the ‘The Emperor of All Maladies’.
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Uitzaaiingen, ook wel metastasen genoemd, zijn de belangrijkste doodsoorzaak bij patiënten 
met kanker. Naast genetische veranderingen die een cruciale rol spelen bij het ontstaan en 
verdere verloop van kanker, heeft de omgeving waarin een tumor zich bevindt veel invloed op 
het metastaseren van kankercellen. Bepaalde eiwitten, zoals groeifactoren, die vrijkomen uit 
cellen die in de directe omgeving van de tumor leven, kunnen door binding aan receptoren op 
de kankercellen bijvoorbeeld het metastaserende gedrag van deze kankercellen verhogen. Niet 
alleen eiwitten in de directe omgeving van kankercellen kunnen metastasering beïnvloeden; 
ook de mechanische/fysische eigenschappen van de omgeving van de tumor, zoals de 
stijfheid/hardheid, hebben hier invloed op. Het cytoskelet (i.e. het cellulaire skelet) speelt een 
belangrijke rol bij interpreteren van deze mechanische signalen. 
 Een van de belangrijkste gebeurtenissen die kankercellen ondergaan om metastaserend 
te worden is een proces dat bekend staat als ‘epithelial-mesenchymal transition’ (EMT). EMT 
zorgt er onder meer voor dat kankercellen van de primaire tumor kunnen weg bewegen, 
de bloedvaten kunnen binnendringen en daarin kunnen overleven, en op een andere plek 
in het lichaam een beginnende metastase kunnen vormen. EMT wordt in belangrijke mate 
gereguleerd door signalen afkomstig uit de omgeving van de tumor, zoals de eerdergenoemde 
groeifactoren. In welke mate ook mechanische signalen en het cytoskelet hierbij een rol spelen 
is echter veel minder goed onderzocht.
 De TRP kanaal familie is een familie van ionkanalen die bekend staat om haar functie 
als waarnemer/doorgever van mechanische/fysische signalen. Verder is bekend dat veel TRP 
kanalen associëren met het cytoskelet en dat ze genexpressie kunnen reguleren. Omdat deze 
eigenschappen een belangrijke rol kunnen spelen bij de ontwikkeling van metastaserend 
gedrag is het aannemelijk dat TRP kanalen een rol kunnen spelen bij progressie van kanker, 
door bijvoorbeeld effecten op de beweeglijkheid van cellen of door inductie van EMT. 
 TRPM7 is een bijzonder lid van de TRP familie, omdat de staart van het eiwit voorzien 
is van een kinase domein. Deze duale functionaliteit is uniek; alleen het sterk gerelateerde 
TRP kanaal TRPM6 bevat een soortgelijk kinase domein. Eerder onderzoek heeft aangetoond 
dat TRPM7 associeert met het cytoskelet en dat deze associatie zowel afhankelijk is van 
een functioneel kanaal domein als een actief kinase domein. Of TRPM7 een rol speelt bij 
metastaserend gedrag van kankercellen was echter niet bekend. In dit proefschrift hebben 
we aangetoond dat TRPM7 een belangrijke rol speelt bij tumorcel metastasering, zowel in 
borstkankercellen als bij neuroblastoma cellen. Vervolgens hebben we in meer detail bekeken 
wat het onderliggende mechanisme zou kunnen zijn.
 Hoofdstuk 1 omvat een algemene inleiding op de biologie van kanker en de rol van 
ionkanalen bij het ontstaan of de progressie van kanker. Ook worden de reeds bekende functies 
van TRPM7 beschreven. Hoofdstuk 2 van dit proefschrift bestaat uit een review artikel waarin 
beschreven wordt van welke TRP kanalen reeds bekend is of deze geactiveerd kunnen worden 
door mechanische stimuli en wat voor een direct en indirecte effecten dit kan hebben op het 
cytoskelet, zowel onder fysiologische omstandigheden als tijdens ziekteprocessen.
 In hoofdstuk 3 tonen we in twee onafhankelijke borstkanker patiëntencohorten aan dat 
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verhoogde expressie van het TRPM7 mRNA, op het moment van diagnose, geassocieerd is met 
een verhoogde kans op metastasen en ermee samenhangend een slechte prognose. Verder 
tonen we aan, gebruik makend van een muis model, dat verlaging van TRPM7 expressie in 
borstkankercellen ervoor zorgt dat deze hun vermogen tot metastaseren grotendeels verliezen. 
Het blijkt dat verlies van TRPM7 de contractiliteit (stijfheid) van borstkankercellen verhoogt wat 
leidt tot een toename in het aantal ‘focal adhesions’, specifieke adhesie structuren die ervoor 
zorgen dat deze cellen in vitro minder beweeglijk zijn en in vivo minder metastaseren.   
 In hoofdstuk 4 wordt dieper op deze bevindingen in gegaan. Uit recent onderzoek 
is gebleken dat de contractiliteit van cellen een effect kan hebben op de regulering van 
genexpressie. Onze hypothese was dan ook dat verhoogde cellulaire contractiliteit,  als gevolg 
van verlies van TRPM7,  een effect zou kunnen hebben op genexpressie in borstkankercellen. 
Dit blijkt inderdaad het geval. Verder tonen we aan dat een verlies van TRPM7 expressie 
ervoor zorgt dat mesenchymale borstkankercellen meer epitheliale kenmerken krijgen, wat 
een gevolg lijkt te zijn van veranderingen in expressie van de transcriptiefactor SOX4, een 
belangrijke regulator van dit proces in borstkankercellen. Bovendien blijkt dat SOX4 gereguleerd 
wordt door contractiliteit, wat impliceert dat TRPM7 via de regulatie van contractiliteit SOX4 en 
daardoor EMT reguleert.
 In hoofdstuk 5 onderzoeken we de rol van TRPM7 in neuroblastoma metastasering. We 
laten hier zien dat overexpressie van TRPM7 in neuroblastoma cellen metastasering bevordert 
in een muismodel. Ook is migratie verminderd in neuroblastoma cellen met verlaagde expressie 
van TRPM7. Verder blijkt TRPM7 in neuroblastoma cellen de EMT-regulerende transcriptie 
factor SNAI2 te reguleren,  bevestigend dat TRPM7 een rol speelt in EMT regulatie.
 Uit eerder onderzoek in ons lab en uit het onderzoek in hoofdstuk 3 weten we dat 
TRPM7 de formatie van adhesiestructuren beïnvloedt. In hoofdstuk 4 en 5 laten we zien 
dat TRPM7 genexpressie kan reguleren. In hoofdstuk 6 tonen we aan dat  zowel TRPM7 
als SOX4 het ontstaan van adhesiestructuren ook beïnvloedt door genexpressie-regulering 
van RhoJ, een lid van de Rho GTPase familie. Van Rho GTPases is bekend dat zij een zeer 
belangrijke rol spelen bij de regulering van het cytoskelet en ermee samenhangend die van 
adhesiestructuren. Verlaging van RhoJ expressie in borstkankercellen zorgt, net als verlaging 
van TRPM7, voor verminderde migratie en een verhoging van het aantal ‘focal adhesions’. 
Dit impliceert dat TRPM7-gereguleerde expressie van RhoJ bijdraagt aan cytoskelet regulatie 
door TRPM7.
 In hoofdstuk 7 vatten we de resultaten uit de proefschrift samen en worden deze in 
relatie tot de literatuur bediscussieerd. Uiteindelijk komen we tot een geïntegreerd model, waarin 
we op basis van onze resultaten voorstellen dat de effecten van TRPM7 op metastasering 
van tumor cellen verband houden met de rol van dit kanaal in de regulatie van cellulaire 
contractiliteit. De processen die als gevolg hiervan worden beïnvloedt dragen in belangrijke 
mate bij aan het maligne gedrag van kankercellen. Een beter inzicht in deze cellulaire routes 
kan uiteindelijk leiden tot nieuwe aangrijpingpunten in de behandeling van gemetastaseerde 
vormen van kanker, waaronder borstkanker en neuroblastoma.
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Dankwoord
Man, man, man. Dat was het dan! Een goeie 5 jaar werk, samengevat in een boekje van 
zo’n 170 pagina’s. Ik ben er toch wel een klein beetje trots op moet ik zeggen. Het was een 
geweldige tijd, maar het is, zoals het een echte promotie betaamt, niet zonder slag of stoot 
gegaan. Ach ja, dat hoort er dus bij. Dit heb ik uiteraard niet zonder steun in welke vorm dan 
ook kunnen doen. Ik heb echter vaak gedacht dat ik niet de persoon ben om een dankwoord 
vol met clichématige verhemelingen van de personen die ik dankbaar ben, vol te schrijven. Nu 
het zover is, denk ik er toch anders over! Disclaimer: dankbaarheid onder woorden brengen 
vind ik lastig en doet waarschijnlijk onrecht aan mijn feitelijke dankbaarheid.
 Beste prof dr. Hoogerbrugge, beste Peter. Bedankt voor je begeleiding en de inzet voor 
het lab! Onze spaarzame gesprekken/discussies deden me altijd dieper nadenken over de stof 
en het belang van wat ik deed voor de kliniek. Jammer dat het door de afstand op meerdere 
vlakken (onderwerp, maar ook fysieke afstand tussen onze werkplekken de laatste tijd) het er 
niet vaker van kwam!
 Frank, bedankt dat je me in 2010 aannam op een project waarvan ik toen niet wist dat 
het om het belangrijkste eiwit ter wereld ging. Ik heb altijd, nee laat ik het niet overdrijven want 
soms heb je even geen zin meer om te werken aan je onderwerp, over het algemeen met 
erg veel plezier gewerkt in je lab. De vrijheid die ik ervaarde tijdens mijn promotie vond ik erg 
fijn. Waar nodig kreeg ik altijd de juiste sturing van je en ik blijf me constant verbazen over je 
schijnbaar onuitputbare bron van kennis. Als persoon heb ik je ook altijd erg gemogen! Ik vind 
het daarom jammer dat onze wegen gaan scheiden!
  Beste Jeroen, copromotor, begeleider, collega, TRPM7 teammember en vriend ;). 
We zijn zeker meer dan collega’s geworden met alleen een passie en tegelijkertijd afschuw 
voor dat verrekte eiwitje. Veel gelachen, erg veel geklaagd, vele weekenden samen op ‘t lab 
doorgebracht, gezelligheid op congressen, verscheidene kapsalons en speciaalbieren (maar 
geen whiskey, kots) samen genuttigd; dit met name om aan te tonen dat TRPM7 inderdaad 
‘the most important protein of the world is’!! We hebben als tweedelig TRPM7 team toch best 
veel laten zien denk ik. Jouw enthousiasme over TRPM7 werkte erg aanstekelijk en onze 
dagelijkse discussies waren niet alleen leuk maar ook nog eens nuttig. Mijn dank aan jou is 
daarom ook groot! Het team gaat nu uit elkaar. Helaas, helaas, maar wie weet komen we 
elkaar later weer tegen!
 De TRPM7 groep van het NKI verdient ook een grote dankjewel. Kees, Jeffrey, Daan, 
Linda, Kasia, bedankt voor jullie input en inzet voor het TRPM7 werk.
 Verder ook veel dank aan de stagiaires die me geholpen hebben! Ilse (ik herinner me 
als ons geklik nog voor de migratie assays), Erik en Veerle (dank aan jullie hulp voor het RhoJ 
werk, wat helaas niet altijd wilde vlotten; ik noem RhoJ kloneren... :P maar er zijn toch erg 
leuke resultaten uit gekomen) en Tanya (bedankt voor je hulp met het EMT werk!!).
 Ik heb geluk gehad dat ik erg veel leuke collega’s heb gehad! Dit hielp veel met het 
verkijgen van werkplezier en het makkelijker kunnen accepteren van klote dagen (door weer 
eens een mislukte proef bijvoorbeeld, haha). Special thanks aan iedereen van het LKO. 
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Liesbeth, Dorette, Laurens en Blanca, met jullie werk ik nu het langs samen. Erg bedankt 
voor alle gezelligheid en steun in wat voor vorm dan ook. Dit zit hem vaak in de kleine, 
onbenoembare dingen, maar mijn waardering voor jullie is groot! Ik ga jullie zeker erg missen. 
Hanneke, old roomie, ik vond het altijd erg gezellig op ons kantoortje in het Trigon (hopelijk jij 
ook tussen de TRPM7 boys)! De nieuwere collega’s, Kirsten (heel veel succes met het TRPM7 
werk en Jeroen natuurlijk) en Miriam (ook veel succes gewenst!). René bij jou kom ik zo! Ook 
mijn ex LKO collega’s, Marc, Yuni (yes you should be able to understand this by now!!), Esther, 
Jorn en Marloes wil ik nog bedanken, jullie waren fijne collega’s!
 Iedereen van het LKI die er nog is en geweest is tijdens mijn tijd op het lab, ook erg 
bedankt voor de leuke tijd!! De combinatie van het LKI en LKO heeft mijns insziens altijd goed 
gewerkt! Ada, zonder jouw inzet voor het lab was volgens mij alles in het honderd gelopen! Ik 
wil je erg bedanken hiervoor! Hopelijk kom je die klote ziekte te boven, ik wens je alle sterkte 
van de wereld toe. Kadem, ook erg bedankt voor al je hulp aan ons lab. Ik vond het erg leuk 
dat je mee kwam met ons naar de nieuwe locatie!
 Dan mijn paranimfen. Corné, je bent een goeie vriend van me geworden. We hebben 
samen de struggles van het promoveren doorstaan, met name in dat verrekte laatste jaar. Van 
de rustige lunch in het restaurant tot ingesloten worden in een cirkel van dansende vrouwen bij 
een niet nader te noemen feest, of om 7 uur ‘s ochtends straalbezopen ‘afteren’ in mijn oude 
studentenhuis; dit hadden we allemaal nodig om er doorheen te komen. Dit kratje bier ga ik 
winnen, maar volgens mij sta jij nog steeds voor. Gelukkig ben jij er ook bijna (maar daar kan 
ik dan waarschijnlijk weer niet bij zijn. Damn you slechts 10 dagen vakantie in de VS). Dan 
Herr Marke, René. Je bent nog niet superlang m’n collega, maar we hebben er toch al wat uren 
samen opzitten (11.30 lunchtime, biertjes @ Aesculaef), waar we als PhD-studenten onder 
elkaar onze struggles aan elkaar kwijt kunnen en daardoor zie ik je inmiddels ook als meer dan 
een collega. Voor jou moet het ergste nog komen, maar je kunt het jonge :P.
 Ik wil ook graag even al m’n vrienden die ik al veeeeel te lang ken en iedereen die ik 
heb leren kennen in mijn tijd hier in Nijmegen en nu als vriend mag zien, bedanken. Ook al ben 
ik af en toe anti-sociaal (sorry voor het afhaken bij feestjes en verjaardagen, oeps), ik ben toch 
erg blij dat ik een vaste groep aan goeie vrienden heb waar ik nog vaak mee om ga. Ik geloof 
dat jullie nog steeds geen flauw idee hebben wat ik doe, maar jullie hebben me (onbewust) 
door het promoveren heen gesleept! Dank u!
 Om even in clichés te blijven hangen: En last but not least, mijn familie. Pa en ma: 
bedankt voor jullie onvoorwaardelijke steun gedurende mijn promotietraject en sorry voor de 
stress die ik met name de laatste paar maanden bij jullie heb veroorzaakt, haha. Ik ben niet de 
persoon die het hardop zegt, maar ik hou erg veel van jullie en zonder jullie was het allemaal 
niet gelukt! Niek, broer, ik vind het top dat we in dezelfde vriendengroep zitten en dat we elkaar 
daardoor nog veel zien. Bente, zusje, we zien elkaar niet meer zo vaak, maar ik vind het altijd 
weer erg leuk je weer te zien. Lieve Oma, jij verdient, als mater familias, ook zeker een plekje 
in mijn dankwoord. Ik vind het prachtig dat je nog zo bij de pinken bent op jouw leeftijd en ben 
erg blij dat je mijn promotie nog kunt meemaken!
 Oké dit is de echte last but not least. Je grote liefde wordt vaak bedankt in de laatste 
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zinnen van je dankwoord. Bij deze: house en techno. Ik ben zo blij dat ik jullie zo’n 8 jaar 
geleden heb ontdekt. Jullie vermaken me, veroordelen me niet, laten me even aan iets anders 
denken dan werk wanneer dat nodig is en klagen nooit. Bedankt dat jullie er altijd voor me zijn!
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